Table of Contents

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q  
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2013  
Or  
o       TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to                 
Commission File Number 001-35348  
Intermolecular, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
 
20-1616267
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
3011 N. First Street
San Jose, California
 
95134
(Address of Principal Executive Offices)
 
(Zip Code)
(408) 582-5700
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x   No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x   No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer  o
 
Accelerated filer  x
 
 
 
Non-accelerated filer  o
 
Smaller reporting company  o
(Do not check if a smaller reporting company)
 
 

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  o   No  x
Shares outstanding of the registrant’s common stock:
Class
 
Outstanding as of November 4, 2013
Common stock, $0.001 par value
 
46,105,067
 


Table of Contents

INTERMOLECULAR, INC.  
FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2013
TABLE OF CONTENTS
 
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 

2

Table of Contents

PART I — FINANCIAL INFORMATION
 
ITEM 1. FINANCIAL STATEMENTS
INTERMOLECULAR, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)
 
September 30, 2013
 
December 31, 2012
ASSETS
 

 
 

Current assets:
 

 
 

Cash and cash equivalents
$
74,266

 
$
78,283

Short-term investments
250

 

Accounts receivable, net of allowance for doubtful accounts of $0 as of September 30, 2013 and $170 as of December 31, 2012
9,565

 
7,294

Accounts receivable, due from related parties
817

 
1,036

Inventory, current portion
1,782

 
1,631

Prepaid expenses and other current assets
1,161

 
1,361

Total current assets
87,841

 
89,605

Inventory, net of current portion
5,096

 
3,160

Property and equipment, net
27,380

 
24,058

Intangible assets, net
7,311

 
6,671

Other assets
164

 
191

Total assets
$
127,792

 
$
123,685

LIABILITIES AND STOCKHOLDERS’ EQUITY
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
3,780

 
$
971

Accrued liabilities
5,102

 
3,386

Accrued compensation and employee benefits
3,742

 
3,397

Deferred revenue
1,446

 
2,301

Related party deferred revenue
1,262

 
829

Note payable
25,000

 
26,514

Total current liabilities
40,332

 
37,398

Deferred rent, net of current portion
304

 
624

Other long-term liabilities

 
146

Total liabilities
40,636

 
38,168

Commitments and contingencies (note 5)


 


Stockholders’ equity:
 

 
 

Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding as of September 30, 2013 and December 31, 2012

 

Common stock, par value $0.001 per share—200,000,000 shares authorized; 45,926,545 and 44,046,970 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively
46

 
44

Additional paid-in capital
192,816

 
186,778

Accumulated deficit
(105,706
)
 
(101,305
)
Total stockholders’ equity
87,156

 
85,517

Total liabilities and stockholders’ equity
$
127,792

 
$
123,685

 
See accompanying notes to unaudited condensed consolidated financial statements

3

Table of Contents

INTERMOLECULAR, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Revenue:
 

 
 

 
 

 
 

Collaborative development program and services revenue
$
11,156

 
$
12,481

 
$
34,858

 
$
35,836

Product revenue
2,748

 
760

 
5,852

 
3,495

Licensing and royalty revenue
3,844

 
3,248

 
11,079

 
10,053

Total revenue
17,748

 
16,489

 
51,789

 
49,384

Cost of revenue:
 

 
 

 
 

 
 

Cost of collaborative development program and services revenue
7,545

 
6,595

 
21,283

 
20,031

Cost of product revenue
1,452

 
554

 
2,585

 
1,635

Cost of licensing and royalty revenue
67

 
55

 
179

 
200

Total cost of revenue
9,064

 
7,204

 
24,047

 
21,866

Gross profit
8,684

 
9,285

 
27,742

 
27,518

Operating expenses:
 

 
 

 
 

 
 

Research and development
6,107

 
5,174

 
17,727

 
16,002

Sales and marketing
1,544

 
1,322

 
4,759

 
3,834

General and administrative
3,008

 
2,650

 
9,042

 
8,190

Total operating expenses
10,659

 
9,146

 
31,528

 
28,026

(Loss) income from operations
(1,975
)
 
139

 
(3,786
)
 
(508
)
Other income (expense):
 

 
 

 
 

 
 

Interest expense, net
(168
)
 
(255
)
 
(649
)
 
(754
)
Other (expense) income, net
(2
)
 
10

 
66

 
16

Total other income (expense), net
(170
)
 
(245
)
 
(583
)
 
(738
)
Loss before provision for income taxes
(2,145
)
 
(106
)
 
(4,369
)
 
(1,246
)
Provision for income taxes
26

 
6

 
32

 
12

Net loss
$
(2,171
)
 
$
(112
)
 
$
(4,401
)
 
$
(1,258
)
Net loss per share of common stock, basic and diluted
$
(0.05
)
 
$
(0.00
)
 
$
(0.10
)
 
$
(0.03
)
Weighted-average number of shares used in computing net loss per share of common stock, basic and diluted
45,191,514

 
43,278,588

 
44,657,529

 
42,725,466

Related Party Transactions
The Condensed Consolidated Statements of Operations shown above include the following related party transactions:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Revenue:
 

 
 

 
 

 
 

Collaborative development program and services revenue
$
1,792

 
$
3,529

 
$
5,604

 
$
9,277

Product revenue

 
760

 

 
2,139

Licensing and royalty revenue
1,358

 
1,768

 
4,082

 
5,332

Total revenue
$
3,150

 
$
6,057

 
$
9,686

 
$
16,748

Cost of Revenue:
 

 
 

 
 
 
 
Cost of collaborative development program and services revenue
$
1

 
$
10

 
$
1

 
$
40

Total cost of revenue
$
1

 
$
10

 
$
1

 
$
40

See accompanying notes to unaudited condensed consolidated financial statements

4

Table of Contents

INTERMOLECULAR, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Loss
(In thousands)
(Unaudited)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Loss for the period
$
(2,171
)
 
$
(112
)
 
$
(4,401
)
 
$
(1,258
)
Other comprehensive loss

 

 

 

Comprehensive loss for the period, net of income tax
$
(2,171
)
 
$
(112
)
 
$
(4,401
)
 
$
(1,258
)

See accompanying notes to unaudited condensed consolidated financial statements


5

Table of Contents

INTERMOLECULAR, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)  
 
Nine Months Ended September 30,
 
2013
 
2012
Cash flows from operating activities:
 

 
 

Net loss
$
(4,401
)
 
$
(1,258
)
Adjustments to reconcile net loss to net cash provided by operating activities:
 

 
 

Depreciation and amortization
6,951

 
5,865

Stock-based compensation
4,088

 
2,687

Impairment of long-lived assets

 
949

Loss on disposal of property and equipment
9

 

Changes in operating assets and liabilities:
 

 
 

Prepaid expenses and other assets
244

 
912

Inventory
(1,694
)
 
(1,233
)
Accounts receivable
(2,052
)
 
5,526

Accounts payable
2,057

 
(364
)
Accrued and other liabilities
1,199

 
(580
)
Deferred revenue
(855
)
 
(1,313
)
Related party deferred revenue
433

 
(8,401
)
Net cash provided by operating activities
5,979

 
2,790

Cash flows from investing activities:
 

 
 

Purchase of short-term investments
(1,001
)
 
(2,201
)
Redemption of short-term investments
751

 
500

Purchase of property and equipment
(9,054
)
 
(3,760
)
Purchased and capitalized intangible assets
(1,113
)
 
(776
)
Net cash used in investing activities
(10,417
)
 
(6,237
)
Cash flows from financing activities:
 

 
 

Proceeds from debt
25,000

 

Payment of debt
(26,514
)
 
(573
)
Proceeds from exercise of common stock options
1,935

 
1,733

Net cash provided by financing activities
421

 
1,160

Net decrease in cash and cash equivalents
(4,017
)
 
(2,287
)
Cash and cash equivalents at beginning of period
78,283

 
81,002

Cash and cash equivalents at end of period
$
74,266

 
$
78,715

 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 

Cash paid for interest
$
618

 
$
927

Cash paid for income taxes, net of refunds received
$
8

 
$
42

Noncash investing activities:
 
 
 
Transfer of property and equipment to inventory
$
393

 
$

 
See accompanying notes to unaudited condensed consolidated financial statements

6

Table of Contents

INTERMOLECULAR, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intermolecular, Inc. and subsidiaries (the "Company") have been prepared without audit in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission ("SEC"). Accordingly, certain information and disclosures normally included in complete financial statements prepared in accordance with GAAP have been condensed or omitted. The information in this report should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on March 4, 2013.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for any other future interim period or full year. The condensed consolidated balance sheet as of December 31, 2012 is derived from the audited consolidated financial statements as of the year then ended. 
Use of Estimates  
The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenue and expenses. Management uses estimates and judgments in determining recognition of revenues, valuations of accounts receivable, inventories, intangible assets, debt, capital stock, warrants and assumptions used in the calculation of income taxes and stock-based compensation, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts such estimates and assumptions when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. 
Concentration of Credit Risk  
Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, short-term investments and accounts receivable. The Company’s cash, cash equivalents and short-term investments consist of demand deposits, money market accounts and certificates of deposit maintained with high quality financial institutions. The Company's accounts receivable consist of non-interest bearing balances due from credit-worthy customers.
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with a remaining maturity of three months or less to be cash equivalents. The Company’s cash equivalents are comprised of money market funds and are maintained with high quality financial institutions.
Short-Term Investments
The Company considers all highly liquid investments purchased with a maturity between three and twelve months to be short-term investments. The Company has short-term investments consisting of certificates of deposit maintained with high quality credit institutions. The carrying value of these investments approximates their fair value due to the short term of their maturities. 
Inventory
Inventories are stated at the lower of cost or market value, with cost determined on an average cost basis. Current inventories consist of work-in-process for products that are expected to be sold in the next twelve months. Noncurrent inventories consist of raw materials in the amount of $4.3 million and $2.4 million as of September 30, 2013 and December 31, 2012 , respectively, and work-in-process for products that are not expected to be sold during the next twelve months in the amount of $0.8 million as of September 30, 2013 and December 31, 2012 . Inventories in excess of salable amounts and spare parts inventories that are considered obsolete are recorded as a cost of revenue in the period in which they occur. The Company did not experience any material inventory impairments during the three and nine months ended September 30, 2013 and 2012 .
    

7


Impairment of Long-Lived Assets
The Company evaluates its long-lived assets, which consist of property and equipment and intangible assets, for indicators of possible impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Impairment exists if the carrying amounts of such assets exceed the estimates of future net undiscounted cash flows expected to be generated by such assets. Should impairment exist, the impairment loss would be measured based on the excess carrying value of the asset over the estimated fair value of the asset. The Company had no impairment of long-lived assets during the three and nine months ended September 30, 2013 . During the nine months ended September 30, 2012 , the Company recorded impairment expenses in the amount of $0.9 million related to retired assets previously supporting a customer collaborative development program and platform prototypes for new application development.
Revenue Recognition
The Company derives its revenue from three principal sources: collaborative development programs and other services; product sales; and technology licensing and royalty fees. Revenue is recognized when all of the following criteria are met:
• Persuasive evidence of an arrangement exists;
• Delivery has occurred;
• The fee is fixed or determinable; and
• Collectability of the fee is probable.

Persuasive evidence of the arrangement represents a written contract signed by both the Company and the customer, or a customer purchase order. The Company assesses whether a price is fixed or determinable by, among other things, reviewing
contractual terms and conditions related to payment terms. The Company assesses collectability based on factors such as the
customer's creditworthiness and past collection history, if applicable. If collection is not probable, revenue recognition is deferred until receipt of payment.
Collaborative development programs and other services —The Company enters into collaborative development programs ("CDPs") and other research and development service agreements with customers under which the Company conducts research and development activities jointly with the customer. The agreements specify minimum levels of research effort required to be performed by the Company. Payments received under the agreements are not refundable if the research effort is not successful. The Company retains rights to certain elements of technology developed in the course of its performance, which the customer has an option to license in the future under the terms defined in the agreement. Most arrangements with customers have fixed monthly fees and requirements to provide regular reporting of research and development activities performed and revenue is recognized in a manner consistent with the fixed monthly fee. Payments received prior to performance are deferred and recognized as revenue when earned over future performance periods. 
The Company considers arrangements that include specifically identified, dedicated equipment to contain a lease provision, as these arrangements convey the right to the customer to use specific equipment and provide the ability to the customer to direct the use of the equipment as well as control more than a minor amount of the output of the equipment. To date the Company has determined these arrangements to contain operating leases, with a lease term that corresponds to the term of the CDP arrangement. The amount of revenue allocated for the lease element is based on its relative fair value, but the impact of the allocation does not change the amount of revenue recognized for the total arrangement as the lease term is consistent with the CDP term. Operating lease income recorded in CDP and services revenue during the nine months ended September 30, 2013 and 2012 was $5.6 million and $7.3 million , respectively.
Future minimum operating lease payments associated with CDP arrangements that contain operating leases were $1.9 million and $8.4 million as of September 30, 2013 and December 31, 2012 , respectively. 
Product maintenance and support services - Included in collaborative development programs and other services revenue, these services entitle customers to receive product updates and enhancements or technical support and maintenance, depending on the offering. The related revenue is recognized ratably over the period the services are delivered. 
Product revenue - The Company recognizes revenue from the sale of products once delivery has occurred (title and risk of loss have passed to the customer), and customer acceptance, if required, has been achieved.
Licensing and royalty revenue - The Company recognizes revenue for licenses to intellectual property when earned pursuant to the terms of the agreements. Time-based license revenue is recognized ratably over the license term. Licensing and royalty revenue that becomes triggered by specific customer actions, such as exercise of a license option or by sales volume, is recognized when it occurs based on royalty reports or other information received from the licensee. Minimum and prepaid royalties and license fees are recognized ratably over the related periods. Revenue on the sale of intellectual property is recognized in full when title transfers if there are no remaining deliverables related to the intellectual property purchase.

8


Multiple-element arrangements - Certain of the Company’s customer arrangements involve the delivery or performance of multiple products, services or licenses. Product sale arrangements include product maintenance and support. Collaborative development programs and other research and development services include licenses of technology and may also include sales of products.
The Company evaluates whether a delivered element has value to the customer without the remaining undelivered elements by determining whether the delivered element could be sold by the Company, or resold by the customer, on a stand- alone basis. The Company concluded that all of its products and services deliverables have value to the customers on a stand-alone basis, as all these deliverables have been or could be sold and used by customers on a stand-alone basis. Intellectual property license arrangements have value on a stand-alone basis if the customer could purchase and use them without the remaining elements of the arrangement. For transactions entered into prior to January 1, 2011, the Company assessed whether there is objective and reliable evidence of fair values of all undelivered elements. Fair values of such elements are determined by reference to the Company-specific objective evidence, such as pricing of these elements when sold separately, substantive renewal prices for product maintenance and support and time-based licenses, or other available evidence. If the fair value of any undelivered elements in a multiple-element arrangement cannot be objectively determined, revenue is deferred until all elements are delivered, or until fair value can objectively be determined for any remaining undelivered elements. However, in situations where the undelivered elements are software-related hardware elements, the Company will recognize revenue under a proportional performance model when fair value for the hardware elements is not available, if the undelivered hardware elements are substantially similar products. If product maintenance and support and time-based licenses are the only undelivered elements without objective and reliable evidence of fair value, all revenue from the arrangement is amortized over the longer of the product maintenance and support term or license period. For purposes of classification in the consolidated statements of operations, revenue is allocated between collaborative development programs and services revenue, product revenue and licensing and royalty revenue based on objective and reliable evidence of fair value for any elements for which it
exists or based on the relative stated invoice amount for elements for which objective and reliable evidence of fair value does not exist.
For all transactions entered into after December 31, 2010, the Company recognizes revenue using estimated selling prices of the delivered goods and services based on a hierarchy of methods as required by GAAP. The Company uses vendor-specific objective evidence of selling price ("VSOE") for determination of estimated selling price of elements in each arrangement if available, and since third-party evidence ("TPE") is not available for those elements where vendor-specific objective evidence of selling price cannot be determined, the Company evaluates factors to determine its estimated selling prices ("ESP") for all other elements. In multiple-element arrangements where hardware and software are sold as part of the solution, revenue is allocated to the hardware and software as a group using the relative selling prices of each of the deliverables in the arrangement based upon the aforementioned selling price hierarchy. 
Deferred Revenue
Deferred revenue represents amounts collected from customers for which the related revenue has not been recognized, because one or more of the revenue recognition criteria have not been met, net of the associated costs. The current portion of deferred revenue represents the amount that is expected to be recognized as revenue within one year from the balance sheet date. When deferred revenues are recognized as revenues, the associated deferred costs are also recognized as cost of revenues.
Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable are recorded at invoiced amounts and unbilled contractually obligated amounts. Trade accounts receivable are presented net of allowances for doubtful accounts, if applicable, and do not bear interest. The allowance for doubtful accounts is based on the Company's assessment of the collectability of its customer accounts. The Company reviews the allowance by considering certain factors such as historical experience, industry data, credit quality, age of balances and current economic conditions that may affect customers' ability to pay.
Concentration of Revenue and Accounts Receivable
Significant customers are those that represent more than 10% of the Company’s total revenue or accounts receivable. For each significant customer, including related parties, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:

9


 
Revenue
 
Accounts Receivable
 
Three Months Ended
 
Nine Months Ended
 
As of
 
As of 
 
September 30,
 
September 30,
 
September 30,
 
December 31,
 
2013
 
2012
 
2013
 
2012
 
2013
 
2012
Customer A
12
%
 
30
%
 
12
%
 
27
%
 
*

 
*

Customer B
11
%
 
27
%
 
18
%
 
29
%
 
14
%
 
25
%
Customer C (1)
*

 
14
%
 
12
%
 
14
%
 
%
 
*

Customer D
*

 
*

 
*

 
*

 
*

 
12
%
Customer E
*

 
*

 
14
%
 
*

 
*

 
40
%
Customer F (1)
18
%
 
%
 
*

 
%
 
24
%
 
%
Customer G
*

 
%
 
*

 
*

 
*

 
*

Customer H
15
%
 
%
 
*

 
%
 
31
%
 
%
 
 
*   less than 10%
(1) Customer C was acquired by Customer F as of July 31, 2013. Revenue and accounts receivable attributed to Customers C and F are combined under Customer F for periods after July 31, 2013.

Share-Based Compensation
The Company applies the fair value recognition and measurement provisions of ASC 718 Compensation — Stock Compensation. Stock-based compensation is recorded at fair value as of the grant date, determined using the Black-Scholes option-pricing model, and recognized as an expense over the employee’s requisite service period (generally the vesting period), which the Company has elected to amortize on a straight-line basis.
The Company accounts for stock options issued to nonemployees based on the fair value of the options determined using the Black-Scholes option-pricing model. The fair value of stock options granted to nonemployees is remeasured each reporting period as the stock options vest and the resulting change in value, if any, is recognized in the Company’s consolidated statements of operations during the period the related services are rendered.
Recent Accounting Pronouncements  
In September 2011, the FASB issued an update to ASC 350 Intangibles-Goodwill and Other (“ASC 350”): Testing Goodwill for Impairment. The update gives an entity an option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, an entity determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test is unnecessary. An entity has the option to bypass the qualitative assessment for any reporting unit in any period and proceed directly to performing the first step of the two-step goodwill impairment test. An entity may resume performing the qualitative assessment in any subsequent period. Under the amendments, an entity no longer is permitted to carry forward its detailed calculation of a reporting unit's fair value from a prior year as previously permitted by ASC 350. The Company adopted this update to ASC 350 in the first quarter of 2013 without any impact on its financial position, results of operations or cash flows.
2. Fair Value of Financial Instruments
The Company measures and reports its cash equivalents and short-term investments at fair value on a recurring basis. The Company does not have any financial liabilities that are measured and reported at fair value. The following tables set forth the fair value of the Company’s cash equivalents and short-term investments by level within the fair value hierarchy (in thousands):

10


 
As of September 30, 2013
 
Fair Value
 
Level I
 
Level II
 
Level III
Assets:
 
 
 
 
 
 
 
Money market funds
$
63,518

 
$
63,518

 
$

 
$

Certificates of deposit
250

 

 
250

 

Total assets measured at fair value
$
63,768

 
$
63,518

 
$
250

 
$

 
As of December 31, 2012
 
Fair Value
 
Level I
 
Level II
 
Level III
Assets:
 
 
 
 
 
 
 
Money market funds
$
70,488

 
$
70,488

 
$

 
$

Total assets measured at fair value
$
70,488

 
$
70,488

 
$

 
$


3. Property and Equipment
Property and equipment consist of the following (in thousands):
 
As of
 
As of
 
September 30, 2013
 
December 31, 2012
Lab equipment and machinery
$
47,371

 
$
38,667

Leasehold improvements
4,073

 
2,873

Computer equipment and software
3,499

 
3,467

Furniture and fixtures
176

 
160

Construction in progress
5,454

 
5,964

Total property and equipment
60,573

 
51,131

Less accumulated depreciation
(33,193
)
 
(27,073
)
Property and equipment, net
$
27,380

 
$
24,058


On May 31, 2013, the Company entered into a loan and security agreement ("Loan Agreement") with Silicon Valley Bank ("SVB") pursuant to which SVB made available to the Company loans under a revolving line to refinance existing indebtedness (including the repayment of all remaining principal and accrued interest under the secured promissory note that the Company issued to Symyx Technologies, Inc. ("Symyx") in November 2011) and for working capital and general business purposes, in a principal amount of up to $26.5 million . Upon repayment, the Symyx note was terminated and Symyx released all security interests and other liens held as security in connection with the Symyx note. Under the Loan Agreement, and as of September 30, 2013 , SVB held a security interest in substantially all of the Company's assets, excluding all intellectual property. As of December 31, 2012 all tangible property and equipment was pledged as collateral against the note payable issued in connection with the closing of the asset purchase transaction with Symyx.
The following table presents depreciation expense included in the Condensed Consolidated Statement of Operations and includes amortization of leasehold improvements (in thousands): 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Depreciation expense
$
2,249

 
$
1,868

 
$
6,493

 
$
5,433

 
The Company maintained dedicated equipment to support contractual customer capacity requirements as part of certain collaborative development programs that are classified as lab equipment and machinery and had a net book value of $1.9 million and $5.9 million as of September 30, 2013 and December 31, 2012 , respectively.

11


4. Intangible Assets
Intangible assets consist of the following (in thousands):
 
As of
 
As of
 
September 30, 2013
 
December 31, 2012
Patents issued
$
4,517

 
$
3,932

Patents pending
3,899

 
3,386

Trademarks
40

 
40

Total intangible assets
8,456

 
7,358

Less patent amortization
(1,145
)
 
(687
)
Intangible assets, net
$
7,311

 
$
6,671


Amortization commences upon patent issuance. The useful life of the patents, once approved, will not exceed 20 years , and will depend on the nature of the patent. The average estimated amortization period of our current portfolio is approximately 17 years from the date of patent issuance. The average estimated remaining amortization period of patents acquired as part of the Symyx asset purchase transaction is approximately 4 years .
The following table presents patent amortization expense included in the Condensed Consolidated Statement of Operations (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Amortization expense
$
156

 
$
145

 
$
458

 
$
432

 
5. Commitments and Contingencies
Leases
The Company entered into an operating lease agreement in May 2010 that expires in May 2015. Rent expense is being recognized on a straight-line basis over the lease term.
The following table presents rent expense included in the Condensed Consolidated Statement of Operations (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Rent expense
$
324

 
$
324

 
$
972

 
$
972


Future commitments and obligations under this operating lease to be satisfied as they become due over the term are as follows (in thousands):
As of September 30, 2013:
 

Three months ending December 31, 2013
$
416

The years ending December 31,
 

2014
1,707

2015
728

Total
$
2,851


During 2013 , the Company has made payments in the amount of $1.2 million related to this operating lease.


12


Symyx Asset Purchase and Note Payable
In connection with the consummation of the Symyx asset purchase transaction in November 2011, the Company issued Symyx a secured promissory note in a principal amount equal to $27.3 million with a term of 24 months and an interest rate equal to 4% . The note was payable in quarterly installments, each in an amount equal to the greater of $0.5 million that quarter or the amount of accrued interest, with a balloon payment at maturity, if applicable. The note was also pre-payable by the Company at any time without penalty or premium, and was secured by tangible personal property, excluding intellectual property. On May 31, 2013, the Company used $25.0 million of the net proceeds from a revolving line with Silicon Valley Bank ("SVB") and $1.5 million of cash to retire and repay all remaining principal and accrued interest upon the note. Over the life of the Symyx note the Company paid a total of $29.0 million , of which approximately $1.6 million related to interest expense.
The following table presents payments made during the three and nine months ended September 30, 2013 in connection with the note payable to Symyx (in thousands):
 
Three Months Ended September 30, 2013
 
Nine Months Ended September 30, 2013
 
Principal
 
Interest
 
Total
 
Principal
 
Interest
 
Total
Symyx payments
$

 
$

 
$

 
$
26,516

 
$
437

 
$
26,953


Silicon Valley Bank Loan Agreement
On May 31, 2013, the Company entered into a loan and security agreement (“Loan Agreement”) with SVB pursuant to which SVB made available to the Company loans under a revolving line to refinance existing indebtedness (including the repayment of the Symyx note) and for working capital and general business purposes, in a principal amount of up to $26.5 million . Under the Loan Agreement, SVB funded an initial credit extension in the principal amount of $25 million on May 31, 2013 and agreed to fund, subject to customary conditions, additional credit extensions under the revolving line on or prior to November 30, 2013. The Loan Agreement has a financial covenant that requires the Company to maintain a certain level of liquidity, and as of September 30, 2013 , the Company was compliant with the terms of that loan covenant. Prior to November 30, 2013, the Company has the option to convert all or any part of the outstanding advances under the revolving line into a term loan. This option to convert the revolving advances into a term loan can only be used once. The revolving line advances bear interest at a floating rate equal to the greater of 2.75% or the prime rate (customarily defined) minus 0.50% . The term loan would bear interest at a fixed rate equal to 3.25% .

The Company is obligated to pay interest on the revolving line credit extensions on a monthly basis and is obligated to pay all outstanding principal and unpaid interest on credit extensions under the revolving line on November 30, 2013. The following table presents payments made during the three and nine months ended September 30, 2013 for interest owed under the terms of the Loan Agreement (in thousands):
 
Three Months Ended September 30, 2013
 
Nine Months Ended September 30, 2013
 
Principal
 
Interest
 
Total
 
Principal
 
Interest
 
Total
SVB payments
$

 
$
176

 
$
176

 
$

 
$
178

 
$
178


For any amount converted into a term loan prior to November 30, 2013, the Company is obligated to pay interest at the applicable rate and $0.5 million of principal on a quarterly basis. The term loan would mature three years from the first day of the month after conversion occurs, but no later than November 30, 2016, and the Company would be obligated to pay all outstanding principal and accrued and unpaid interest on that date. At the Company's option, the Company may prepay the outstanding principal balance of the term loan in full or in part, subject to a pre-payment fee of 0.25% of the outstanding principal balance of the term loan if the term loan is outstanding for less than one year. In the event of a termination of the revolving line for any reason before November 30, 2013, including the repayment of the loan upon any prepayment, the Company is obligated to pay a final payment fee equal to 0.25% of the outstanding revolving advance being repaid.
Litigation
On August 23, 2013, the Company received a copy of a complaint from the California Division of Labor Standards and Enforcement ("DLSE") filed by an employee in the Company’s research and development group claiming that the employee is owed back pay due to an incorrect classification as an exempt employee for overtime purposes. The Company commenced a review of the employee's claim as well as a review of the Company’s policies regarding classification of employees for overtime purposes. The Company has also agreed to enter mediation with the attorney who represents the

13


employee that filed the claim with the DLSE as well as at least ten other employees who are similarly situated. While the Company is committed to reaching a reasonable resolution through mediation, the Company believes it has meritorious defenses to the claims and intends to vigorously defend against any of them in this regard. Nevertheless, as of September 30, 2013, the Company accrued its best estimate of the amount of probable loss associated with the matter and classified the resulting expense as research and development in its Condensed Consolidated Statements of Operations. While the Company cannot predict the outcome of this matter, or of any legal or administrative proceedings related to this matter that have commenced or may be commenced in the future, the Company believes the matter will not have a material adverse effect on its business, operating results, financial condition or cash flows.
6. Stockholders’ Equity
Stock-Based Compensation
The fair value of the employee stock options granted during the period was estimated on the respective grant date using a Black-Scholes option-pricing model with the following weighted-average assumptions: 
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2013
 
2012
 
2013
 
2012
Expected term (in years)
6.0

 
6.0

 
6.0

 
6.0

Risk-free interest rate
1.7
%
 
0.9
%
 
1.2
%
 
1.2
%
Expected volatility
59
%
 
60
%
 
60
%
 
60
%
Expected dividend rate
%
 
%
 
%
 
%

Stock-based compensation expense, net of estimated forfeitures, was included in the following line items on the Condensed Consolidated Statements of Operations (in thousands):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2013
 
2012
 
2013
 
2012
Cost of revenue
$
379

 
$
250

 
$
1,151

 
$
780

Research and development
285

 
212

 
969

 
642

Sales and marketing
302

 
199

 
859

 
550

General and administrative
358

 
272

 
1,109

 
715

Total stock-based compensation
$
1,324

 
$
933

 
$
4,088

 
$
2,687


The following table presents stock-based compensation expense, net of estimated forfeitures, by grant type (in thousands):
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2013
 
2012
 
2013
 
2012
Stock options
$
943

 
$
851

 
$
2,911

 
$
2,489

Restricted stock awards and restricted stock units (RSUs)
381

 
82

 
1,177

 
198

Total stock-based compensation
$
1,324

 
$
933

 
$
4,088

 
$
2,687


The following table presents unrecognized compensation expense, net of estimated forfeitures, related to the Company’s equity compensation plans as of September 30, 2013 , which is expected to be recognized over the following weighted-average periods, (in thousands, except for weighted-average period): 

14


 
Unrecognized
Compensation
Expense
 
Weighted-
Average Period
(in years)
Stock options
$
6,953

 
2.6
RSUs
$
4,269

 
3.1
 
The following table presents details on grants made by the Company for the following periods: 
 
Nine Months Ended
 
Nine Months Ended
 
September 30, 2013
 
September 30, 2012
 
Shares Granted
 
Weighted-
Average Grant
Date Fair Value
 
Shares Granted
 
Weighted-
Average Grant
Date Fair Value
Stock options
1,132,970

 
$
4.72

 
1,192,679

 
$
4.57

RSUs
699,000

 
$
8.97

 
274,070

 
$
6.48


The total intrinsic value of stock options exercised for the nine months ended September 30, 2013 and 2012 was $10.1 million and $6.9 million , respectively.
RSUs that vested during the nine months ended September 30, 2013 had fair values of $0.5 million as of the vesting date. No RSUs vested during nine months ended September 30, 2012.
Common Stock Warrants
As of September 30, 2013 and December 31, 2012 the Company had 912,368 outstanding warrants to purchase shares of common stock. Of these outstanding warrants, 90,000 were exercisable as of September 30, 2013 and December 31, 2012 . During the three months ended September 30, 2013, the Company modified warrants to purchase 822,368 shares of common stock held by certain customers to allow for the cashless "net exercise" of the warrants at the customers' option. The modification did not change the exercise price or any other terms of the warrants.
Common Stock  
As of September 30, 2013 and December 31, 2012 , the Company had reserved shares of common stock for issuance as follows:
 
September 30, 2013
 
December 31, 2012
Number of stock options outstanding
6,451,590

 
7,426,417

Number of RSUs outstanding
778,924

 
254,863

Shares available for future grant
5,798,815

 
5,001,956

Number of warrants outstanding
912,368

 
912,368

Total shares reserved
13,941,697

 
13,595,604

 
7. Net Loss per Share of Common Stock
The following table sets forth the computation of the Company’s basic and diluted net loss per share of common stock during the three and nine months ended September 30, 2013 and 2012 (in thousands, except for share and per share amounts):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Net loss attributable to common stockholders
$
(2,171
)
 
$
(112
)
 
$
(4,401
)
 
$
(1,258
)
Shares used in computing net loss per share of common stock, basic and diluted
45,191,514

 
43,278,588

 
44,657,529

 
42,725,466

Net loss per share of common stock, basic and diluted
$
(0.05
)
 
$
(0.00
)
 
$
(0.10
)
 
$
(0.03
)


15


The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Stock options to purchase common stock
6,451,590

 
7,763,639

 
6,451,590

 
7,763,639

RSUs
778,924

 
256,513

 
778,924

 
256,513

Common stock subject to repurchase

 
7,500

 

 
7,500

Common stock warrants
912,368

 
912,368

 
912,368

 
912,368

8. Income Taxes
Income tax expense for the nine months ended September 30, 2013 was $32,000 or 0.7% on a pre-tax loss of $4.4 million . The difference between the Company's effective tax rate and the federal statutory rate of 35% is primarily attributable to the differential in foreign taxes, non-deductible stock-based compensation expense, other currently non-deductible items and movement in its valuation allowance. The Company maintained a valuation allowance as of September 30, 2013 against all of its deferred tax assets.
 
The Company intends to maintain a full valuation allowance until sufficient positive evidence exists to support its reduction.
9. Related Party Transactions
In March 2013, the Company amended the CDP agreement that it had entered into in March 2010 with a related party and that it and the related party had amended in March 2012. Under the amended agreement, the two companies will work together to conduct research and development and other activities. Depending on the output of the research and development, the primary rightholder will be the Company or the other party. However, if the other party is not the primary rightholder, it will be able to license the developed technology from the Company. The other party’s vice chairman of the board of directors is a director of the Company and is also a managing member of a significant shareholder of the Company. As of September 30, 2013 , this shareholder was a beneficial owner of approximately 9.3% of the Company’s common stock. As of September 30, 2013 and December 31, 2012 the Company had accounts receivable in the amount of $0.1 million and $0.4 million , respectively, and had a deferred revenue balance in the amount of $0 and $0.1 million , respectively, related to the amended agreement. The following table presents related party revenue included in the Condensed Consolidated Statement of Operations from this amended agreement (in thousands): 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Related party revenue
$
1,030

 
$
1,050

 
$
3,347

 
$
3,439


In November 2006, the Company entered into an Alliance Agreement with a related party that was a beneficial owner of approximately 8.4% of the Company’s common stock as of September 30, 2013 . The other party and the Company each have an independent board member that serves on both companies’ boards of directors. Under the agreement, the two companies will work together to conduct research and development and other activities with respect to materials and high productivity combinatorial technology for use in semiconductor applications. Depending on the output of the research and development, the primary rightholder could be either company. However, the party that is not the primary rightholder will be assigned the right to use the output property. Under the agreement, the other party will pay the Company fees for services and both parties may provide royalties to the other for licensed technology sold to third parties. Since November 2006, the agreement has been amended numerous times with the last amendment signed in April 2013. As of September 30, 2013 and December 31, 2012 the Company had accounts receivable in the amount of $0.7 million and $0.6 million , respectively, and had a deferred revenue balance in the amount of $1.3 million and $0.7 million , respectively, related to the amended agreement. The following table presents related party revenue and cost of revenue included in the Condensed Consolidated Statement of Operations from the amended agreement (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Related party revenue
$
2,120

 
$
5,007

 
$
6,339

 
$
13,309

Related cost of revenue
$
1

 
$
10

 
$
1

 
$
40


16


10. Information about Geographic Areas
Revenue
Revenue by geography is based on the billing address of the customer. The following table sets forth revenue by geographic area (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
United States
$
10,172

 
$
12,889

 
$
35,016

 
$
37,288

Japan
3,694

 
3,321

 
11,501

 
10,203

APAC other
1,071

 
243

 
2,352

 
1,795

Europe and Middle East
2,811

 
36

 
2,920

 
98

Total
$
17,748

 
$
16,489

 
$
51,789

 
$
49,384


Long-Lived Assets  
Substantially all of the Company’s long-lived assets are located in the U.S. An insignificant amount of long-lived assets reside in the Company’s foreign subsidiaries and branches in Hong Kong, Japan and Taiwan.
11. Subsequent Event
On October 16, 2013, the Company and SBC&D Co. (the “Lessor”) entered into a first amendment (the "First Amendment") to the Original Lease Agreement (as defined below) for the Company's facility at 3011 N. First Street, San Jose, California.
The First Amendment amends the original lease agreement dated May 11, 2010 (“Original Lease Agreement”) between the Company and Novellus Systems, Inc. (the "Landlord"), contingent upon the Lessor acquiring title to the facility from Landlord (such date, the “Effective Date”), expected to occur in December 2013 pursuant to a purchase agreement dated October 10, 2013 between Lessor and Landlord. The Original Lease Agreement is scheduled to expire on May 31, 2015.
The amendment provides for (i) extension of the term of the lease for a period of approximately one hundred thirty-nine ( 139 ) months from the Effective Date, (ii) elimination of the early termination option contained within the Original Lease Agreement and (iii) elimination of the cap with respect to the payments the Company makes for the operating costs of the facility or Lessor’s obligation to provide certain other utilities to the facility. The First Amendment will maintain the rental rate of the Original Lease Agreement through February 2016 and will increase the monthly basic rent to $196,000 effective March 1, 2016 and automatically increase 2.5% each year thereafter through the end of the extended term of the lease. In addition, the First Amendment would provide the Company with four months of free rent and a tenant improvement allowance of $1.0 million in the aggregate in equal installments over the course of the ten months after the Effective Date to be used for the modification, refurbishment, construction or installation of improvements to the facility.


17


ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Our Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is provided in addition to the accompanying consolidated condensed financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash flows. Our MD&A is organized as follows:
Overview . Discussion of our business and overall analysis of financial and other highlights affecting the Company in order to provide context for the remainder of MD&A.
Strategy . Our overall strategy.
Basis of Presentation . A summary of the primary elements of our financial results.
Critical Accounting Estimates . Accounting estimates that we believe are most important to understanding the assumptions and judgments incorporated in our reported financial results and forecasts.
Results of Operations . An analysis of our financial results comparing the three and nine months ended September 30, 2013 to the three and nine months ended September 30, 2012 .
Liquidity and Capital Resources . An analysis of changes in our balance sheets and cash flows, and discussion of our financial condition and potential sources of liquidity.
The following discussion and analysis should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) and in our Annual Report on Form 10-K (the “2012 Form 10-K”) and subsequent quarterly reports on Form 10-Q, as filed with the Securities and Exchange Commission. This Form 10-Q contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are often identified by the use of words such as, but not limited to, “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” in Part II, Item 1A of this Form 10-Q and in our 2012 Form 10-K and subsequent quarterly reports on Form 10-Q. Furthermore, such forward-looking statements speak only as of the date of this Form 10-Q. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. 
Overview
We have pioneered a proprietary approach to accelerate research and development, innovation and time-to-market for the semiconductor and clean energy industries. Through paid collaborative development programs ("CDPs") with our customers, we develop proprietary technology and intellectual property ("IP") for our customers focused on advanced materials, processes, integration and device architectures. This technology enables our customers to bring optimized, high-volume manufacturing-ready integrated devices to market faster and with less risk than conventional approaches to research and development ("R&D"). We provide our customers with proprietary technology through various fee arrangements and grant them rights to associated IP, primarily through royalty-bearing licenses. Through paid CDPs and our own development, we have established a portfolio of greater than 1,000 patents and patent applications. Our proprietary approach is broadly applicable to high-volume integrated device markets, which include the markets for semiconductors, flat glass coatings and glass-based devices, solar cells, light-emitting diodes ("LEDs"), flat-panel displays, advanced batteries and other energy efficiency applications.
We were founded in 2004 and are headquartered in San Jose, California. Our total revenue increased to $17.7 million and $51.8 million for the three and nine months ended September 30, 2013 from $16.5 million and $49.4 million for the three and nine months ended September 30, 2012 . Our net loss increased to $2.2 million for the three months ended September 30, 2013 , from a net loss of $0.1 million for the three months ended September 30, 2012 and increased to a net loss of $4.4 million during the nine months ended September 30, 2013 from a net loss of $1.3 million during the nine months ended September 30, 2012 . Since inception, we have incurred net losses leading to an accumulated deficit of $105.7 million as of September 30, 2013 .


18

Table of Contents

Strategy
Our mission is to drive our customers' success by transforming R&D and accelerating innovation in markets that derive competitive advantage from the interaction of materials science, processes, integration and device architecture. We currently target high-volume semiconductor and high-growth emerging clean energy markets, including DRAM, stand-alone non-volatile memory, embedded memory, complex logic, flat glass coatings and glass-based devices, solar cells, LEDs, displays and energy-efficiency technologies. Within these broad markets, we target customers that have track records of technological innovation, deploy significant resources and are pursuing technical advancements that are critical to their success and strategy, including ATMI, Elpida (a wholly owned subsidiary of Micron Technology), Epistar, First Solar, GLOBALFOUNDRIES, Guardian Industries, Micron Technology, SanDisk, Taiwan Semiconductor Manufacturing Company (“TSMC”) and Toshiba. ATMI and Elpida have commenced shipping products incorporating technology developed through our CDPs and pay us licensing and royalty fees. To date, we have received the majority of our revenue from customers in DRAM, stand-alone non-volatile memory, complex logic, solar cells, and energy-efficiency applications in flat glass coatings and glass-based devices, and we have not yet received a material amount of revenue from customers in embedded memory, LEDs, displays and other energy-efficiency technologies.
Basis of Presentation
How We Generate Revenue  
Our customer engagement process generates revenue in three ways: CDP and services revenue; product revenue; and licensing and royalty revenue. CDPs are our primary engagement model with customers and are structured to result in licensing and/or royalty revenue. When we initially engage with a customer, we generate revenue from micro-CDPs, CDPs and licensing of our high productivity combinatorial (“HPC”) platform. Our micro-CDPs are smaller, customer-paid programs that require significantly less investment from our team but allow us to demonstrate the capabilities of our HPC platform to a customer without requiring a customer to commit to a multi-year agreement. We use these micro-CDPs to demonstrate the capabilities and value of our HPC platform to these new customers, with the objective of engaging with these customers in a full CDP. When technology developed through CDPs is incorporated in commercialized products, we generate licensing and/or royalty revenue. In certain cases, we sell HPC processing tools to our customers who pay a recurring license fee to operate those tools with our combinatorial processing capabilities.
CDP and services revenue -  CDP revenue may include payments for full time equivalent employees, milestone payments, subscription payments for dedicated and shared workflow tools used in the CDP and reimbursed payments for consumables and outside services from third parties. Individual CDPs typically range from one to three years. Services revenue outside of CDPs is substantially comprised of support and maintenance fees and extended warranty agreements. CDP and services revenue is recognized in a manner consistent with activities performed.
Product revenue - Product revenue consists of sales of our workflow hardware and embedded software. In support of our business strategy, we selectively sell our proprietary tools to increase opportunities for CDPs and licensing fees and royalties. As our other revenue streams increase we expect our product revenue to decrease as a percentage of our overall revenue. Product revenue has been recognized upon shipment since January 1, 2011. Product sales that originated prior to January 1, 2011 were generally recognized on a straight-line basis over the maintenance period once delivery occurred (title and risk of loss passed to the customer), and customer acceptance, if required, was achieved.
Licensing and royalty revenue - Licensing and royalty revenue consists of licensing fees and royalties for granting our customers rights to our proprietary technology and IP. Specifically, this includes licensing the HPC capabilities of our workflows, licensing our informatics and analysis software, and licensing fees and royalties on products that incorporate technology developed through our CDPs. In certain instances, minimum license fees and royalties may be guaranteed by customer contracts and are recognized as revenue ratably over the related periods. In the last three years, licensing and royalty revenue has generally been the fastest growing element of our revenue. Over the long term, we expect licensing and royalty revenue to be an increasing and significant component of our revenue.
Cost of Revenue
Our cost of revenue is variable and depends on the product mix and type of revenue earned in each period relating to our customer programs. As products are commercialized that incorporate technology developed through our CDPs, we expect our cost of revenue to decrease as a percentage of total revenue when licensing and royalty revenue become an increasing component of our revenue. As a result of our asset purchase transaction with Symyx Technologies, Inc. ("Symyx") in 2011, the amortization of acquired patents is being recorded in cost of revenue.


19

Table of Contents

Cost of CDP and services revenue - Our cost of CDP and services revenue is primarily comprised of salaries and other personnel-related expenses (including stock-based compensation) for our collaborative research and development scientists, engineers and development fab process operations employees. Additionally, our cost of revenue includes costs of wafers, targets, materials, program-related supplies, third-party professional fees and depreciation of equipment used in CDPs.
Cost of product revenue -  Our cost of product revenue primarily includes our cost of products sold and will fluctuate based on the type of product and configuration sold. Cost of product revenue has been recognized upon product shipment since January 1, 2011. For product sales that originated prior to January 1, 2011, our cost of product revenue was recognized in a similar manner as the corresponding product revenue and was generally recognized on a straight-line basis over the maintenance period. The variability in cost of product revenue as a percentage of revenue is related to the quantity and configuration of products sold during the period and the corresponding maintenance period over which product revenue and cost of product revenue is being recognized.
Cost of licensing and royalty revenue -  Our cost of licensing and royalty revenue is primarily comprised of the amortization of acquired patents and licensing obligations.
Research and Development
Our R&D expenses consist of costs incurred for development and continuous improvement of our HPC platform, expansion of software capabilities and application research and development that are not associated with customer programs. R&D costs include personnel-related expenses (including stock-based compensation expenses) for our technical staff as well as consultant costs, parts and prototypes, wafers, chemicals, supply costs, facilities costs, utilities costs related to laboratories and offices occupied by technical staff, depreciation on equipment used by technical staff, and outside services, such as machining and third-party R&D costs. Overhead costs that are not allocated to a customer program are recognized as expenses within R&D. We expect our R&D expenses will continue to increase for the foreseeable future as we continue to devote substantial internal resources to develop and improve our HPC platform and extend the applicability of our platform to a broader set of applications within the industries we serve.
Sales and Marketing
Our sales and marketing expenses consist primarily of personnel-related costs (including stock-based compensation) for our sales and marketing employees, as well as payments of commissions to our sales employees, facility costs and professional expenses. Professional expenses consist of external website and marketing communication consulting costs and market research. We expect that our sales and marketing expenses will continue to increase for the foreseeable future as we increase the number of our sales and marketing employees to support the growth in our business and as we incur increasing external marketing communication costs.
General and Administrative
General and administrative expenses consist primarily of personnel-related costs (including stock-based compensation) as well as professional services and facilities costs related to our executive, finance, legal, human resources, management information systems and information technology functions. Professional services consist of outside accounting, information technology, consulting and legal costs. We also incur significant accounting and legal costs related to compliance with rules and regulations enacted by the Securities and Exchange Commission, including the costs maintaining compliance with Section 404 of the Sarbanes-Oxley Act, as well as insurance, investor relations and other costs associated with being a public company. In addition to these expenses, we expect that our general and administrative expenses will continue to increase for the foreseeable future.
Interest Expense, net
Interest expense historically consisted of interest accrued on our note payable to Symyx in connection with the Symyx asset purchase transaction that closed in November 2011, which was paid in full in May 2013 with a line of credit from Silicon Valley Bank. Interest expense after May 2013 consists primarily of interest accrued on our line of credit with Silicon Valley Bank. Interest income represents interest earned on our cash, cash equivalents and short-term investments. We expect interest income will vary each reporting period depending on our average investment balances during the period and market interest rates.
Critical Accounting Estimates
Our consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States and include our accounts and the accounts of our wholly-owned subsidiaries. The preparation of our consolidated financial statements requires our management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosures for contingent assets and liabilities as of the date of the financial

20

Table of Contents

statements, and the reported amounts of revenue and expenses during the applicable periods. Management bases its estimates, assumptions and judgments on historical experience and on various other factors that management believed were reasonable under the circumstances. Different assumptions and judgments would change the estimates used in the preparation of our consolidated financial statements which, in turn, could change the results from those reported. Our management evaluates its estimates, assumptions and judgments on an ongoing basis.
There have been no material changes in the matters for which we make critical accounting estimates in the preparation of our condensed consolidated financial statements during the three and nine months ended September 30, 2013 as compared to those disclosed in our 2012 Form 10-K. For further information on our critical and other significant accounting policies, see our 2012 Form 10-K.
Recent Accounting Pronouncements
There are no recent accounting pronouncements that have not yet been adopted that are expected to have any impact on our financial position, results of operations or cash flows.
Results of Operations
Comparison of the Three and Nine Months Ended September 30, 2013 and 2012
 
Three Months Ended September 30,
 
 
 
 
 
Nine Months Ended September 30,
 
 
 
 
 
2013
 
2012
 
$ Change
 
% Change
 
2013
 
2012
 
$ Change
 
% Change
 
(in thousands)
 
 
 
 
 
(in thousands)
 
 
 
 
Revenue:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collaborative development program and services revenue
$
11,156

 
$
12,481

 
$
(1,325
)
 
(11
)%
 
$
34,858

 
$
35,836

 
$
(978
)
 
(3
)%
Product revenue
2,748

 
760

 
1,988

 
262
 %
 
5,852

 
3,495

 
2,357

 
67
 %
Licensing and royalty revenue
3,844

 
3,248

 
596

 
18
 %
 
11,079

 
10,053

 
1,026

 
10
 %
Total revenue
17,748

 
16,489

 
1,259

 
8
 %
 
51,789

 
49,384

 
2,405

 
5
 %
Cost of revenue:
9,064

 
7,204

 
1,860

 
26
 %
 
24,047

 
21,866

 
2,181

 
10
 %
Gross profit
8,684

 
9,285

 
(601
)
 
(6
)%
 
27,742

 
27,518

 
224

 
1
 %
Operating expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
6,107

 
5,174

 
933

 
18
 %
 
17,727

 
16,002

 
1,725

 
11
 %
Sales and marketing
1,544

 
1,322

 
222

 
17
 %
 
4,759

 
3,834

 
925

 
24
 %
General and administrative
3,008

 
2,650

 
358

 
14
 %
 
9,042

 
8,190

 
852

 
10
 %
Total operating expenses
10,659

 
9,146

 
1,513

 
17
 %
 
31,528

 
28,026

 
3,502

 
12
 %
(Loss) income from operations
(1,975
)
 
139

 
(2,114
)
 
 
 
(3,786
)
 
(508
)
 
(3,278
)
 
 
Other income (expense):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest expense, net
(168
)
 
(255
)
 
87

 
 
 
(649
)
 
(754
)
 
105

 
 
Other (expense) income, net
(2
)
 
10

 
(12
)
 
 
 
66

 
16

 
50

 
 
Total other income (expense), net
(170
)
 
(245
)
 
75

 
 
 
(583
)
 
(738
)
 
155

 
 
Loss before provision for income taxes
(2,145
)
 
(106
)
 
(2,039
)
 
 
 
(4,369
)
 
(1,246
)
 
(3,123
)
 
 
Provision for income taxes
26

 
6

 
20

 
 
 
32

 
12

 
20

 
 
Net loss
$
(2,171
)
 
$
(112
)
 
$
(2,059
)
 
 
 
$
(4,401
)
 
$
(1,258
)
 
$
(3,143
)
 
 

Revenue

Our revenue increased by $1.3 million, or 8%, to $17.7 million during the three months ended September 30, 2013 from $16.5 million during the three months ended September 30, 2012 due to increases in product revenue and licensing and royalty revenue offset by a decrease in CDP and services revenue.

Our revenue increased by $2.4 million, or 5%, to $51.8 million during the nine months ended September 30, 2013 from $49.4 million during the nine months ended September 30, 2012 due to increases in product revenue and licensing and royalty revenue offset by a decrease in CDP and services revenue.

CDP and services revenue decreased by $1.3 million, or 11%, to $11.2 million during the three months ended September 30, 2013 from $12.5 million during the three months ended September 30, 2012. This decrease was primarily

21

Table of Contents

attributable to a $5.2 million decrease in revenue due to the realignment of the CDP with GLOBALFOUNDRIES and the scheduled completion of certain other CDPs, offset with $3.1 million in revenue derived from new customer engagements, including a government service contract, and by a $0.7 million increase in revenue from the expansion of existing customer engagements. Of the growth from new customer engagements, $2.9 million in revenue was derived from three CDPs.

CDP and services revenue decreased by $1.0 million, or 3%, to $34.9 million during the nine months ended September 30, 2013 from $35.8 million during the nine months ended September 30, 2012. This decrease was primarily attributable to a $9.4 million decrease in revenue due to the realignment of the CDP with GLOBALFOUNDRIES and the scheduled completion of certain other CDPs, offset with $5.3 million in revenue derived from new customer engagements, including a government service contract, and by a $3.1 million increase in revenue from the expansion of existing customer engagements. Of the growth from new customer engagements, $5.0 million in revenue was derived from three CDPs.

Product revenue increased by $2.0 million, or 262%, to $2.7 million during the three months ended September 30, 2013 from $0.8 million during the three months ended September 30, 2012. This increase was attributable to the sale of elements of a product workflow and embedded software.

Product revenue increased by $2.4 million, or 67%, to $5.9 million during the nine months ended September 30, 2013 from $3.5 million during the nine months ended September 30, 2012. This increase was attributable to the sale of elements of product workflows and embedded software.
    
Licensing and royalty revenue increased by $0.6 million, or 18%, to $3.8 million during the three months ended September 30, 2013 from $3.2 million during the three months ended September 30, 2012. This increase was primarily attributable to an increase in minimum license fees for the sales of products subject to licensing fees and royalties as guaranteed by customer contracts offset by a scheduled reduction in minimum license fee revenues.

Licensing and royalty revenue increased by $1.0 million, or 10%, to $11.1 million during the nine months ended September 30, 2013 from $10.1 million during the nine months ended September 30, 2012. This increase was primarily attributable to an increase in minimum license fees for the sales of products subject to licensing fees and royalties as guaranteed by customer contracts offset by a scheduled reduction in minimum license fee revenues.

The following table presents revenue by geographic region (based on invoiced locations) during the three and nine months ended September 30, 2013 and 2012 in dollars (in thousands) and as a percentage of revenue for the periods presented:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
 
Revenues
 
% of Revenues
 
Revenues
 
% of Revenues
 
Revenues
 
% of Revenues
 
Revenues
 
% of Revenues
 
(in thousands)
 
 
 
(in thousands)
 
 
 
(in thousands)
 
 
 
(in thousands)
 
 
United States
$
10,172

 
57
%
 
$
12,889

 
79
%
 
$
35,016

 
67
%
 
$
37,288

 
75
%
Japan
3,694

 
21
%
 
3,321

 
20
%
 
11,501

 
22
%
 
10,203

 
21
%
APAC other
1,071

 
6
%
 
243

 
1
%
 
2,352

 
5
%
 
1,795

 
4
%
Europe and Middle East
2,811

 
16
%
 
36

 
%
 
2,920

 
6
%
 
98

 
%
Total
$
17,748

 
100
%
 
$
16,489

 
100
%
 
$
51,789

 
100
%
 
$
49,384

 
100
%

Cost of Revenue

Cost of revenue increased by $1.9 million, or 26%, to $9.1 million during the three months ended September 30, 2013 from $7.2 million during the three months ended September 30, 2012. This change is primarily attributable to a $0.9 million increase in direct product cost consistent with the increase in product revenue from the three months ended September 30, 2012, as well as an increase in CDP and services cost of revenue from new and ongoing customer engagements, which resulted in a $1.0 million increase in direct labor, materials and other costs associated with these programs.

Cost of revenue increased by $2.2 million, or 10%, to $24.0 million during the nine months ended September 30, 2013 from $21.9 million during the nine months ended September 30, 2012. This change is primarily attributable to a $1.0 million increase in direct product cost consistent with the increase in product revenue from the nine months ended September 30, 2012,

22

Table of Contents

as well as an increase in CDP and services cost of revenue from new and ongoing customer engagements, which resulted in a $1.3 million increase in direct labor, materials and other costs associated with these programs.

Gross Margin

Our gross profit as a percentage of net revenues, or gross margin, has been and will continue to be affected by a variety of factors, including the mix of CDP and services revenue, product revenue, and licensing and royalty revenue recognized during the period. We achieve a higher gross margin on licensing and royalty revenue as compared to CDP and services and product revenue.

Gross margin for the three months ended September 30, 2013 was 48.9% compared to 56.3% for the three months ended September 30, 2012. This decrease is primarily attributable to the realignment of our CDP with GLOBALFOUNDRIES and the timing of cost reductions relative to the decrease in corresponding revenue. To the extent that we are successful in growing our revenue and increasing licensing and royalty revenue as a percentage of revenue we expect our gross margins to increase as a percentage of total revenue.

Gross margin for the nine months ended September 30, 2013 was 53.6% compared to 55.7% for the nine months ended September 30, 2012. This decrease is primarily attributable to the realignment of our CDP with GLOBALFOUNDRIES and the timing of cost reductions relative to the decrease in corresponding revenue. To the extent that we are successful in growing our revenue and increasing licensing and royalty revenue as a percentage of revenue we expect our gross margins to increase as a percentage of total revenue.

Research and Development

Research and development expenses increased by $0.9 million, or 18%, to $6.1 million during the three months ended September 30, 2013 from $5.2 million during the three months ended September 30, 2012. This increase is primarily attributable to $1.0 million in higher personnel costs related to nonrecurring adjustment in employee compensation, and to a lesser extent increased headcount and higher stock-based compensation expense. Research and development expense included stock-based compensation of $0.3 million and $0.2 million during the three months ended September 30, 2013 and 2012, respectively.

Research and development expenses increased by $1.7 million, or 11%, to $17.7 million during the nine months ended September 30, 2013 from $16.0 million during the nine months ended September 30, 2012. The change is primarily attributable to $1.8 million in higher personnel costs related to nonrecurring adjustment in employee compensation, and to a lesser extent increased headcount and higher stock-based compensation expense and $0.4 million in engineering parts and other expenses associated with new application development. These costs are partially offset by a $0.5 million decrease in depreciation expense due to an asset impairment expense related to the retirement of assets previously supporting new application development during the nine months ended September 30, 2012. Research and development expense included stock-based compensation of $1.0 million and $0.6 million during the nine months ended September 30, 2013 and 2012, respectively.

Sales and Marketing

Sales and marketing expenses increased by $0.2 million, or 17%, to $1.5 million during the three months ended September 30, 2013 from $1.3 million during the three months ended September 30, 2012. The change is primarily due to higher personnel costs related to increased wages, stock-based compensation and other related benefits. Sales and marketing expense included stock-based compensation of $0.3 million and $0.2 million during the three months ended September 30, 2013 and 2012, respectively.

Sales and marketing expenses increased by $0.9 million, or 24%, to $4.8 million during the nine months ended September 30, 2013 from $3.8 million during the nine months ended September 30, 2012. The change is primarily due to higher personnel costs related to increased wages, stock-based compensation and other related benefits. Sales and marketing expense included stock-based compensation of $0.9 million and $0.6 million during the nine months ended September 30, 2013 and 2012, respectively.

General and Administrative

General and administrative expenses increased by $0.4 million, or 14%, to $3.0 million during the three months ended September 30, 2013 from $2.7 million during the three months ended September 30, 2012. This increase is primarily attributable to $0.3 million in higher personnel costs related to increased wages, stock-based compensation and other related

23

Table of Contents

benefits. General and administrative expense included stock-based compensation of $0.4 million and $0.3 million during the three months ended September 30, 2013 and 2012, respectively.

General and administrative expenses increased by $0.9 million, or 10%, to $9.0 million during the nine months ended September 30, 2013 from $8.2 million during the nine months ended September 30, 2012. This increase is primarily attributable to $1.0 million in higher personnel costs related to increased headcount, wages, stock-based compensation and other related benefits. These costs are partially offset by a $0.1 million decrease in professional fees and other administrative expenses. General and administrative expense included stock-based compensation of $1.1 million and $0.7 million during the nine months ended September 30, 2013 and 2012, respectively.

(Loss) Income from Operations

Our operating loss increased by $2.1 million, from an operating income of $0.1 million during the three months ended September 30, 2012 to an operating loss of $2.0 million during the three months ended September 30, 2013. Our operating expenses increased by $1.5 million to $10.7 million during the three months ended September 30, 2013 from $9.1 million during the three months ended September 30, 2012. We expect our operating expenses to continue to increase as we expand and invest in our business, making investments in both personnel and capital resources leading to increased depreciation expense. We are focused on our long-term plan to successfully grow our revenue, increasing licensing and royalty revenue as a percentage of our total revenue, and have expenses increase at a slower rate over time than our revenue, thereby increasing income from operations in the future.

Our operating loss increased by $3.3 million, to an operating loss of $3.8 million during the nine months ended September 30, 2013 from an operating loss of $0.5 million during the nine months ended September 30, 2012. Our operating expenses increased by $3.5 million to $31.5 million during the nine months ended September 30, 2013 from $28.0 million during the nine months ended September 30, 2012. We expect our operating expenses to continue to increase as we expand and invest in our business, making investments in both personnel and capital resources leading to increased depreciation expense. We are focused on our long-term plan to successfully grow our revenue, increasing licensing and royalty revenue as a percentage of our total revenue, and have expenses increase at a slower rate over time than our revenue, thereby increasing income from operations in the future.

Interest Expense, net

On May 31, 2013, we entered into a loan and security agreement with Silicon Valley Bank (“SVB”) and repaid the remaining principal and accrued interest under the secured promissory note that we issued to Symyx in November 2011.

Interest expense, net decreased by $0.1 million to $0.2 million during the three months ended September 30, 2013 from $0.3 million during the three months ended September 30, 2012 and is primarily comprised of interest expense associated with our credit facility with SVB for the three months ended September 30, 2013 and primarily comprised of interest expense associated with our note payable to Symyx for the three months ended September 30, 2012.

Interest expense, net decreased by $0.1 million to $0.6 million during the nine months ended September 30, 2013 from $0.8 million during the nine months ended September 30, 2012 and is primarily comprised of interest expense associated with our note payable to Symyx and to a lesser extent interest on our credit facility with SVB.

Other (Expense) Income, net

Other (expense) income, net for the three and nine months ended September 30, 2013 and 2012 consists of municipal development grant proceeds and foreign exchange gains and losses that were not significant during these periods.

Provision for Income Taxes

Provision for income taxes during the three and nine months ended September 30, 2013 and 2012 consisted of income taxes on our foreign entities and were not significant during these periods.

Net Loss

Our net loss increased by $2.1 million, to a net loss of $2.2 million during the three months ended September 30, 2013 from a net loss of $0.1 million during the three months ended September 30, 2012. The difference between operating (loss)

24

Table of Contents

income and net loss during the three months ended September 30, 2013 and 2012 was primarily related to interest expense associated with our credit facility with SVB in 2013 and note payable to Symyx in 2012.

Our net loss increased by $3.1 million, to a net loss of $4.4 million during the nine months ended September 30, 2013 from a net loss of $1.3 million during the nine months ended September 30, 2012. The difference between operating loss and net loss during the nine months ended September 30, 2013 and 2012 was primarily related to interest expense associated with our note payable to Symyx and to a lesser extent interest on our credit facility with SVB.

Liquidity and Capital Resources
Since inception, we have substantially financed our operations through private and public sale of equity securities and, to a lesser extent, cash flow from operations. As of September 30, 2013 , we had $74.5 million of cash, cash equivalents and short-term investments, $47.5 million of net working capital, and debt outstanding of $25.0 million .
On May 31, 2013, we entered into a loan and security agreement (“Loan Agreement”) with SVB pursuant to which SVB made available to us loans under a revolving line to refinance existing indebtedness (including the repayment of the Symyx note) and for working capital and general business purposes, in a principal amount of up to $26.5 million. Under the Loan Agreement, SVB funded an initial credit extension in the principal amount of $25.0 million on May 31, 2013 and agreed to fund, subject to customary conditions, additional credit extensions under the revolving line on or prior to November 30, 2013. Prior to November 30, 2013, we have the option to convert all or any part of the outstanding advances under the revolving line into a three year term loan. Our option to convert the revolving advances into a term loan can only be used once. The revolving line advances bear interest at a floating rate equal to the greater of 2.75% or the prime rate (customarily defined) minus 0.50%. The term loan would bear interest at a fixed rate equal to 3.25%.

In connection with our entry into the Loan Agreement, on May 31, 2013, we used $25.0 million of the net proceeds from the new revolving line and $1.5 million of cash to retire and repay all remaining principal and accrued interest upon the Symyx note, the balance of which was required to be repaid by November 2013. Upon repayment, the Symyx note was terminated and Symyx released all security interests and other liens held as security in connection with the note. Pursuant to the terms of the Symyx note, we were permitted to prepay the note at any time without penalty or premium. Accordingly, there were no early termination penalties or other penalties associated with the termination of the Symyx note.
We are obligated to pay interest on the revolving line credit extensions on a monthly basis and are obligated to pay all outstanding principal and unpaid interest on credit extensions under the revolving line on November 30, 2013. During the three and nine months ended September 30, 2013 , we paid SVB $176,000 and $178,000 , respectively, of interest for the amounts drawn under the Loan Agreement during such period. For any amount converted into a term loan prior to November 30, 2013, we are obligated to pay interest at the applicable rate and $0.5 million of principal on a quarterly basis. The term loan would mature three years from the first day of the month after conversion occurs, but no later than November 30, 2016, and we would be obligated to pay all outstanding principal and accrued and unpaid interest on that date. At our option, we may prepay the outstanding principal balance of the term loan in full or in part, subject to a pre-payment fee of 0.25% of the outstanding principal balance of the term loan if the term loan is outstanding for less than one year. In the event of a termination of the revolving line for any reason before November 30, 2013, including the repayment of the loan upon any prepayment, we are obligated to pay a final payment fee equal to 0.25% of the outstanding revolving advance being repaid.
To date, we have incurred significant losses. During the nine months ended September 30, 2013 and 2012, we incurred net losses of $4.4 million and $1.3 million , respectively. As of September 30, 2013 , our accumulated deficit was $105.7 million .
We believe that we have the financial resources needed to meet business requirements for the next 12 months. Our future capital requirements will depend on many factors, including our rate of revenue growth, expansion of our sales and marketing activities and overhead expenses, the timing and extent of our spending to support our R&D efforts and our ability to expand CDPs in the semiconductor and clean energy industries, whether we are successful in obtaining payments from customers, the financial stability of our customers, whether we can enter into additional collaborations in our target industries, the progress and scope of collaborative R&D projects performed by us and our customers, the effect of any acquisitions of other businesses or technologies that we may make in the future, the filing, prosecution and enforcement of patent claims, how much we need to develop or enhance our solutions or HPC platform and any necessary responses to competitive pressures. To the extent that existing cash and cash equivalents, short-term investments, and cash from operations are insufficient to fund our operations and repay our outstanding debt when it may become due, we may need to raise additional funds through public or private equity or debt financing. We may also seek to invest in or acquire complementary businesses, applications or technologies, any of which could also require us to seek additional equity or debt financing. Additional funds may not be available on terms favorable to us or at all. We maintain almost all of our cash in the United States and therefore are not subject to restrictions or tax obligations as we access the cash.

25

Table of Contents

Cash Flows
The following summary of our cash flows for the periods indicated has been derived from our condensed consolidated financial statements included elsewhere in this filing (in thousands):
 
Nine Months Ended September 30,
 
2013
 
2012
Net cash provided by operating activities
$
5,979

 
$
2,790

Net cash used in investing activities
$
(10,417
)
 
$
(6,237
)
Net cash provided by financing activities
$
421

 
$
1,160


Cash Flows from Operating Activities
We experienced positive cash flows from operating activities during the nine months ended September 30, 2013 and 2012 of $6.0 million and $2.8 million , respectively.
Net cash provided by operating activities during the nine months ended September 30, 2013 of $6.0 million reflects a net loss of $4.4 million and non-cash charges of $7.0 million for depreciation and amortization and $4.1 million for stock-based compensation. Depreciation and amortization increased by $1.1 million from the year ago period due to a larger fixed asset install base and stock-based compensation increased by $1.4 million from the year ago period due to grants of options and restricted stock. Net operating assets and liabilities cash flow decreased by $0.7 million primarily due to a $2.1 million increase in accounts receivable as a result of timing of collections and realignment of our CDP with GLOBALFOUNDRIES and an increase in inventory of $1.7 million primarily related to procurement of components of workflow elements to be used in future builds. Deferred revenue decreased by $0.4 million due to earn out of existing deferred revenue balances. Accounts payable and accrued and other liabilities contributed $3.3 million to operating cash flow due to timing of invoices. During the nine months ended September 30, 2012 we impaired $0.9 million of long-lived assets and we did not have similar impairments during the nine months ended September 30, 2013 .
Cash Flows from Investing Activities
Our investing activities consist primarily of purchases and maturities of short-term investments, capital expenditures to purchase property and equipment and our investments in intangible assets relating to our patents and trademarks. In the future, we expect we will continue to make significant capital expenditures to support our expanding operations and incur costs to protect our investment in our developed technology and IP.
During the nine months ended September 30, 2013 , cash used in investing activities was $10.4 million primarily as a result of $9.1 million in capital expenditures and $1.1 million in capitalized patent and trademark costs. We also purchased $1.0 million in certificates of deposit classified as short-term investments and had $0.8 million in certificates of deposit mature during that period.
Cash Flows from Financing Activities
To date, we have financed our operations primarily with proceeds from the sale of our redeemable convertible preferred stock and proceeds received from our initial public offering. During the nine months ended September 30, 2013 we entered into a Loan Agreement with SVB to refinance existing indebtedness under the secured promissory note that we issued to Symyx in November 2011.
During the nine months ended September 30, 2013 , cash provided by financing activities of $0.4 million was primarily related to positive cash flow related to the issuance of common stock as a result of option exercises in the amount of $1.9 million , which was offset by cash used in financing activities from refinancing our note payable to Symyx. We paid the principal of our note payable to Symyx in the amount of $26.5 million offset by the initial credit extension in the principal amount of $25.0 million from the SVB credit facility.
Contractual Obligations and Commitments
The following summarizes our contractual obligations as of September 30, 2013 (in thousands):

26

Table of Contents

 
Payments Due by Period
 
Total
 
Less Than
One Year
 
1 - 3 Years
 
3 - 5 Years
 
More Than
5 Years
 
(in thousands)
Operating lease obligations
$
2,851

 
$
416

 
$
2,435

 
$

 
$

Credit facility
25,000

 
25,000

 

 

 

Contractual interest payments on credit facility
172

 
172

 

 

 

Purchase obligations(1)
2,793

 
2,793

 

 

 

Total
$
30,816

 
$
28,381

 
$
2,435

 
$

 
$

(1) Purchase obligations consist of firm, non-cancelable agreements to purchase property and equipment and inventory related items.

Operating lease agreements represent our obligations to make payments under our non-cancelable lease agreement for our facility in San Jose, California. During the nine months ended September 30, 2013 , we made regular lease payments of $1.2 million under this operating lease agreement.
On October 16, 2013, the Company and SBC&D Co. (the “Lessor”) entered into an amendment to the original lease agreement for our facility at 3011 N. First Street, San Jose, California. The amendment provides for an extension of the term of the lease for a period of approximately one hundred thirty-nine (139) months from the effective date, which is contingent upon Lessor acquiring title to the facility. If Lessor successfully acquires title to the facility in December 2013, as expected, our additional obligations, beyond the original termination date of May 2015, under the amended lease are expected to be approximately $24.4 million.
On May 31, 2013, we entered into the Loan Agreement with SVB pursuant to which SVB made available to us loans under a revolving line to refinance existing indebtedness (including the repayment of the promissory note that we issued to Symyx in November 2011) and for working capital and general business purposes, in a principal amount of up to $26.5 million. Upon repayment, the Symyx note was terminated and Symyx released all security interests and other liens held as security in connection with the Symyx note. Under the Loan Agreement, SVB funded an initial credit extension in the principal amount of $25.0 million on May 31, 2013 and agreed to fund, subject to customary conditions, additional credit extensions under the revolving line on or prior to November 30, 2013. Prior to November 30, 2013, we have the option to convert all or any part of the outstanding advances under the revolving line into a term loan. Our option to convert the revolving advances into a term loan can only be used once. The revolving line advances bear interest at a floating rate equal to the greater of 2.75% or the prime rate (customarily defined) minus 0.50%. The term loan would bear interest at a fixed rate equal to 3.25%. As of September 30, 2013 , the revolving line bears interest at 2.75% and the amount outstanding was $25.0 million.
We are obligated to pay interest on the revolving line credit extensions on a monthly basis and are obligated to pay all outstanding principal and unpaid interest on credit extensions under the revolving line on November 30, 2013. For any amount converted into a term loan prior to November 30, 2013, we are obligated to pay interest at the applicable rate and $0.5 million of principal on a quarterly basis. The term loan would mature three years from the first day of the month after conversion occurs, but no later than November 30, 2016, and we would be obligated to pay all outstanding principal and accrued and unpaid interest on that date. At our option, we may prepay the outstanding principal balance of the term loan in full or in part, subject to a pre-payment fee of 0.25% of the outstanding principal balance of the term loan if the term loan is outstanding for less than one year. In the event of a termination of the revolving line for any reason before November 30, 2013, including the repayment of the loan upon any prepayment, we are obligated to pay a final payment fee equal to 0.25% of the outstanding revolving advance being repaid.
Off-Balance Sheet Arrangements
As of September 30, 2013 , we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which are established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
  ITEM 3.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and foreign currency exchange rates. We do not hold or issue financial instruments for trading purposes.

27

Table of Contents

Interest Rate Sensitivity
Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio and our outstanding debt obligations. Our cash, cash equivalents and short-term investment accounts as of September 30, 2013 totaled $74.5 million , consisting of $74.3 million in cash and money market funds with maturities of less than three months from the date of purchase and $0.3 million in certificates of deposit with maturities of less than twelve months from the date of purchase. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our consolidated financial condition or our results of operation.
Our exposure to market risk also relates to the increase or decrease in the amount of interest expense we must pay on any outstanding debt instruments, primarily certain borrowings under our credit facility with SVB. The revolving line advances bear interest at a floating rate equal to the greater of 2.75% or the prime rate (customarily defined) minus 0.50%. As of September 30, 2013 , the revolving line bears interest at 2.75% and the amount outstanding was $25.0 million. A hypothetical 1.00% basis point increase in the interest rate for a one year period on the amount outstanding at September 30, 2013 would result in an annual interest expense increase of approximately $250,000. Upon conversion of all or any part of the outstanding advances under the revolving line into a term loan pursuant to the Loan Agreement, the interest rate on our debt obligations with SVB would bear interest at a fixed rate equal to 3.25%. If converted, the fixed rate structure would mean that we would not have any further exposure to changes in our interest expense as a result of changes in rates. However, in the event we enter into other long-term debt arrangements, we could be subject to fluctuations in interest rates which could have a material impact on our future financial condition and results of operation. In addition, the Loan Agreement also includes several potential events of default such as payment default, material adverse change conditions and insolvency conditions that could cause interest to be charged at the rate that is otherwise applicable plus 5.0%. As of September 30, 2013 , we were in compliance with the covenants in the Loan Agreement. If we are ever unable to meet the covenants in the Loan Agreement, we could also be required to renegotiate the terms of credit under the Loan Agreement, including the interest rate, and there can be no assurance that any renegotiated terms of credit would not materially impact our earnings.
 
Foreign Currency Exchange Risk
As we expand internationally, our consolidated results of operations and cash flows will become increasingly subject to fluctuations due to changes in foreign currency exchange rates. Our revenue is denominated in U.S. dollars. Our expenses are generally denominated in the currencies in which our operations are located, which is primarily in the United States, with an insignificant portion of expenses incurred in our wholly-owned subsidiaries in Hong Kong and Japan and our wholly-owned branch in Taiwan in their local currencies. The effect of a hypothetical 10% change in foreign currency exchange rates applicable to our business would not have a material impact on our consolidated financial statements. To date, we have not entered into any material foreign currency hedging contracts although we may do so in the future.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2013 . The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of September 30, 2013 , our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations on Effectiveness of Controls

28

Table of Contents

Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost effective control system, misstatements due to error or fraud may occur and not be detected.

29

Table of Contents

PART II — OTHER INFORMATION  

ITEM 1. LEGAL PROCEEDINGS
On August 23, 2013, we received a copy of a complaint from the California Division of Labor Standards and Enforcement ("DLSE") filed by an employee in the company’s research and development group claiming that the employee is owed back pay due to an incorrect classification as an exempt employee for overtime purposes. We have commenced a review of the employee's claim as well as a review of our policies regarding classification of employees for overtime purposes. We have also agreed to enter mediation with the attorney who represents the employee that filed the claim with the DLSE as well as at least ten other employees who are similarly situated. While we are committed to reach a reasonable resolution through mediation, we believe we have meritorious defenses to the claims and intend to vigorously defend against any them in this regard. While we cannot predict the outcome of this matter, or of any legal or administrative proceedings related to this matter that have commenced or may be commenced in the future, we believe the matter will not have a material adverse effect on our business, operating results, financial condition or cash flows. Nevertheless, as of September 30, 2013, the Company accrued its best estimate of the expense associated with the matter.
From time to time, we may become involved in other legal proceedings and claims arising in the ordinary course of our business, including but not limited to legal proceedings and claims brought by employees or former employees relating to working conditions or other issues. We are not currently a party to any legal proceedings the outcome of which, if determined adversely to us, we believe would individually or in the aggregate have a material adverse effect on our business, operating results, financial condition or cash flows.
ITEM 1A.                 RISK FACTORS
We describe our business risk factors below. This description includes any material changes to and supersedes the description of the risk factors disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission on March 4, 2013 ("2012 Form 10-K") and our Quarterly Report on Form 10-Q for the second quarter of 2013. You should carefully consider the risks described below together with the other information set forth in this Form 10-Q, which could materially affect our business, financial condition or future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and operating results.
We have marked with an asterisk (*) those risks described below that reflect material substantive changes from the risks described under “Risk Factors” included in our Quarterly Report on Form 10-Q for the second quarter of 2013.
Risks Related to Our Business, Financial Condition and Results of Operations

We have a limited operating history, which makes it difficult for investors to evaluate our current business and future prospects.*

We do not have a long history of operating results on which you can base your evaluation of our business. We are still proving our business model, and we have not yet demonstrated our ability to generate significant revenue, particularly licensing and royalty revenue which represented 21% of total revenue in the nine months ended September 30, 2013 and 24%, 27% and 19% in fiscal years 2012, 2011 and 2010, respectively. As a result, it may be difficult for analysts and investors to evaluate our future prospects. If we do not generate significant licensing and royalty revenue, we may never achieve sustained profitability. Furthermore, because of our limited operating history and because the semiconductor and clean energy industries are rapidly evolving, we have limited experience in analyzing and understanding the trends that may emerge and affect our business. If we are unable to obtain significant licensing and royalty revenue from products that use or incorporate technology developed under our collaborative development programs ("CDPs"), our financial condition and results of operations would be materially and adversely affected.

Our operating results may fluctuate from quarter to quarter, which may make it difficult to predict our future performance.*

Our revenue, expenses and operating results have fluctuated, and may in the future continue to fluctuate significantly from quarter to quarter due to a number of factors, many of which are outside our control. Factors that may contribute to these fluctuations include the following, as well as other factors described elsewhere in this Form 10-Q:

our dependence on a limited number of customers;

30

Table of Contents


the length of our sales cycles for CDPs, which makes it difficult to predict the timing of new or expanded CDPs;

the length of our development cycles for CDPs, which makes it difficult to predict the timeframe in which technology developed under CDPs will be available for commercialization;

fluctuations in the volume and prices of products manufactured and sold by our customers that use or incorporate technology developed under our CDPs ("CDP Products") and that generate licensing and royalty revenue for us;

our revenue mix, which may vary from quarter to quarter as (i) we enter into new CDPs and related customer arrangements; (ii) existing CDPs, particularly for significant customers, are completed, extended, or undergo a change in scope; (iii) licensing arrangements take effect; (iv) we enter into product sale transactions and/or (v) we enter into IP sale transactions;

the highly cyclical nature of and price volatility in the semiconductor industry;

the financial stability of any of our customers;

the timing and extent to which we enter into new CDPs or complete, extend the duration, expand the scope or reduce the duration or scope of existing CDPs;

one-time offsets to revenue associated with the vesting of contingent warrants issued to two of our customers that are currently outstanding;

non-cash charges relating to stock-based compensation, amortization of intangible assets and impairment expenses related to inventory and long-lived assets;

any involvement in significant litigation, and in particular intellectual property litigation;

any payments resulting from our intellectual property indemnification policies and obligations;

any need for significant additional capital to finance our business;

any delay in shipments caused by shortages of components used or incorporated in products sold into the market, design errors, manufacturing problems, or difficulties or delays gaining required export licenses for such products;

warranty claims, product recalls and product liability for our HPC tools and for CDP Products; and

business interruptions such as earthquakes and other natural disasters.

You should not rely on quarter-to-quarter comparisons to predict our future performance. Unfavorable changes in any of these or other factors may adversely affect our business, financial condition and results of operations.

We have incurred operating losses since our inception and may not be able to achieve or maintain sustained profitability.*

We have generated net losses each year since our inception, including $4.4 million in the nine months ended September 30, 2013 , and $0.8 million, $30.0 million and $1.8 million for the fiscal years ended December 31, 2012, 2011 and 2010, respectively. Our accumulated deficit as of September 30, 2013 was $105.7 million . We will need to significantly increase revenue and operating margins (through greater licensing revenue and other mechanisms) to achieve sustained profitability, which we may not be able to accomplish.

Our ability to achieve and maintain profitability will depend, in large part, on our success in addressing the following four challenges, as well as the other risk factors in this Item 1A:

We may be unable to achieve broad customer acceptance of our HPC platform and approach as an alternative to conventional research and development activities.

31

Table of Contents


Historically, semiconductor companies have conducted R&D activities internally using conventional research methods, and they have vigorously protected the confidentiality of their R&D activities. In order for us to increase revenue, we must convince these companies that our technology and capabilities justify collaborating with us on their basic R&D programs. A significant cultural transition is required for a customer's internal R&D team to embrace us as a collaborative partner. This contributes to the long sales cycles we experience, and may require us to make significant investments in the expansion of our sales and marketing efforts. We must also convince potential customers in the clean energy industry that our HPC platform and approach are useful tools in an emerging industry. We cannot assure you we will achieve the levels of customer acceptance necessary for us to maintain and grow a profitable business. Failure to achieve the necessary customer acceptance to extend or add current or new customer relationships would adversely affect our revenue and profitability.

We may be unable to successfully collaborate with all of our customers to achieve the technological innovations sought by our customers.

Even if we achieve sufficient levels of customer acceptance of our HPC platform as an effective tool for R&D, we will not achieve significant revenue or profitability from a CDP if a project to which we have devoted technology and significant resources fails to produce any measurable success or value to our customers in the form of differentiated technology and intellectual property. CDPs are extremely complex and time-consuming to implement and costly to maintain. We rely to some degree on the efforts and resources of the customer. Differences of opinion over the implementation and management of the program may occur, which could lead to material delays and/or a failure to achieve the successful development of technology. In addition, there are a limited number of CDPs to which we can commit our resources at any given time. For a variety of reasons, including but not limited to insufficient R&D budgets of our customers or us, we may fail to achieve the technological innovations sought by our customers in a reasonable amount of time or at all. We do not know whether our customers will have sufficient resources to maintain or increase the level of investment in R&D required for a successful CDP. If a customer reduces the scope of its CDP with us, it will result in a greater concentration of risk of success being placed upon the remaining scope of our engagement, and we cannot guarantee that the remaining scope of the engagement will lead to a successful result. If a CDP does not generate sufficient revenue to recover the upfront costs and cash we invested in the CDP, this would adversely affect our results of operations.

Our customers may not be successful in commercializing products that use or incorporate technology and IP developed under our CDPs with them.

If we are successful in developing valuable technology for our customers, they still face significant challenges in commercializing products that use or incorporate such technology. The markets for products related to our engagements are intensely competitive and are characterized by rapid technological change. These changes result in frequent product introductions, short product life cycles and the necessity of continually increasing product capabilities. We cannot assure you that our customers will dedicate the resources necessary to successfully execute their business strategies for these products. Our customers are not contractually obligated to us to make or sell any CDP Products. They may not have the financial strength to cost-effectively manufacture the CDP Products at high volume and in quantities sufficient to meet demand, or the competitiveness to price, market and sell the CDP Products in intensely competitive markets. They may experience delays in shipments caused by shortages of components incorporated in the CDP Products, design errors or other manufacturing problems associated with the CDP Products. A decline in demand or average selling prices in the end markets for CDP Products could result in declining sales revenue for our customers and could adversely affect our business and results of operations. Any failure of a customer to achieve market success for CDP Products could also negatively affect such customer's willingness to work with us on other collaborations and could more generally harm our reputation and business prospects. Even if a customer is able to successfully commercialize a CDP Product, there may be a significant delay before we receive any licensing or royalty revenue due to the complexities inherent in production and manufacturing in our customers' target markets.

Existing and potential customers may be resistant to paying license and royalty fees; and we may face challenges in monitoring and enforcing royalty agreements with existing customers.

Our royalty-bearing licenses with our customers lay the framework for ongoing royalty revenue from CDP Products. Although our R&D activities under CDPs generate revenue for us, in order to achieve profitability we must be able to structure, negotiate and enforce agreements for the calculation and payment of higher-margin

32

Table of Contents

license and royalty revenue. Unless we adequately demonstrate the value of our platform to our customers and potential customers, we may face resistance to structuring royalty arrangements in the future that are acceptable to us, or our customers and our potential customers may not agree to enter into royalty-bearing licenses with us at all.

If we are able to negotiate appropriate agreements, we will need to rely on our customers to make those payments on a timely basis. Licensing and royalty revenue we may receive in the future may be based on sales of CDP Products. In order to accurately report our financial results on a timely basis, we will need to receive timely, complete and accurate information from our customers regarding their sales and resulting payments they owe us. If the information that we receive is not accurate, we may not receive the full amount of revenue to which we are entitled under these arrangements on a timely basis, which could result in adjustments to our financial results in a future period. Although we typically have audit rights with these parties, performing this type of audit could be harmful to our collaborative relationships, expensive and time-consuming and may not be sufficient to reveal any discrepancies in a timeframe consistent with our financial reporting requirements.

If a project to which we have devoted technology and significant resources fails to produce any measurable success or value to our customer in the form of differentiated technology and intellectual property that our customer can successfully commercialize, we may not earn licensing and royalty revenue sufficient to recover our upfront investment in the CDP, which could adversely affect our revenue and profitability.

In some cases, the revenue we receive from our customers during the development stage is not sufficient for us to fully recover our costs and cash invested in HPC platforms dedicated to customer engagements, and our business model relies on licensing and royalty revenue based on the sales by our customers in the end-markets of CDP Products. Our CDPs involve complex R&D, and our ability to develop the differentiated technology and intellectual property sought by our customers is inherently uncertain and difficult to predict. If a project fails to produce any measurable value to a customer, or if we are otherwise not successful in maintaining and managing a CDP, we may not receive sufficient amounts of licensing and royalty revenue to recover our upfront investment in the CDP.

We depend on a limited number of customers, and a loss of any of them, or a significant reduction in revenue from any of them, would adversely affect our business, financial condition and results of operations.*

Our customer base is highly concentrated. Revenue has historically come from a few customers, and we expect that revenue from a relatively small number of customers will continue to account for a high percentage of our revenue for the foreseeable future. Our three largest customers accounted for 44% of revenue in the nine months ended September 30, 2013 , and 67% and 64% of our revenue in the fiscal years ended December 31, 2012 and 2011, respectively. Our largest customer accounted for 18% , 28% and 29% of our revenue in each of these periods, respectively. Our concentration of customers is somewhat a reflection of the concentrated nature of manufacturers in the DRAM, flash memory and complex logic markets, and our revenue is and may continue to be heavily reliant on key high-volume customers. In addition, as with any of our customers, our profitability and success are dependent, in part, upon the receipt of licensing and royalty revenue on the sale of CDP Products by our customers, and we cannot control the timing of customer product introductions or their success or failure in the marketplace. The loss of any of these customers or a decrease or delay in the manufacturing or sales volumes of the CDP Products, or their failure to pay amounts due to us or renew or extend their existing relationships with us, and the related impact on our future anticipated licensing and royalty revenue, would materially and adversely affect our business, financial condition and results of operations, and we may not be able to replace the business from these customers.

As an example, in April 2013 our customer GLOBALFOUNDRIES, Inc. ("GLOBALFOUNDRIES") reduced the scope of its CDP with us to address its highest priority applications. Accordingly, we have experienced a reduction in the scope of R&D activities and associated CDP revenue, which has adversely affected our business, financial condition and results of operations in the most recent fiscal quarter, and may continue to do so into the future. In addition, our customer Elpida Memory, Inc. ("Elpida") filed for protection under the Corporate Reorganization Act in Japan in February 2012, and was subsequently acquired by Micron Technology, Inc. (“Micron”), a leading provider of memory chips, in July, 2013. Future filings for bankruptcy protection by existing customers or further consolidation among existing or potential customers may increase our dependence on a limited number of customers, which would subject us to additional risk for the reasons set forth above.

Our sales cycles are long, and we commit significant resources to a project before we have any commitment that a potential customer may agree to use our platform or service. One or more failures to enter into a CDP after we have devoted significant resources to a project could adversely affect our business, financial condition and results of

33

Table of Contents

operations.

Our sales efforts require us to educate our potential customers about the benefits of our solutions, which often requires significant time and expense, including a significant amount of our senior management's time and effort. Our sales cycles to date have typically ranged from 9 to 24 months and may be even longer in the future. Furthermore, we need to target those individuals within a customer's organization who have overall responsibility for the profitability of their products. These individuals tend to be senior management or executive officers. We may face difficulty identifying and establishing contact with these individuals. In addition, our customers' technology and product pipelines are highly confidential and they may choose to withhold certain information from us during the sales cycle to protect their own proprietary technology. Our ability to implement our HPC platform and methodology is heavily dependent upon the information provided to us by our customers. If our customers reveal the complexities of their specifications after we enter into a CDP with them, that complexity may cause delays unanticipated at the time we entered into the program. During our sales cycles, we incur significant expenses and, in many cases, may begin to build new systems, configure, modify, expand or customize existing systems, develop software and design workflows to meet our customers' requirements prior to obtaining contractual commitments, without any assurance of resulting revenue. Where a potential customer engagement requires a new dedicated HPC platform, we may invest in new capacity ahead of a customer commitment. Our cycles to build, configure, modify, expand or customize the HPC platform to date have ranged from three to nine months and may be even longer in the future. Investment of time and expense in a particular customer engagement that does not ultimately result in material revenue will adversely affect our revenue and other results of operations. Other factors impacting the length of our sales cycles include, but are not limited to, the following:

the limited number of customers that are appropriate sales targets for our platform and that are willing to enter into licensing agreements with us;

our ability to enter into CDPs with customers who are or will become market leaders in larger, growing market segments;

our customers' budgetary constraints and internal review procedures that must be completed to begin collaboration with us, including but not limited to those customers whose R&D expenditure and product purchasing decisions are impacted by potential delays in or cancellation of funding by governmental agencies; and

the significant cultural transition required for a customer's internal R&D team to embrace us as a collaborative partner.

Semiconductor industry technology is rapidly changing. If we are unable to anticipate trends in technology development and introduce new technologies reflecting the latest innovations, it could adversely affect our business, financial condition and results of operations.

Our customers expect us to be continuously innovative in their sectors and expect that the technology developed under our CDPs will help them develop new products that keep pace with or push the limits of technological innovation. We rely heavily on the judgment of our management and advisers to anticipate the technology trends in the semiconductor industry and we must continually devote significant engineering resources to keep up with the rapidly growing and evolving varieties of semiconductor architecture, materials, applications, processes and equipment used in semiconductor design and manufacturing. In particular, we must be prepared for the cost, technical complexity and timing of a proposed industry transition from 300mm to 450mm wafers.

These innovations are inherently complex and require long development cycles. If we are not able to accurately predict industry changes, or if we are unable to adapt our HPC platform to meet our customers' needs on a timely basis, our existing solutions will be rendered obsolete and our existing and potential customers may choose to develop their own solutions internally as an alternative to ours. If we lose customers, it could have a material adverse impact on our results of operations.

The semiconductor industry is highly cyclical, subject to significant downturns, price volatility, and other dynamics that make the industry very unpredictable. These factors can have a material adverse impact on our business both directly, and indirectly through the impact on our customers in the industry.

The semiconductor industry is highly cyclical and has been subject to significant economic downturns at various times, characterized by diminished product demand, accelerated erosion of average selling prices and production overcapacity.

34

Table of Contents

The semiconductor industry also periodically experiences increased demand and production capacity constraints. The timing and length of these cycles is extremely difficult to predict, which makes it challenging for us to forecast our operating results, make business decisions and identify risks that may affect our business, financial condition and results of operations. In addition, the semiconductor industry has historically experienced price volatility. Because the substantial majority of our revenue comes from customers in semiconductor industry, we may experience significant fluctuations in operating results due to the cyclicality and price volatility of the industry.

The industry has also been affected in recent years by uncertainty in the credit markets. For example, pressures in the DRAM sector caused financial difficulties for our customer, Elpida, before it was acquired by Micron. In addition, future uncertainty may cause sudden changes in our customers' manufacturing capacity requirements and spending, which depend in part on capacity utilization, demand for products using or incorporating our technology by consumers, inventory levels relative to demand, and access to affordable capital.

Industry consolidation (including but not limited to consolidation of semiconductor manufacturing towards foundries and large-scale manufacturers, and the subsequent concentration of research and innovation in manufacturing process development) has increased in recent years, and we may continue to see consolidation in the future. This will likely result in a smaller number of companies, but more large companies with greater financial resources - companies that may be less likely to become our customers than smaller companies with more limited R&D resources. Furthermore, if any of our existing customers is acquired, the acquiror may not continue to engage in a CDP with us or may choose to focus its product development and commercialization on technologies not covered by our CDP.

The clean energy industry in general is in a very early stage of development, and the solar industry may experience economic challenges. As a result, we may not earn significant revenue from our initiatives in this industry for an extended period.

The clean energy industry is comprised of several sectors including energy-efficient glass, solar cells, light emitting diodes ("LEDs"), flat-panel displays, advanced batteries and other energy-efficiency technologies. Most sectors of the clean energy industry are in the very early stages of development. Many of the associated technologies have not yet achieved commercial viability in comparison to available alternatives, and may never achieve widespread market adoption. Many of the associated technologies will require substantial investments of capital to achieve scale, which may not be available on attractive terms, if at all. Certain technologies may depend on government subsidies to be commercially viable, and those subsidies may not be available from federal and state governments facing increasing financial constraints. If sectors of the clean energy industry take an extended period to achieve market acceptance, and to garner significant revenue, we may not earn material revenue from our initiatives in this area until market acceptance, if ever. Furthermore, it may be difficult for us to predict which clean energy companies and which technologies may become market leaders, and we may invest time and resources in collaborations with companies who are ultimately unsuccessful in the clean energy industry, which could adversely affect our operating results.
    
The solar industry may again experience a challenging environment as it has in the recent past. The demand for solar products is also influenced by macroeconomic factors such as global economic conditions, including the ongoing debt crisis in Europe. A global economic downturn that affects the availability of financing can slow enterprise solar projects; it can also affect individual customers, who may be reluctant to assume high up-front costs and will have more difficulty getting access to capital to cover those costs. Any negative market and industry trends in the clean energy industry, including the solar industry could materially and adversely affect our existing and potential customers in the solar segment and ultimately have a negative impact on our clean energy business.

If a project to which we have devoted technology and significant resources fails to produce any measurable success or value to our customers in the form of differentiated technology and intellectual property that they may use in their products, we may not receive meaningful amounts of, or any, licensing and royalty revenue. In this case, we may not recover the upfront costs and cash invested in the CDP, which could adversely affect our results of operations. In addition, even if we successfully develop differentiated technology and intellectual property under a CDP that our customer is able to commercialize, there may be a significant delay before we receive any licensing or royalty revenue due to the complexities inherent in production and manufacturing in our target markets.

If we are unable to scale our development services to accommodate a greater volume of CDPs, our growth prospects would be limited and our business, financial condition and results could be adversely affected.
 
Our customers require a significant amount of individualized attention as well as dedicated lab space at our facilities

35

Table of Contents

for CDPs. We have limited space and internal capacity, both in terms of personnel as well as capital equipment resources, to meet these types of demands for our customers. In addition, because of the significant confidentiality concerns associated with the projects and products we work on and the restrictions on resource and information sharing we have implemented in response, we are not able to fully capitalize upon economies of scale. If the demand for our services and products exceeds our capacity to meet such demand, we may be required to turn down potential opportunities, which would cause us to lose potential revenue, and our potential customers may take their business to a competitor or decide to develop or expand internal R&D capabilities. If we are unable to scale our development services to meet demand, our growth may be hindered and our business and operating results could be adversely affected.

We may be unable to make the substantial R&D investments required to remain competitive in our business.

The semiconductor and clean energy industries require substantial investment in R&D to develop and bring to market new and enhanced technologies and products. To remain competitive, we anticipate that we will need to increase our levels of R&D expenditures to keep pace with the development efforts of our customers. We are continually working to develop and broaden our HPC platform, including our software and informatics capabilities, to address a wider range of markets and customers for multiple applications within semiconductors, flat glass, solar cells, LEDs, flat-panel displays, advanced batteries and other energy-efficiency technologies. This is an extremely complex and costly process. We expect R&D expenses to increase in absolute dollars for the foreseeable future, due to the increasing complexity and number of platforms and solutions we plan to develop both for our customers and internally, the expansion of our customer base and any associated increase in upfront R&D costs.

Although we are making progress in certain areas, we have limited expertise and experience in other fields. We may be required to invest significantly greater resources than anticipated in our R&D efforts. If we are unable to build new systems, or configure, modify, expand or customize existing systems for these applications and develop our expertise to support these fields, our business growth might be limited, and our business and results of operations could be materially and adversely affected.

Our strategy includes conducting proprietary R&D efforts in collaboration with and on behalf of multiple customers. Any failure on our part to adequately protect against potential conflicts of interest and breaches of confidentiality by us would harm our reputation and our relationships with our customers, and our business prospects and operating results would be materially and adversely affected. Moreover, some customers may hesitate to grant us access to their proprietary information, which could impair our ability to provide value for such customers.

Our strategy includes conducting proprietary R&D efforts in collaboration with and on behalf of customers who in some cases may have overlapping interests and technologies. We seek to structure our collaborative agreements and business practices to minimize any potential conflicts among customers and the possibility of any breaches of confidentiality. We may need access to some of our customers' proprietary information, and they may be reluctant to share it with us because of the risk of a potential conflict between us and/or our customers and other potential customers and the risk of a breach of confidentiality. In an effort to address these significant potential conflicts of interest and confidentiality concerns, we have implemented internal restrictions on resource and information sharing. However, we cannot ensure that our customers will perceive these measures to be adequate and effective, or that they will be, in all circumstances. Our failure to adequately and effectively address these concerns could result in our inability to attract new customers or retain existing customers, or lead to our having incomplete information with respect to existing customers that could impair our ability to fully address the customers' needs and demonstrate the value of our technology to the customers. Even though we make significant efforts to isolate each development activity from other development activities, we may fail to meet our contractual confidentiality commitments to one or more customers. Moreover, even if we meet these commitments, conflicts of interest between a customer and us, or between or among customers, could nevertheless arise. In either event, we may become involved in a dispute with our customers regarding the solutions developed during the collaboration or the rights to these solutions, including possible litigation. Disputes of this nature could harm the relationship between us and our customers, have a material adverse effect on our ability to enter into new CDPs and cause our revenue and operating results to decline significantly.

Our business strategy requires us to evaluate, integrate and develop elements of our customers' value chains, including development and manufacturing processes. Our ability to evaluate these effectively may sometimes depend on the cooperation from our customers' materials suppliers and equipment manufacturers as well as access to their data and tools. If these third parties do not cooperate with us or provide us access to the necessary data, materials, tools or equipment, we may not be able to deliver effective solutions to our customers, which would adversely affect our business and results of operations.

36

Table of Contents


We have to evaluate multiple elements of our customers' value chains to help them test and develop end products that meet their specifications, including the materials, tools and equipment used by them during the manufacturing process. Our ability to evaluate a customer's value chain effectively may sometimes depend on cooperation from such customer's materials suppliers and equipment manufacturers and on access to their data and tools. Our evaluation of the materials and equipment in the value chain must be unbiased to maintain credibility with our customers, and our evaluation sometimes results in recommendations that our customers change materials and tools providers or equipment manufacturers. Our recommendations may negatively impact our relationships with materials and tools providers and equipment manufacturers. Tensions in our relationships with these providers and manufacturers may cause these parties to limit or deny our access to their newest materials and equipment, which would in turn limit our ability to complete our development activities with our customers or control the quality of the combinatorial methods applied to our development efforts on their behalf, which would adversely affect our business and operations.

Failure of our suppliers to timely deliver sufficient quantities of the components or materials that we use in our collaborations may result in delays or other disruptions in executing our CDPs, which could adversely affect our business, financial condition and results of operations.

We have historically relied on a small number of contract manufacturing companies for the manufacture and assembly of a majority of our HPC tools. While we are not dependent on any single contract manufacturing company, key parts of our tools are currently available only from a limited number of sources. In addition, components of our capital equipment are available from only a few suppliers. If supplies from these vendors are delayed or interrupted for any reason, we may not be able to get equipment or components for our tools or our own research efforts in a timely fashion or in sufficient quantities or under acceptable terms, if at all. Even though alternative sources of supply would be available, it could be time-consuming and expensive for us to qualify new vendors and work with them to integrate our designs into the tools they manufacture for us. In addition, we depend upon our vendors to provide components of appropriate quality and reliability. Consequently, if supplies from these vendors were delayed or interrupted for any reason, it could materially and adversely affect our business.

Our future growth may present challenges to our management and administrative systems and resources, which could adversely affect our business, financial condition and results of operations.

In order to successfully expand our business we will need to continue to grow in all operational areas and to successfully integrate new employees. In particular, we expect continued growth as we expand our R&D capacity for current and additional CDPs. The expansion of our business may place a strain on our management, as well as our operational systems and facilities, which may make it difficult for us to implement our business strategy. We have experienced employment and labor claims against us by our employees in the past, and we may experience such claims in the future. For example, on August 23, 2013, we received a copy of a complaint from the California Division of Labor Standards and Enforcement filed by an employee claiming that the employee is owed back pay due to an incorrect classification as an exempt employee for overtime purposes. The addition of new employees may also increase the likelihood of employment and labor claims against us.

To effectively manage our operations and growth, we must continue to expend funds to enhance our operational, legal, financial and management controls, reporting systems and procedures, and to attract and retain sufficient numbers of talented employees. If we are unable to implement these enhancements efficiently, effectively and quickly, we will not be able to successfully grow our business as planned. Our future operating results will also depend on our management's ability to:

improve our R&D efforts;
 
improve our sales, marketing and customer support programs;

enhance our operational and financial control systems;

expand, train and manage our employee base and promptly replace departing employees with key skills; and

effectively address new issues related to our growth as they arise.

We may not manage our expansion successfully, which could materially and adversely affect our business, financial condition and results of operations.

37

Table of Contents


Acquisitions,strategic investments or joint ventures may harm our business and operating results, cause us to incur debt or assume contingent liabilities, or dilute our stockholders.

We have made and may in the future make strategic investments or acquisitions or enter into joint ventures with third parties where there is an opportunity to expand the potential applications and reach of our capabilities, including our HPC platform. Exploring and implementing any investments, acquisitions or joint ventures may place strain upon our ability to manage our future growth and may divert management attention from our core businesses. There are also other risks associated with this strategy. We cannot assure you that we will be able to make investments or acquire businesses on satisfactory terms, that any business acquired by us or in which we invest will be integrated successfully into our operations or be able to operate profitably, or that we will be able to realize any expected growth, synergies or benefits from such investments, acquisitions or joint ventures. Our relative inexperience in effecting such transactions heightens these risks. In addition, to finance any acquisitions, investments or joint ventures, we may utilize our existing funds, or might need to raise additional funds through public or private equity or debt financings. We may be unable to obtain financing to fund future acquisitions or investments on attractive terms, or at all. Additionally, equity financings may result in dilution to our stockholders. We cannot predict the number, timing or size of investments, acquisitions or joint ventures, or the effect that any such transactions might have on our operating results.

Our financial obligation to Silicon Valley Bank (“SVB”) could adversely affect our financial health and our ability to raise additional capital to fund our operations and limit our ability to react to changes in the economy or our industry.*

On May 31, 2013, we entered into a loan and security agreement (“Loan Agreement”) with SVB pursuant to which SVB made available to us loans under a revolving line to refinance existing indebtedness (including the repayment of all remaining principal and accrued interest under the secured promissory note that we issued to Symyx Technologies, Inc. in November 2011) and for working capital and general business purposes, in a principal amount of up to $26.5 million. Under the Loan Agreement, SVB funded an initial credit extension in the principal amount of $25.0 million on May 31, 2013 and agreed to fund, subject to customary conditions, additional credit extensions under the revolving line on or prior to November 30, 2013. Prior to November 30, 2013, we have the option to convert all or any part of the outstanding advances under the revolving line into a term loan. Our option to convert the revolving advances into a term loan can only be used once. The revolving line advances bear interest at a floating rate equal to the greater of 2.75% or the prime rate (customarily defined) minus 0.50%. The term loan would bear interest at a fixed rate equal to 3.25%.

We are obligated to pay interest on the revolving line credit extensions on a monthly basis and are obligated to pay the outstanding principal and unpaid interest on credit extensions under the revolving line on November 30, 2013. During the nine months ended September 30, 2013 , we paid SVB $178,000 of interest for the amounts drawn under the Loan Agreement during such period. For any amount converted into a term loan prior to November 30, 2013, we are obligated to pay interest at the applicable rate and $0.5 million of principal on a quarterly basis. The term loan would mature three years from the first day of the month after conversion occurs, but no later than November 30, 2016, and we would be obligated to pay all outstanding principal and accrued and unpaid interest on that date. At our option, we may prepay the outstanding principal balance of the term loan in full or in part, subject to a pre-payment fee of 0.25% of the outstanding principal balance of the term loan if the term loan is outstanding for less than one year. In the event of a termination of the revolving line for any reason before November 30, 2013, including the repayment of the loan upon any prepayment, we are obligated to pay a final payment fee equal to 0.25% of the outstanding revolving advance being repaid.

Our obligations to SVB will require us to dedicate a substantial portion of our cash flow from operations to payments on interest and principal, thus reducing the availability of our cash flow to fund working capital, capital expenditures, research and development efforts, execution of our business strategy and other general corporate purposes. Such limitations increase our vulnerability to adverse general economic and industry conditions and limit our flexibility in planning for, or reacting to, changes in the economy, our industry and new opportunities that may arise. In addition, we granted SVB a security interest in substantially all of our assets, excluding all intellectual property. Under the Loan Agreement, we cannot grant an interest in our intellectual property to any other person. We are also subject to certain affirmative and negative covenants under the Loan Agreement, including limitations on our ability to: undergo certain change of control events; dispose of our assets; merge or acquire other entities; create, incur, assume, guarantee or be liable with respect to indebtedness; grant liens on any assets; make any dividends in cash; and make or permit any payment on subordinated debt, in each case subject to certain exceptions. In addition, we are subject to a financial covenant under which, if our unrestricted cash, cash equivalents and other short-term investments are less than $60 million, we must maintain a ratio of our short-term assets (including cash, net accounts receivable and short-term investments) to certain liabilities (including our outstanding and owed obligations to SVB and any other liabilities

38

Table of Contents

maturing in less than one year) of 1.5:1.0. Under the Loan Agreement, subject to certain exceptions, we are also required to maintain with SVB our primary operating and other deposit accounts and securities accounts. The Loan Agreement also includes several potential events of default such as payment default, material adverse change conditions and insolvency conditions that could cause interest to be charged at the rate that is otherwise applicable plus 5.0%. Any uncured events of default may result in SVB's right to declare all outstanding obligations immediately due and payable and to exercise any other remedies permitted under the Loan Agreement. These obligations and restrictions may make it more difficult for us to borrow funds in the future to fund working capital, capital expenditures and other purposes, which could materially and adversely affect our business, financial condition and results of operations.

We may need additional capital in the future to finance our business.*

Our future capital requirements may be substantial as we continue to develop our business and expand our collaborative development efforts. Although we believe that, based on our current level of operations and anticipated growth, our existing cash, cash equivalents and marketable securities, as well as our access to capital pursuant to the Loan Agreement with SVB, will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months, we may need additional capital if our current plans and assumptions change. In particular we may be required to raise additional capital if we choose to expand our business through strategic investments or acquisitions. Our need for additional capital will depend on many factors, including our rate of revenue growth, our expansion of our sales and marketing activities and overhead expenses, the timing and extent of our spending to support our R&D efforts and our ability to expand CDPs in the semiconductor and clean energy industries, whether we are successful in obtaining anticipated levels of payments from customers, the financial stability of our customers, whether we can enter into additional collaborations in our target industries and markets, the progress and scope of collaborative R&D projects performed by us and our customers, the effect of any acquisitions of other businesses or technologies that we may make in the future, the filing, prosecution, maintenance and enforcement of patent claims, how much we need to develop or enhance our solutions or HPC platform and any necessary responses to competitive pressures.

If our capital resources are insufficient to meet our capital requirements, and our revenue is insufficient to support any of these activities, then we will have to raise additional funds. If future financings involve the issuance of equity securities, our then-existing stockholders may suffer dilution. If we raise additional future debt financing, we may be subject to restrictive covenants similar or more restrictive than those we are subject to under the Loan Agreement with SVB, which would further limit our ability to conduct our business. We may not be able to raise sufficient funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and continue to incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate R&D programs, curtail or cease operations, obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may not be able to successfully execute our business plan or continue our business.

If we lose one or more of our key personnel without obtaining adequate replacements in a timely manner, or if we are unable to retain and recruit skilled personnel, our operations could become disrupted and the growth of our business could be delayed or restricted.

Our success depends, in large part, on the continued contributions of our senior management team, in particular, the services of Mr. David Lazovsky, our President and Chief Executive Officer, and Dr. Tony Chiang, our Chief Technology Officer. If we lose the services of Mr. Lazovsky or Dr. Chiang, it could slow the execution of our business plan, hinder our development processes and impair our sales efforts, and searching for a replacement could divert our other senior management's time and increase our operating expenses. In addition, our customers could become concerned about our future strategy and operations, which could harm our reputation.

None of our senior management is bound by written employment contracts to remain with us for a specified period. The loss of any of our senior management could harm our ability to implement our business strategy and respond to the rapidly changing market conditions in which we operate. Upon hiring or promotion, new senior management personnel must spend a significant amount of time learning our technology, business model and management systems and their new roles, in addition to performing their regular duties. Accordingly, until new senior personnel become familiar with our technology, business model and systems or with their new roles, we may experience disruption to our ongoing operations. Moreover, the loss of a member of our senior management or our professional staff would require the remaining management to divert attention to seeking a replacement.


39

Table of Contents

Our future success and competitiveness depends on our ability to retain and motivate our unique team of highly skilled scientists and engineers, and to recruit and hire similarly qualified replacements for any who leave the company. These scientists and engineers have expertise across various disciplines, fields and technologies, including engineering, materials science, process development and integration, equipment, device process technologies and device integration. In addition, as we grow, we will have to continue to retain, attract and motivate qualified and talented personnel, including our scientists and engineers, management, sales and marketing and legal and finance personnel. Because our CDPs are customer-specific and project-specific and last for a significant period of time, the loss of key scientists or engineers or other personnel could have an adverse effect on a particular CDP and on our ability to deliver results to a customer in a timely manner or at all. We do not know whether we will be able to retain all of these employees or hire appropriate replacements for any who leave the company, as we continue to pursue our business strategy. Competition for personnel is intense in the semiconductor and clean energy industries.

We may encounter difficulties in hiring qualified scientists and engineers because there is a limited pool of scientists and engineers with the specialized expertise required to understand and implement our platform in conjunction with our customers. Further, we may have difficulty or delays in obtaining deemed export licenses for some scientists and engineers who we may wish to hire, in obtaining visas permitting entry for some of our employees who are foreign nationals into the United States, and in obtaining visas permitting entry into other key countries for several of our key personnel, which could disrupt our ability to strategically locate our personnel. The loss of the services of key employees or our inability to retain, attract and motivate qualified scientists and engineers could have a material adverse effect on our business, financial condition and results of operations.

If we cannot compete successfully in our industry, our results of operations and financial condition would be adversely affected.

Competition in our markets may intensify in the future, which could slow our ability to grow or execute our strategy and could lead to increased pricing pressure, negatively impacting our revenue and ability to attain and maintain profitability. Our current and potential customers may choose to develop their own methods to accelerate R&D activities, including their own combinatorial development methods internally, particularly if we are slow in developing or deploying our solutions or improving them to meet market needs. We currently face indirect competition from the internal R&D groups of our current and potential customers, particularly those of our customers who work with us to develop knowledge of combinatorial methods and who may then use our methods independently. Several of them also design, develop, manufacture and market semiconductor products based on their own solutions or other architectures and develop their own intellectual property internally. They often compete with each other and with us in various applications. Our customers are generally much larger and have significantly greater resources than us. We also face indirect competition from university collaborations, consortia and alliance partnerships. In addition, there may be other providers of high-throughput or combinatorial solutions for the design of and accelerating R&D relating to integrated devices of which we are not aware and there may be new entrants to the industry in the future, particularly if acceptance of these solutions grows. In addition, we believe that the demand for solutions that address the need for better integration between the design and manufacturing processes may encourage direct competitors to enter into our market. Other potential competitors include fabrication facilities that may decide to offer solutions competitive with ours as part of their value proposition to their customers. If these potential competitors change the pricing environment or are able to attract industry partners or customers faster than we can, we may not be able to grow and execute our strategy as quickly or at all.

A substantial portion of our revenue is derived from business arrangements with related parties, and such arrangements could create conflicts of interest that could adversely affect our business and results of operations.*

Some of our customers and other business partners hold a significant stake in our capital stock. Related party transactions disclosed in our financial statements accounted for $9.7 million ( 18.7% ) of our revenue in the nine months ended September 30, 2013 , and $21.1 million (31.6%), $21.0 million (39.0%) and $26.0 million (60.9%) of our revenue for the years ended December 31, 2012, 2011 and 2010, respectively. ATMI, which beneficially owned approximately 8.4% of our outstanding stock as of September 30, 2013 , accounted for $6.3 million ( 12.2% ) of our revenue in the nine months ended September 30, 2013 , and $16.5 million (24.7%), $15.8 million (29.3%) and $22.1 million (51.8%) of our revenue during the years ended December 31, 2012, 2011 and 2010, respectively. For more information about these transactions, see Note 9 to our condensed consolidated financial statements in this Form 10-Q.

We believe that the transactions and agreements that we have entered into with related parties are on terms that are at least as favorable as could reasonably have been obtained at such time from unrelated third parties. However, these relationships could create, or appear to create, potential conflicts of interest when our board of directors is faced with decisions

40

Table of Contents

that could have different implications for us and our related parties or their affiliates. In addition, conflicts of interest may arise between us and our related parties and their affiliates. The appearance of conflicts, even if such conflicts do not materialize, might adversely affect the public's perception of us, as well as our relationship with other companies and our ability to enter into new relationships in the future, including new CDPs with competitors of such related parties, which could have a material adverse effect on our ability to do business.

We may be subject to warranty claims, product recalls and product liability.

From time to time, we may be subject to warranty or product liability claims relating to our HPC tools that could result in unanticipated expenses as we compensate affected customers for product quality issues. Although we maintain product liability insurance, the insurance is subject to significant deductibles and there is no guarantee that coverage will be available or adequate to protect against all such claims. Alternatively, we may elect to self-insure with respect to certain matters. If an HPC tool sold to our customers is recalled, we may incur repair, return and/or replacement costs, contract damage claims from our customers and reputational harm. Costs or payments made in connection with warranty and product liability claims and product recalls could materially and adversely affect our financial condition and results of operations.

Compliance with environmental, health and safety laws and regulations could increase costs or cause us to incur substantial liabilities.

We are subject to various foreign, federal, state and local environmental laws and regulations governing, among other matters, emissions and discharges of hazardous materials into the air and water, the use, generation, storage, handling, transportation and disposal of, and exposure to, hazardous materials and wastes, remediation of contamination and employee health and safety. In addition, under certain of these environmental laws, liability can be joint and several and without regard to comparative fault. Our operations involve the use of hazardous materials and produce hazardous waste, and we could become liable for any injury or contamination that could arise due to such use or disposal of these materials. Failure to comply with environmental laws and regulations could result in the imposition of substantial civil and criminal fines and sanctions, could require operational changes or limits or the installation of costly equipment or otherwise lead to third party claims. Future environmental laws and regulations, stricter enforcement of existing laws and regulations, or the discovery of previously unknown contamination or violations of such laws and regulations could require us to incur costs or become the basis for new or increased liabilities, which could impair our operations and adversely affect our business and results of operations.

Global or regional economic, political and social conditions could adversely affect our business, financial condition and results of operations.

We operate in multiple jurisdictions throughout the world and are subject to foreign business, political and economic risks. In particular, we are subject to risks arising from adverse changes in global economic conditions. Global economic uncertainties in the key markets of many of our customers may cause our customers to delay or reduce R&D and technology purchases and investments. The impact of this on us is difficult to predict, but if businesses defer using our HPC platform or licensing our technology, require fewer CDPs or development tools, or if consumers defer purchases of new products that use or incorporate technology developed under our CDPs, our revenue could decline. A decline in revenue would have an adverse effect on our results of operations and our financial condition.

In addition, some of our largest customers are located outside of the United States, primarily in Asia, which further exposes us to foreign risks. Also, a substantial portion of the consumer products market that serves as the end-market for the products we help our customers to develop is located in Asia. As a result, our operations are subject to substantial influence by political and economic conditions. Reduced end user demand as well as disruptions to the supply chain for our customers resulting from these or other events could lead to a reduction in our revenue and an adverse impact on our financial condition. Our licensing and royalty revenue is derived from sales of products that use or incorporate technology developed under our CDPs. To the extent that sales for these products are denominated in U.S. dollars, the currency conversion and foreign exchange laws and regulations in the foreign countries in which we do business may delay or preclude us from receiving payment from our customers, which would have an adverse impact on our operations and financial condition. Additionally, to the extent that sales for these customer products are denominated in a foreign currency, an increase in the value of the U.S. dollar relative to such foreign currencies could also adversely affect our licensing and royalty revenue irrespective of the volume of such products sold, which could adversely affect our business and operating results.

We derive a significant portion of our revenue from customers in foreign countries. We expect that a significant portion of our total future revenue will continue to be derived from companies based in foreign countries. If the U.S. dollar

41

Table of Contents

increases in value relative to the currencies in any of these countries, the cost of our CDPs, which have historically been billed in U.S. dollars, will be more expensive to existing and potential customers in those countries, which could adversely affect our ability to generate new or expand existing CDPs.

We are also subject to general geopolitical risks in connection with international operations, such as political, social, and economic instability, terrorism, interference with information or communication of networks or systems, potential hostilities, changes in diplomatic and trade relationships, and disease outbreaks, and any disruptive effect these events would have on our business operations. Although to date we have not experienced any material adverse effect on our operations as a result of these types of factors, we cannot assure investors that these factors will not have a material adverse effect on our business, financial condition, and operating results or require us to modify our current business practices. Inconsistencies among, and unexpected changes in, a wide variety of foreign laws and regulatory environments with which we are not familiar, including, among other issues, with respect to employees, currency controls, foreign exchange, protection of our intellectual property, and a wide variety of operational regulations and trade and export controls under domestic, foreign, and international law may also have unexpected, adverse impacts on our operations and financial condition.

Business interruptions could delay or prevent our business activities, which could have a material adverse effect on our business, financial condition and results of operations.

Our headquarters are located in the San Francisco Bay Area near known earthquake fault zones and are vulnerable to significant damage from earthquakes. We are also vulnerable to other types of natural disasters and other events that could disrupt our operations, such as cybersecurity breaches, terrorist acts and other events that may be beyond our control. We do not carry insurance for earthquakes and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Our business can also be impacted if our customers experience business interruptions as a result of events such as the 2011 earthquake and tsunami in Japan. Any losses or damages we or our customers incur could have a material adverse effect on our cash flows and success as an overall business.

Our ability to use our net operating loss carryforwards to offset future taxable income, and our ability to use our tax credit carryforwards, may be subject to certain limitations.*


In general, a corporation that undergoes an “ownership change” under Section 382 of the Internal Revenue Code is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards (NOLs) to offset future taxable income and its ability to utilize tax credit carryforwards. During the three months ended September 30, 2013, we completed our 2012 tax return and finalized our U.S. federal NOLs in the amount of $37.5 million. In general, an “ownership change” occurs if the aggregate stock ownership of certain stockholders (generally, 5% shareholders, applying certain aggregation and look-through rules) increases by more than 50 percentage points over such stockholders' lowest percentage ownership during the testing period (generally, three years). We have not determined whether an ownership change has occurred in the past. If we have experienced an ownership change in the past, our ability to utilize NOLs and tax credit carryforwards could be limited. Furthermore, future changes in our stock ownership, such as certain stock issuances and transfers between stockholders, some of which changes are outside of our control, could result in ownership changes under Section 382 of the Internal Revenue Code. For these reasons, we may not be able to utilize a material portion of our NOLs and tax credit carryforwards, even if we attain profitability.

According to the American Taxpayer Relief Act of 2012 (HR 8) signed into law on January 3, 2013, the federal research credit, which was allowed to expire on January 1, 2012, was retroactively extended through 2013. The federal research credit for the retroactive extensions will be reflected in the 2013 tax provision.


42

Table of Contents

Specific Risks Relating to Our Intellectual Property

We may be unable to effectively protect our intellectual property, which would negatively affect our ability to compete.*

We depend on our proprietary HPC platform for our success and ability to compete. If others are able to reproduce our technology, our business will suffer significantly unless we can prevent them from competing with us. As of September 30, 2013, we owned or had exclusive licenses to 1,084 U.S. patents and patent applications (some of which also have foreign counterparts), which we believe protect our rights in our HPC platform and our rights in the technology developed under the CDPs. While we have been filing patent applications to seek protection for the further advancements of our HPC platform, patent laws provide only limited protection. Furthermore, we may not be able to sustain the high rate of patenting we maintained in the previous two years due to the expense and resource-intensiveness of the patenting process. For these and other reasons, we cannot assure you that we have sought or that we will seek patent protection of all our rights in our HPC platform and our rights in the technology developed under our CDPs in all jurisdictions. We also cannot assure you that all maintenance fees have been paid or that all filings have been made with the appropriate regulatory or governmental authorities with respect to any IP rights (including patents) registered or applied for outside of the U.S. that we purchase. In addition, patent protection in foreign countries may be limited or unavailable where we need this type of protection. A more detailed description of how we protect our IP rights (including patents) is set forth in Part I, Item 1: “Business - Intellectual Property” of our 2012 Form 10-K.

The patent positions of technology companies, including ours, are often uncertain and involve complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets or other forms of legal protection. We apply for patents covering our HPC platform and further advancements of our HPC platform as we deem appropriate. However, we may not obtain patents on all inventions for which we seek patents. Further, any patent claims we file for may be challenged during prosecution or any patent claims we are issued may be challenged after issuance. This may result in the claims being narrowed in scope or extinguished as a result of these challenges. Additional uncertainty may result from the recent passage of patent reform legislation by the United States Congress, legal precedent as handed down by the United States Federal Circuit and Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. For these reasons, among others, our existing patents and any future patents we obtain may not be sufficiently effective in preventing others from practicing our technologies or from developing similar or superior products. In that case, our revenue and operating results could decline.

Our strategy includes obtaining patent protection for technology developed in collaboration with our customers. A portion of our revenue from our customers derives from the licenses granted by us to our customers under these patents. In certain instances our ability to obtain patent protection may require customer approval. If the customer does not provide its approval, we cannot proceed with patent protection and the technology will be subject to trade secret protection only. If we are unable to obtain patent protection, we would not be able to enforce patent rights to the technologies in question.

We have developed in the past, and may develop in the future, patented technology with U.S. federal government funding. When new technologies are developed with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise “march-in” rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, U.S. government-funded technology may be subject to restrictions on transfer to foreign entities, and some U.S. government-funded data may be subject to public disclosure under the Freedom of Information Act.

Many of our customers and competitors have significant operations outside the United States. However, foreign laws may not afford us sufficient protections for our intellectual property, and we may not always seek patent protection outside the United States. We believe that our success depends, in part, upon our ability to obtain international protection for our IP rights. However, the laws and judicial systems of some foreign countries may not be as comprehensive as those of the United States and may not be sufficient to protect or enforce our proprietary rights abroad. Accordingly, our international competitors could obtain foreign patent protection for, and market overseas, products and technologies for which we are seeking patent protection in the United States, and may also be able to successfully enforce such patents in such foreign countries against us or against our customers.


43

Table of Contents

Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.

We rely in part on confidentiality and trade secret protection to protect our confidential and proprietary information and processes. However, trade secrets are difficult to protect. We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective. We require new employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual's relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that all rights in and to the inventions conceived by the individual in the course of rendering services to us shall be assigned to us. Nevertheless, employees, collaborators or consultants may still disclose or misuse our confidential information, and we may not be able to meaningfully protect such information or our trade secrets. In addition, others may independently develop substantially equivalent information or techniques or otherwise lawfully gain access to our trade secrets, and thereafter communicate this information to others without maintaining its confidentiality. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection or enforce our trade secrets could adversely affect our competitive business position.

Significant litigation over intellectual property in the industry may cause us to become involved in costly and lengthy litigation, which could subject us to liability, require us to stop licensing our developed technology or force us to develop new technology.

Whether or not patents are granted to us, litigation may be necessary to enforce our IP rights, to defend against a claim of infringement of IP rights of others or to determine the validity and scope of our proprietary rights or the proprietary rights of others. Because infringement is a fact-intensive inquiry, and because patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing (or, in some cases, are not published until they issue as patents), we cannot be certain that we do not now, and will not in the future, infringe a third party's patent rights. We may also become party to claims by our customers to IP rights developed by us in connection with a CDP. If our customers become involved in disputes with third parties over allegations that our customers' practice of our IP rights infringes the IP rights of such third parties, it may also become necessary for us to become involved in such disputes.

Any claim, even if without merit, could be time consuming to defend, result in costly litigation, or require us to enter into licensing agreements, resulting in unexpected operating costs and reduction in our operating profit. Moreover, our opponents in any litigation may have significantly more resources with which to defend against or assert claims in the litigation. A successful claim of infringement against us in connection with the use of our technologies could force us to stop using our technologies that incorporate the infringed IP; pay substantial monetary damages or royalties; grant cross-licenses to third parties relating to our own IP; obtain a license from the owner of the infringed IP, which may not be available to us on acceptable terms or at all; or re-engineer our platform or products to avoid further IP infringement, which may be technically impossible or commercially infeasible. The occurrence of any of these eventualities could adversely affect our business. Even if we are successful in defending such a claim, litigation could also divert our resources, including our managerial and engineering resources. Any infringement claim or other litigation against or by us could have a material negative effect on our business.

Our intellectual property indemnification policies and obligations may adversely impact our business and operating results.

Any assertion by a third party asserting ownership or other rights to technology developed under our CDPs could result in our customers becoming the target of litigation and we may be bound to indemnify our customers under the terms of our license agreements. These obligations could result in substantial expenses to us, which could have a material adverse effect on our business, financial condition and results of operations. In addition to the time and expense required for us to satisfy our support and indemnification obligations to our customers, any litigation could severely disrupt or shut down the business of our customers, which in turn could damage our relations with them and have a material adverse effect on our reputation, business, financial condition and results of operations.


44

Table of Contents

Risks Related to Ownership of Our Common Stock

Our stock price may be volatile, which may cause the value of our common stock to decline and subject us to securities class action litigation.

The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early stage companies have historically been particularly volatile. The stock markets in general have experienced price and volume fluctuations that have affected, and continue to affect, the market prices of equity securities of many companies. A portion of most future fluctuations in our stock price will likely be related to the risk factors described in this section. However, as is the case for many companies with volatile stock prices, price fluctuations may be disproportionate, or even unrelated, to their operating performance. In the past, many companies that have experienced volatility in the market price of their stock have become subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management's attention from other business concerns, which could seriously harm our business. Factors that could contribute to volatility in our stock price include but are not limited to the following:

fluctuations in our financial results or outlook, or those of our customers or of companies perceived to be similar to us;

changes in estimates of our financial results or recommendations by securities analysts;

changes in market valuations of similar companies;

changes in our capital structure, such as future issuances of securities or the incurring of debt;

announcements by us or our competitors of significant contracts, acquisitions or strategic alliances; and

litigation involving us, our general industry or both;

additions or departures of key personnel;

regulatory developments in the U.S., countries in Asia, and/or other foreign countries;

investors' general perception of us; and

general economic and political conditions in the US and globally, such as recessions, interest rate changes and international currency fluctuations.    

We have incurred and will continue to incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could harm our results of operations.

As a public company, we have incurred and will continue to incur significant accounting, legal and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We have incurred and will continue to incur costs associated with existing and evolving corporate governance requirements, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act, as well as rules implemented by the Securities Exchange Commission, or SEC, and the exchange on which we list our common stock. These rules and regulations have substantially increased our financial and legal compliance costs and may cause further increases in the future. These rules and regulations also make it more expensive for us to maintain director and officer liability insurance.

If we experience material weaknesses or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.

As a public company, we are required, under Section 404 of the Sarbanes-Oxley Act, to conduct a comprehensive evaluation of our disclosure controls and procedures over financial reporting. The results of this assessment need to be included in our annual report and we are required to disclose any material weaknesses identified by our management in our internal control over financial reporting, as well as an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. A material weakness is a control deficiency or combination of

45

Table of Contents

control deficiencies that results in more than a remote likelihood that a material misstatement of annual or interim
financial statements will not be prevented or detected.

We devoted significant resources to hiring personnel and compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404 for the year ended December 31, 2012. In future years, we may need to devote more resources to Section 404 compliance, and we may not be able to complete our annual evaluations, testing and any required remediations in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. Lack of effective controls could severely inhibit our ability to accurately report our financial condition or results of operations. We cannot assure you that there will not be material weaknesses and/or significant deficiencies in our internal controls in the future. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm were to issue an adverse opinion on the effectiveness of our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, which would cause the price of our common stock to decline.

The concentration of our capital stock ownership by our executive officers, directors and 5% stockholders will limit your ability to influence corporate matters.*

Our executive officers, directors, current five percent or greater stockholders and entities affiliated with them together beneficially owned approximately 70.0% of our common stock outstanding as of September 30, 2013 . Entities affiliated with Redpoint Ventures, entities affiliated with CMEA Ventures and entities affiliated with U.S. Venture Partners beneficially owned approximately 16.5% , 12.0% and 9.3% , respectively, of our common stock outstanding as of September 30, 2013 . This significant concentration of share ownership may adversely affect the trading price for our common stock because investors often perceive disadvantages in owning stock in companies with concentrated stock ownership. Also, these stockholders, acting together, will be able to influence our management and affairs and determine the outcome of matters requiring stockholder approval, including the election of directors and the approval of significant corporate transactions, such as mergers, consolidations or the sale of substantially all of our assets. Consequently, this concentration of ownership may have the effect of delaying or preventing a change of control, including a merger, consolidation or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control, even if that change of control would benefit our other stockholders.

A significant portion of our total outstanding shares may be sold into the public market at any given time, which could cause the market price of our common stock to drop significantly, even if our business is doing well.*

If our existing stockholders sell, or if the market believes our existing stockholders will sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. As of September 30, 2013 , we had 45,926,545 shares of common stock outstanding. All of these shares can be resold at any time, subject in some cases to the volume limitations and other restrictions of Rule 144 promulgated under the Securities Act of 1933, as amended, or the Securities Act, and upon the lapse of our right of repurchase with respect to any unvested shares. Certain of our officers and directors sell shares from time to time pursuant to 10b5-1 automated sales plans, and investors may react negatively to any insiders disposing of shares of our stock.

In addition, as of September 30, 2013 , the holders of 17,379,494 shares of our common stock are entitled to certain rights with respect to the registration of such shares under the Securities Act. If we register such shares of common stock, these stockholders could sell those shares in the public market without being subject to the volume and other restrictions of Rule 144.

We also registered approximately 13.0 million shares of our common stock reserved for issuance under our equity plans. These shares can be freely sold in the public market upon issuance, subject to vesting restrictions and the lock-up restrictions described above.

If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. If any of the analysts who may cover us change their recommendation regarding our stock adversely, or provide more favorable relative recommendations about our

46

Table of Contents

competitors, our stock price would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

Anti-takeover provisions contained in our certificate of incorporation and bylaws, as well as provisions of Delaware law, could impair a takeover attempt.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:

staggered board of directors;

authorizing the board to issue, without stockholder approval, preferred stock with rights senior to those of our common stock;

authorizing the board to amend our bylaws and to fill board vacancies until the next annual meeting of the stockholders;

prohibiting stockholder action by written consent;

limiting the liability of, and providing indemnification to, our directors and officers;

eliminating the ability of our stockholders to call special meetings; and

requiring advance notification of stockholder nominations and proposals.
  
Section 203 of the Delaware General Corporation Law prohibits, subject to some exceptions, “business combinations” between a Delaware corporation and an “interested stockholder,” which is generally defined as a stockholder who becomes a beneficial owner of 15% or more of a Delaware corporation's voting stock, for a three-year period following the date that the stockholder became an interested stockholder.

These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws could discourage potential takeover attempts, reduce the price that investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions.
ITEM 2.                        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS  
(a) Sales of Unregistered Securities
None.
(b) Use of Proceeds from Public Offering of Common Stock
On November 17, 2011, the Securities and Exchange Commission ("SEC") declared effective our registration statement on Form S-1 (File No. 333-175877), as amended, filed in connection with the initial public offering of our common stock. Pursuant to the registration statement, we issued and sold 5,681,796 shares of our common stock and Symyx Technologies, Inc. ("Symyx"), a wholly-owned subsidiary of Accelrys, Inc., sold 3,968,204 shares of our common stock, each at a public offering price of $10.00 per share. After deducting underwriting discounts, commissions and offering expenses paid or payable by us, our net proceeds from the offering were approximately $49.2 million.

There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on November 18, 2011 pursuant to Rule 424(b). Following the date on which the SEC declared effective the registration statement, we used a portion of the net proceeds of our initial public offering to pay Symyx $1.4 million in satisfaction of our agreement to reimburse Symyx for 50% of their underwriter discounts and commissions. In addition, in connection with an agreement for the purchase of intellectual property and the termination of our royalty obligations under an existing license agreement, we issued a promissory note to Symyx upon the consummation of our initial public offering. Between our initial public offering and May 31, 2013, we used an aggregate of $4.0 million of the net proceeds of our initial public offering to repay the principal and accrued interest on the note when due and payable in accordance with

47

Table of Contents

the terms of the note. On May 31, 2013, we repaid Symyx an aggregate of $26.5 million for all remaining principal and accrued interest on the note through the use of $1.5 million of the net proceeds of our initial public offering and $25 million of the net proceeds from our new revolving line of credit with Silicon Valley Bank. Pursuant to our loan and security agreement with Silicon Valley Bank (the “Loan Agreement”), a portion of the net proceeds of our initial public offering will be used to pay interest on the revolving line credit extensions on a monthly basis and a portion of the net proceeds of our initial public offering may be used to pay the outstanding principal and unpaid interest on credit extensions under the revolving line on November 30, 2013. During the nine months ended September 30, 2013, we paid Silicon Valley Bank $178,000 of interest for the amounts drawn under the Loan Agreement. For any amount we elect to convert into a term loan prior to November 30, 2013, a portion of the net proceeds of our initial public offering will be used to pay interest at the applicable rate and $0.5 million of principal on a quarterly basis. The term loan would mature three years from the first day of the month after conversion occurs, but no later than November 30, 2016, and we may use a portion of the net proceeds of our initial public offering to pay all outstanding principal and accrued and unpaid interest on that date. In the meantime, we invest any unused portion of the proceeds from our initial public offering in short and intermediate-term, interest-bearing obligations, investment-grade instruments, or guaranteed obligations of the U.S. government.

48

Table of Contents

ITEM 6.                 EXHIBITS
Exhibit
 
 
 
Incorporated by Reference
 
Filed
Number
 
Exhibit Description
 
Form
 
Date
 
Number
 
Herewith
2.1
 
Asset Purchase Agreement by and between Intermolecular, Inc. and Symyx Technologies, Inc. dated as of July 28, 2011 (1)
 
S-1/A
 
09/09/11
 
2.1
 
 
3.1
 
Amended and Restated Certificate of Incorporation of Intermolecular, Inc.
 
10-K
 
03/16/12
 
3.1
 
 
3.2
 
Amended and Restated Bylaws of Intermolecular, Inc.
 
10-K
 
03/16/12
 
3.2
 
 
4.1
 
Specimen Common Stock Certificate
 
S-1/A
 
11/07/11
 
4.1
 
 
4.2
 
Warrant to purchase shares of common stock issued to Timane S.a.r.l. dated June 20, 2008
 
S-1
 
07/29/11
 
4.2
 
 
4.3
 
Form of warrant to purchase shares of common stock issued to Toshiba Corporation and SanDisk Corporation dated March 15, 2010
 
S-1/A
 
10/26/11
 
4.3
 
 
4.4
 
Fourth Amended and Restated Investor Rights Agreement dated as of March 4, 2011, by and among Intermolecular, Inc. and certain stockholders named therein, as amended by Amendment No. 1 to Fourth Amended and Restated Investor Rights Agreement dated as of June 14, 2011
 
S-1
 
07/29/11
 
10.1
 
 
4.5
 
Secured Promissory Note, issued by the Company to Symyx Technologies, Inc. on November 23, 2011
 
10-K
 
03/16/12
 
4.5
 
 
10.28
 
Equipment Supply and Technology Licensing Agreement for the Dry Equipment effective September 29, 2013, by and between Ulyanovsk Center for Technology Transfer of the Russian Federation and Intermolecular Inc.
 
 
 
 
 
 
 
X
10.29
 
Equipment Supply and Technology Licensing Agreement for the Wet Equipment effective September 29, 2013, by and between Ulyanovsk Center for Technology Transfer of the Russian Federation and Intermolecular Inc.
 
 
 
 
 
 
 
X
10.30
 
Joint Development Program Agreement effective September 29, 2013, by and between Ulyanovsk Center for Technology Transfer of the Russian Federation and Intermolecular Inc.
 
 
 
 
 
 
 
X
10.31
 
First amendment to the Lease Agreement between SBC&D Co. and Intermolecular, Inc., dated as of October 16, 2013.
 
 
 
06/03/13
 
10.1
 
X
31.1
 
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
X
31.2
 
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
X
32.1
 
Certification of Chief Executive Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
X
32.2
 
Certification of Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
X
101.INS*
 
XBRL Instance Document
 
 
 
 
 
 
 
X
101.SCH*
 
XBRL Taxonomy Extension Schema Document
 
 
 
 
 
 
 
X
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
 
 
 
 
X
101.DEF*
 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
 
 
 
 
X
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
 
 
X
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
X

49

Table of Contents

(1) All exhibits, schedules and similar attachments to this exhibit have been omitted. Copies of such exhibits, schedules and similar attachments will be furnished supplementally to the SEC upon request.
† Certain portions have been omitted pursuant to a confidential treatment request. Omitted information has been filed separately with the SEC.
* Pursuant to Rule 406T of SEC Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.
 
 
 
 

50

Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
INTERMOLECULAR, INC.
 
 
(Registrant)
Date: November 7, 2013
 
By:
/s/ C. Richard Neely, Jr.
 
 
 
C. Richard Neely, Jr.

 
 
 
Chief Financial Officer

51
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



Equipment Supply and Technology  
Licensing Contract


No. US/87799546/00001
 


September, 29 th 2013
San Jose, California, United States
 
The present equipment supply and technology licensing contract (hereinafter referred to as the “Contract”) is concluded between

Limited   Liability Company Ulyanovsk Center for Technology Transfer  a Russian Federation corporation doing business at 67 Krymova St., Ulyanovsk, Russia, 432071, hereinafter referred to as the " Buyer ", on the one part,



and Intermolecular, Inc. , a Delaware, USA corporation doing business at 3011 North First St., San Jose, CA 95134, USA, hereinafter referred to as the " Seller ",

and Limited liability Company  “ Russkie Tehnoparki ” a Russian Federation corporation doing business at 1 Sirenevyi bulv., c.c. Troitsk, Moscow, Russia, 142191 hereinafter referred to as the " Customer’s Engineer ",



(the Seller and the Buyer, as well as the Project Company, as defined below, in case of transfer of the Equipment to such Company in accordance with the Contract, jointly referred to as the “Parties” and individually referred to as the “Party”)

in accordance with the Minutes of open request for proposals No. 1/У-ЭС (the open tender for the right of concluding a contract dated September 03rd, 2013) for supply of Complex R&D equipment, consisting of two Combinatorial R&D Platforms:
-      one vacuum cluster tool (AP-30) with two combinatorial PVD chambers (P-30) («Dry» equipment),
-      one combinatorial wet process tool (F-20) including one informatics server with software (S-80) («Wet» equipment),


 
concluded this Contract regarding Dry equipment as follows:

 
1.      Subject of contract
 
1.1      Seller has developed proprietary Equipment (as more fully defined in Section 1.6.10 below) and Informatics Software (as more fully defined in Section 1.6.18 below) to enable research, design, experimentation, development and commercialization in the area of and with the use of HPC Technology (as more fully defined in Section 1.6.17 below).
 
1.2      Seller is in the business of selling Equipment and licensing HPC Technology.
 
1.3      Buyer is engaged in the research, design, development and commercialization of materials, manufacturing processes, and technologies in the Field as more fully defined in Section 1.6.11 below.
 
1.4      Buyer desires to purchase from Seller and Seller desires to sell to Buyer Equipment and associated licenses to HPC Technology and Informatics Software from Seller. Customer’s Engineer exercises control for compliance by the Seller of its obligations under the Contract.
 

1 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


1.5      Annexes
 
The following annexes are hereby incorporated into the Contract:
 
1.5.1.      Pricing Sheet
 
1.5.2.      Сombinatorial R&D Platform description
 
1.5.3.      Delivery Schedule
 
1.5.4.      Payment Schedule
 
1.5.5.      Acceptance Criteria
 
1.5.6.      Seller Maintenance and Support Services
 
1.5.7.      Installation and Facility Requirements
 
1.5.8.      Documents at Sign-Off
 
1.5.9.      HPC Technology
 
1.5.10.      Acceptance completion act
 
1.5.11.      Start-up Act

 
1.6      Definitions
 
The following definitions are hereby incorporated into the Contract:

 
1.6.1.      Acceptance Criteria shall have the meaning set forth in Annex 1.5.5.
 
1.6.2.      Affiliate means a corporation, company or other entity now or hereafter, directly or indirectly, owned or controlled by, or owning or controlling, or under common control with Buyer or Seller respectively, but such corporation, company or other entity shall be deemed to be a Affiliate only so long as such ownership or control exists. For purposes of this definition "control" of a corporation, company or other entity shall mean -



 
i.      to have more than fifty percent (50%) of the voting rights or of the outstanding shares or securities representing the right to vote for either the election of the board of directors or a similar managing authority, or a supervisory board, or
 
ii.      if there do not exist outstanding shares or securities as may be the case in a partnership, joint venture or unincorporated association, to have more than fifty percent (50%) of the ownership interest representing the right to make decisions for such entity.
 
 
 
1.6.3.      Background Technology of a Party means Intellectual Property Rights and Know-How,
 
i.      that is owned, acquired, or licensed by the Party at any time during the term of this Contract; and
 
ii.      that is not created within the scope of this Contract.
 
1.6.4.      Buyer Site means Buyer’s facilities located at Ulyanovsk, Russia, or a replacement location subsequently agreed to by the Parties in writing. All special requirements for Buyer Site are specified by the Parties in Annex 1.5.7.
 
1.6.5.      THIS SECTION INTENTIONALLY LEFT BLANK.
 
1.6.6.      Confidential Information means any non-public information disclosed by one Party to the other in connection with this Contract and as further defined in Section 12.
 
1.6.7.      Contract Price is defined in Section 2.
 
1.6.8.      Dry Equipment means the Equipment.
 
1.6.9.      Effective Date means the later of the dates next to the signatures of the Parties below.
 
1.6.10.      Equipment means the equipment described in Annex 1.5.2. Equipment does not include software described in Annex 1.5.2.
 

2 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


1.6.11.      Field means the field of glass coatings, photovoltaics, power electronics and displays.
 
1.6.12.      HPC Derivatives means any and all improvements, derivatives and modifications of HPC Technology developed by either Party or both Parties as a direct result of using the Combinatorial R&D Platform pursuant to the Contract. HPC Derivatives shall not include any rights whatsoever in the Background Technology of Buyer.
 
1.6.13.      HPC-Enabled Informatics Software means Informatics Software that enables Equipment to use HPC Technology. Use of HPC-Enabled Informatics Software by Buyer requires an HPC License, in addition to a license to use the Informatics Software.
 
1.6.14.      Non-HPC-Enabled Informatics Software means Informatics Software and other software that in combination operates Equipment without enabling it to use HPC Technology.
 
1.6.15.      HPC Mode means the mode of using the Equipment which requires use of HPC-Enabled Informatics Software and an HPC License.
 
1.6.16.      HPC License means the license as set forth in Section 17.1
 
1.6.17.      HPC Technology means Intellectual Property Rights and Know-How related to techniques, methodologies, processes, test vehicles, synthetic procedures, technology, systems, or combination thereof used for the simultaneous parallel or rapid serial
 
1.       design,
 
2.       synthesis,
 
3.       processing,
 
4.       process sequencing,
 
5.       process integration,
 
6.       device integration,
 
7.       analysis, or
 
8.       characterization,
 

of two (2) more compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such as a result of using either alone or in combination the Equipment and Informatics Software.
The structure and definition of assets contained in the HPC Technology is provided in Annex 1.5.9. If any of such assets are not patented in the territory of Russian Federation, the Buyer shall under the present Contract be deemed to have only received a license to the Know-How representing such assets.
After the Seller has been granted patents, allowed in the territory of Russian Federation the Parties shall perform certain license agreements in accordance with Russian legislation providing for the rights of use of such inventions as prescribed by the present Contract.
If any information provided to Buyer by Seller is not Intellectual Property Rights or Know-How, then Buyer shall be deemed to have been granted the rights to use relevant design projects, scientific research results and documentation without a license.
The Know-How representing HPC Technology consists of methods and systems to perform combinatorial processing using Atomic Layer Deposition systems and Physical Vapor Deposition (commonly known as dry systems) and fluids based systems (commonly known as wet systems).

 
1.6.18.      Informatics Software means software in the form of machine readable, object code, and related documentation, together with any Informatics Updates, if any, that may be provided by Seller to Buyer. Informatics Software may consist of either HPC-Enabled Informatics Software or Non-HPC-Enabled Informatics Software.
 
1.6.19.      Informatics Improvements means improvements, additions, or modifications to the Informatics Software developed and released by Seller to add features, support additional Equipment or support new uses or applications of the Equipment. Seller will periodically offer Informatics Improvements for license to Buyer.
 

3 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


1.6.20.      Informatics Updates means error corrections, bug fixes or workarounds to the Informatics Software that are developed and released by Seller solely to ensure that the Informatics Software performs in accordance with the Specifications, along with any improvements to the Informatics Software that may be developed and release by Seller from time to time and which it makes available to customers at no charge. Seller shall make Informatics Updates available to Buyer at no charge. Informatics Updates do not include Informatics Improvements.
 
1.6.21.      Intellectual Property Rights means allowed and enforceable on the territory of Russian Federation Statutory Rights in and to any and all of the following -
 
i.      patents and patent applications claiming any inventions or discoveries made, developed, conceived, or reduced to practice, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof,
 
ii.      copyrights,
 
iii.      trademarks, service marks, trade names, trade dress, domain names and similar rights,
 
iv.      mask work rights, and
 
v.      Any other moral, intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction in the world.
 
1.6.22.      Know-how means any know-how, technology, trade secrets, information (including inventions eligible for statutory protection), software (including source code), circuitry, circuit designs, design descriptions, specifications, formulas, processes, process conditions, materials, material stacks, structures, architectures, specifications for the procurement of parts and drawings, whether in tangible or intangible form and all other experience, drafts, ideas, concepts and business information, rights to which objects are allowed and enforceable on the territory of the Russian Federation.
 
i.      Know-How does not include Intellectual Property Rights, however Know-How shall include without limitation copyrights or intellectual property rights (other than Intellectual Property Rights) that are not Statutory Rights.
 
1.6.23.      License Fees shall have the meaning as defined in Section 2.4.
 
1.6.24.      Pricing Sheet means the price as set forth in Annex 1.5.1
 
1.6.25.      Seller Site means Seller’s facilities located at the following address: 3011 North First Street, San Jose, CA, USA.
 
1.6.26.      Sign-Off means satisfaction and signing of the Acceptance Criteria and completion of the activities set forth in Section 4.12. Parties shall perform such activities upon satisfaction and signing of the Acceptance Criteria to confirm the transfer of title and license of rights, incl. performing of Acceptance completion act (Annex 1.5.10.) stating transfer of title.
 
1.6.27.        Specifications means  the specifications listed in Annex 1.5.2 for:
 
i.                     Equipment,
 
ii.                   Informatics Software.
 
1.6.28.        Statutory Rights means rights that come into force in the Russian Federation by (i) application to or registration with a governmental entity, and (ii) approval of such application or registration by such entity.
 
1.6.29.        Support means the maintenance and support services as described in Annex 1.5.6.
 
1.6.30.        Term shall have the meaning defined in Section 15.1.
 
1.6.31.        Third Party means a party other than Seller, Buyer, Customer’s Engineer or their Affiliates.
 
1.6.32.        THIS SECTION INTENTIONALLY LEFT BLANK.
 
1.6.33. Wet Equipment means the equipment described in Annex 1.5.2 of the Equipment Supply and Technology Licensing Contract for Wet Equipment to be signed by the Parties concurrently with this Contract.
 
1.6.34.        Dry Combinatorial R&D Platform means the Combinatorial R&D Platform referred to in the Preamble of the Contract, which comprises one or more of the following items provided such items are described in the Pricing Sheet:
 
i.                    Equipment;
 
ii.                   HPC License;
 
iii.                  Informatics Software License.
 
 
 
2. Contract price
 

4 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


2.1               Purchase of Software means license.
 
Any software provided to Buyer under this Contract is licensed, not sold, to Buyer and any reference to the “sale” or “purchase” of software shall be deemed to mean “license.”
 
2.2               Purchase
 
Subject to the terms and conditions set forth in this Contract including but not limited to the licenses set forth in Section 17 and the payments set forth in Section 2.4 and Section 2.5, and the training referenced in Section 2.8, Buyer hereby agrees to purchase the Dry Combinatorial R&D Platform from Seller and Seller hereby agrees to sell the Dry Combinatorial R&D Platform to Buyer.
 
2.3               The price of the Equipment and Services shall be in USD (United Stated Dollars), USD shall be the Contract currency. Payment currency is USD, payments shall be in USD.
 
2.4      License and Equipment Fees.
 
Buyer shall pay Seller the fees for the HPC License, the Informatics Software License and the Equipment in accordance with the Pricing Sheet. In the event Buyer does not make the payments due to Seller when due in accordance with Annex 1.5.4, Seller shall have the right but not the obligation to terminate the licenses granted to Buyer in Sections 17.1 and 17.2. Seller shall inform Buyer of such termination and no later than [***] after receiving such notice, Buyer shall cease use of the Equipment in HPC Mode.
 
2.5      Support fees
Buyer shall pay Seller the fees for the Support in accordance with the Pricing Sheet.
 
2.6               Pricing Sheet
 
The Pricing Sheet is hereby incorporated by reference into this Contract. Seller will invoice Buyer in accordance with the terms of the Pricing Sheet, Payment Schedule and the Contract. The Pricing Sheet together with this Contract shall constitute the complete agreement regarding the purchase of the Dry Combinatorial R&D Platform.
 
2.6.1.           Notwithstanding the foregoing, nothing contained in any invoice shall in any way modify the terms and conditions of this Contract, or add any additional terms or conditions.
 
2.6.2.           The Pricing Sheet shall be subject to the terms and conditions of this Contract. In the event of a conflict between the terms of the Pricing Sheet and the terms of this Contract, the terms of this Contract shall control.
 
2.7   Upon the complete satisfaction of payment to Seller by Buyer, in accordance with Section 3 and Annex 1.5.4, Buyer ownership interest in and title to the Equipment shall be free and clear of any and all encumbrances.

 
2.7.1. Except as provided in Section 17.5.1, in the event Buyer wishes to transfer ownership of the Dry Equipment to a Third Party, Buyer shall first offer the Dry Equipment for sale back to Seller at the fair market value of the Dry Equipment. Seller shall have [***] from the date of such offer to agree to purchase the Dry Equipment. If Seller does not exercise its right to purchase the Equipment within [***] from the date of the offer, Buyer is entitled to sell the Equipment to a Third Party.

 
2.7.2. In the event of a foreclosure of Buyer’s assets by a Third Party (hereinafter “Foreclosing Party”) to which Buyer’s assets have been pledged subject to a pre-existing loan agreement between Buyer and the Foreclosing Party, Seller shall not have any first right to purchase the Dry Equipment, provided that any such sale pursuant to a foreclosure shall be limited to the sale of the hardware included in the Equipment and not any software or associated licenses. The purchaser of the Dry Equipment pursuant to this Section 2.7.1. shall request such licenses from Seller. Upon receiving such request Seller shall grant such licenses to such purchaser at Seller’s then-prevailing standard prices for such licenses.
 
2.8. Training
Seller agrees to provide training to certain UCTT personnel in accordance with the terms of Section 2.1 of the JDP Agreement between UCTT and IMI to be signed concurrently herewith. Said terms of said Section 2.1 are incorporated herein by reference. For the avoidance of doubt, notwithstanding the inclusion of this Section 2.1 in this Contract and in the JDP Agreement and in any other agreement, Seller shall provide such training only once. Seller’s satisfaction of this obligation under either one of the agreements shall be deemed to satisfy Seller’s obligation under all agreements.
At the Buyer’s request the Seller will provide additional training to the personnel pointed by the Buyer under terms and conditions agreed by the Parties separately and for an additional fee based on Seller’s then prevailing standard rates for such training.

 

5 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


 

 
3.         Terms of payment
 
3.1               Payment Method  
 
All payments hereunder shall be made in U.S. dollars by Buyer and in accordance with the Payment Schedule in Annex 1.5.4.
 
3.2               Late payments
 
All payments not paid when due shall bear simple interest at a rate of [***] per month or the highest rate allowed by law, whichever is less.
 
3.3               Taxes
 
3.3.1 Seller shall be responsible for the payment of the [***]related to the sale [***]that is owed within the [***].
3.3.2 Except as provided in Section 3.3.1, payments due to Seller are exclusive of all present and future taxes, duties, levies and other charges by any name (including any interest, penalties or additions thereto) imposed by any foreign, federal, state, local or other taxing authorities (including, without limitation, export, sales, use, excise and value-added taxes) on or with respect to the transactions or payments under this Contract.
 
3.4               Records; Inspection
 
3.4.1.           Buyer shall keep complete, true and accurate books of account and records on its own behalf for the purpose of determining the amounts payable under this Contract. Such books and records shall be kept at Buyer for at least [***] following the end of the calendar quarter to which they pertain.
 
3.4.2.           Such records will be open for inspection during such [***] period by an independent auditor reasonably acceptable to Buyer, solely for the purpose of verifying amounts payable to Seller hereunder. Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice.
 
3.4.3.           Inspections conducted under this Section 3.4 shall be at the expense of Seller, unless a variation or error producing an increase exceeding [***]percent ([***]%) of the amounts payable for any period covered by the inspection is established and confirmed in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by Buyer. Each Party agrees to hold in confidence pursuant to Section 8 all information concerning payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for that Party to reveal such information in order to enforce its rights under this Contract or if disclosure is required by law.
 
4.         Terms and Conditions of Equipment Supply
 
4.1               Seller will install the Equipment for Sign-Off at the Seller Site. The Acceptance Criteria shall be applied in accordance with Section 4.12.
 
4.2. Upon Sign-Off, the Dry Equipment shall remain installed at the Seller Site for a period of [***] (“Period”). Upon the expiration of the Period, and no later than [***] days thereafter, Seller will prepare the Dry Equipment for shipment to the Buyer Site. Buyer will, at its own expense, arrange for the shipment of the Dry Equipment to Buyer Site. Seller will take measures for the safety and integrity of the Equipment while the Equipment is at the Seller Site (which measures shall be similar to the measures Seller takes for the safety and integrity of its own equipment) and shall be responsible for packaging of the Equipment in accordance with Section 4.10.
 
4.3  In the event Buyer has not shipped the Equipment to Buyer Site within [***] days after the end of the Period (“Extended Period”), Buyer shall pay Seller [***] as a storage charge for Seller having stored the Equipment for each additional month beyond the Extended Period that Buyer has not shipped the Equipment, Such payments shall be due and payable to Seller [***] days after expiration of each such additional month.
 
4.4               Delivery of the Dry Equipment shall be deemed to have occurred upon Sign-Off. During the period that the Dry Equipment remains at Seller Site in accordance with Section 4.2, the Dry Equipment should be clearly marked as the sole property of Buyer while it is at Seller's facility, and Seller will not grant any third party any right, title or interest (such as a chattel mortgage or security interest) in or to any of the Equipment while it is located at Seller's facility.
 
4.5               Buyer, and not Seller, shall be solely responsible for (i) the shipment and transportation of Equipment from Seller Site to Russia, (ii) for receiving the Equipment, (iii) for ensuring that the Equipment clears customs and (iv) for insuring the Equipment against any risks during any of the foregoing.
Seller agrees to furnish Buyer with such documentation and information about the Equipment, as Buyer may reasonably request, in order to comply with Russian customs and import requirements, for entry of the equipment into Russia.
 

6 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


4.6               Seller will unpack, install, start-up and adjust the Equipment at Buyer Site in accordance with the Delivery Schedule in Annex 1.5.3.
 
Buyer shall have no more than [***] from the date of installation (“Review Period”) at Buyer Site to inspect the Equipment for conformity with the Specifications. If, during such Review Period, Buyer reasonably determines that the Equipment is not in conformity with the Specifications, Buyer’s sole remedy and Seller’s sole obligation will be to re-install the Equipment to ensure such conformity.


 
Upon expiration of the Review Period and provided that the Equipment conforms with the Specifications and all deficiencies revealed during the Review Period have been rectified by the Seller to the Buyer’s satisfaction, the Seller, the Buyer and the Customer’s Engineer will execute the Start-up Act in the form attached hereto as Annex 1.5.11.

 
4.7               Seller will act in an agency capacity and assist Buyer in obtaining insurance for the Dry Equipment during the period when the Dry Equipment is located at Seller Site. Such insurance shall be for the full value of the Dry Equipment.
 
4.8               Buyer is solely responsible for and, in accordance with Annex 1.5.7, shall prepare the Buyer Site for installation of the Dry Combinatorial R&D Platform and shall ensure that all necessary infrastructure specified in Annex 1.5.7 is available.
 
4.9. Notwithstanding anything to the contrary in the Contract, title and risk of loss in the Equipment will transfer to Buyer upon Sign-Off at the Seller Site in accordance with Section 4.12. Seller will provide Buyer with a bill of sale confirming the transfer of title from Seller to Buyer.
 
4.10            For shipment, the Equipment will be packaged in double bags and vacuum-sealed, put in wooden crates. Due to the sensitive nature of components, the Equipment requires shipment by air.

 
4.11            Seller will unpack the Equipment at the Buyer Site.
 
4.12 The Sign-Off shall include the examination of the installation of the Equipment and also examination of presence of necessary documents (Operation manual, certificates as described in Annex 1.5.8) in accordance with the Acceptance Criteria. Such examination shall be conducted jointly by the Acceptance Commission which is defined as one representative of the Seller, the Buyer and the Customer’s Engineer. Upon successful examination and confirmation that the Acceptance Criteria are met, the Seller, the Buyer and the Customer’s Engineer shall execute the Acceptance completion act in the form attached hereto as Annex 1.5.10.
 
 
 
5.         Technical documentation
 
The technical documents (operation manual as listed in Annex 1.5.8, spare parts catalogue) will be delivered with the equipment in form of a CD in Russian/English. The costs of translation to Russian language are included in the total Contract Price.
 
The following documents will be delivered with the equipment when it ships:
 
     International Consignment Note
 
     Proforma Invoice with translation into Russian
 
     Packing List
 
     Export Declaration
 
     Certificate of Origin
 
 
 
6.         Packing, packaging and labeling
 
6.1               The cost of [***] and [***] is included in the Contract Price.
 
6.2               The casing and packaging shall become the Buyer’s property, once the Equipment has been supplied.
 
6.3               Packaging of the Equipment shall secure its absolute safety during the transport. The Seller shall be liable to the Buyer and shall be obliged to reimburse any losses that arose because of spoilage, damage or breakage of the goods entailed by undue or low quality packaging.
 
6.4               There shall be labeling in English and in Russian on each separate package of the Equipment and it shall contain the following information:
 

7 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


6.4.1.           •The Seller’s name and address;
 
6.4.2.           • The Buyer’s name and address;
 
6.4.3.           • The final delivery address;
 
6.4.4.           • Contract Number;
 
6.4.5.           • Number of the package lot, in accordance with the packing list;
 
6.4.6.           • Gross and net weight;
 
6.4.7.           • Packaging dimensions;
 
6.4.8.           • Name of the equipment;
 
6.4.9.           • Special requirements (if any).
 
7.         Acceptance And Support Services
 
7.1               Dry Combinatorial R&D Platform Assembly
 
Seller shall complete the assembly and configuration of the Dry Combinatorial R&D Platform and make it available for Buyer’s Sign-Off at the Seller Site provided during the process of assembly and configuration, Buyer cooperates with Seller as reasonably requested by Seller.
 
7.2               Buyer Acceptance
 
7.2.1.           Upon completion of assembly and configuration of the Dry Combinatorial R&D Platform, Seller will provide Buyer with a written notice that the Dry Combinatorial R&D Platform is available for Sign-Off.
 
7.2.2.           Seller shall demonstrate to Buyer that the Dry Combinatorial R&D Platform satisfies the acceptance criteria set forth in Annex 1.5.5 (“Acceptance Criteria”) and allow Buyer to conduct tests to ensure compliance with the Acceptance Criteria.
 
7.2.3.           This demonstration and testing shall take place at the Seller Site (Buyer agrees to attend at its own expense) and shall commence no later than [***] days following the written notice from Seller to Buyer.
 
7.2.4.           Upon completion of said demonstration and testing, Buyer will either (i) confirm in writing that acceptance of the Dry Combinatorial R&D Platform has occurred in compliance with Section 4.12, and Buyer shall make the payment associated therewith as set forth in the Pricing Sheet (“Buyer Acceptance”), [***].
 
7.3               Support
 
Subject to the terms and conditions set forth in this Contract including but not limited to the licenses set forth in Section 17 and the payments set forth in Sections 2.4 and 2.5, Seller agrees to provide Support to the Buyer. Any support or services other than the Support, including services not covered by a warranty or pursuant to pre-paid maintenance, will be provided at Seller’s then-current rates (plus reasonable travel expenses and other out-of-pocket expenses, if any) pursuant to a statement of work signed by the Parties.
 
8.         Warranty; Limitation of Liability
 
8.1               By Seller
 
Seller represents and warrants that:
 
8.1.1.           It has the right and authority to enter into this Contract, and to fully perform its obligations hereunder; and
 
8.1.2.           This Contract is a legal and valid obligation binding upon it and enforceable in accordance with its terms.
 
8.1.3. The title to the Dry Equipment conveyed to Buyer by Seller shall be good, and the Dry Equipment shall be delivered free from any security interest or other lien or encumbrance to any Third Party.
 
8.1.4. The Dry Equipment is fit for the purpose of performing combinatorial processing.
 
8.1.5. That as of the Effective Date, to the best of the Seller’s knowledge, the Dry Equipment and Buyer’s ownership, use and possession of the Dry Equipment in the manner as instructed by and in accordance with the documentation and manuals provide herewith and appended as Annex 1.5.7 and 1.5.8 does not infringe any patent, copyright, trademark or trade secret rights of a Third Party issued prior to the Effective Date.
 
8.1.6 The Dry Equipment, the HPC License and the Informatics Software License provided by the Seller to the Buyer hereunder are altogether sufficient for the use of the Equipment in the HPC Mode in the Field.
 
8.1.7. The Seller has obtained all necessary licenses, permissions and authorizations required for the export of the Equipment and the provision of the HPC-License and Informatics Software License to the Buyer or the Project Company, as well as for providing Training on the Equipment to the personnel of the Buyer or the Project Company (as the case may be).

 

8 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


8.2               By Buyer
 
Buyer represents and warrants that:
 
8.2.1.           It has the right and authority to enter into this Contract, and to fully perform its obligations hereunder; and
 
8.2.2.           This Contract is a legal and valid obligation binding upon it and enforceable in accordance with its terms.
 
8.3               Warranty on the hardware included in the Equipment
 
Seller warrants to Buyer that for a period of [***] (“Warranty Period”) from Sign-Off, the hardware comprising the Equipment (“Hardware”) will be free from defects in materials and workmanship and shall conform in all material respects to its specifications.
 
If, during the Warranty Period, the Hardware does not meet the warranty specified above, Seller shall, at its option, repair or replace at no cost to Buyer any defective or nonconforming component of the Hardware in accordance with Annex 1.5.6. The foregoing represents Buyer’s sole remedy for breach of the warranty on the Hardware.
 
The warranty set forth in this section shall apply only to the Seller supplied components of the Hardware and will specifically excludes consumables and any components to be provided by Buyer.
 
8.4               Warranty on the software included in the Equipment
 
Seller will warrant to Buyer that for a period of [***] (“Warranty Period”) from Sign Off, the software included in the Equipment (“Software”) will conform in all material aspects to its specifications.
 
Seller will correct any nonconformities reported to Seller in writing or in electronic form during the Warranty Period in accordance with Annex 1.5.6. The foregoing represents Buyer’s sole remedy for breach of the warranty for the Software.
 
8.5               Exclusions
 
The warranties and remedies set forth in Sections 8.3 and 8.4 will be void as to the following:
 
8.5.1.           any Hardware or Software that has been damaged, modified, or altered (other than by Seller or approved by Seller)
 
8.5.2.           any Hardware or Software that has been subjected to physical, electrical or other environmental abuse or misuse, including improper storage or conditions not in accordance with Seller’s specifications,
 
8.5.3.           any damage or non-conformities, in whole or in part, arising from use of the Hardware or Software with any other hardware, software, firmware, devices, or other products not provided by Seller or chemicals not recommended or approved for use by Seller.
 
8.6               Disclaimer
 
Except as provided above for the Hardware and the Software,   Seller does not otherwise warrant the Equipment and does not warrant that operation of the Equipment will be uninterrupted or error free.
 
Seller specifically disclaims any representation, warranty or guarantee that the use of the Hardware or Software, will be successful, in whole or in part. It is understood that the failure of Buyer to successfully develop or commercialize technology shall not constitute a breach of any representation or warranty or other obligation under this Contract.
 
Except as otherwise expressly set forth above, seller makes no representations and extends no warranties or conditions of any kind, either express or implied with respect to any information disclosed hereunder, any activities conducted hereunder or any deliverables provided hereunder, and hereby expressly disclaim any warranties of merchantability, or fitness for a particular purpose or validity of any technology, patented or unpatented, or non-infringement of the intellectual property rights of third parties.
 
9.         Limitation of Liability
 
9.1               To the maximum extent permitted by applicable law, and except for any breach of any confidentiality obligation under this contract, in no event shall either party or its affiliates be liable to the other party, its affiliates or to any third party claiming through or under the other party hereto, for any lost profits, lost revenue, loss of data, equipment downtime or for any special, consequential, indirect or incidental damages, however caused and under any theory of liability (including contract, strict liability, negligence or other legal or equitable theory) arising in any way out of this contract, whether or not such party has been advised of the possibility of such damages.
 
9.2               Except for a breach of a confidentiality obligation, in no event shall either party’s cumulative liability to the other under this contract exceed the amounts received by such party from the other party in the past [***] preceding the claim.
 

9 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


9.2.1. The limitation of liability described above in Section 9.2 does not apply to any loss or damage to the Dry Equipment that is solely attributable to and solely caused by the gross negligence or willful act of the Seller or Seller’s personnel. For the avoidance of doubt, if Buyer or Buyer personnel are jointly or severally responsible for such loss or damage, then Seller’s liability for such loss or damage that is attributable to Seller shall be subject to the limitation of liability described above in Section 9.2.
 
9.3               The Parties acknowledge and agree that the foregoing limitations of liability are an essential element of this agreement and that in their absence the terms of this agreement would be substantially different.  
 
10.      Force Majeure
 
Neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses (except for payment obligations then owing) on account of failure of performance by the defaulting Party if the failure is occasioned by war, strike, fire, act of God, earthquake, flood, lockout, embargo, act of terrorism, governmental acts or orders, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing Party and such Party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance.
 
 
 
11.      Dispute Resolution
 
11.1            All disputes between the Parties in connection with or arising out of this Contract shall first be discussed in good faith between the Parties in order to try to find an amicable solution.
 
11.2            If no solution can be found to settle the dispute, then such dispute shall be finally settled by arbitration in accordance with the default rules and procedures of American Arbitration Association (“AAA”) sitting in New York City, NY, USA and conducted in English.
 
11.3            Within 30 days of notice that a Party wants to submit a dispute to arbitration, the Parties shall each select one independent arbitrator and will attempt to mutually agree upon a third independent arbitrator. Each arbitrator will have expertise in the thin film technology industry and will not be an employee, affiliate or contractor for either Party.
 
11.4            If the Parties are unable to agree on the third arbitrator within fifteen (15) days, the two arbitrators shall select the third arbitrator within thirty (30) days.
 
11.5            If the amount in dispute is less than [***], then the Parties shall agree upon a single arbitrator meeting the above conditions within thirty (30) days of the notice of arbitration or such arbitrator shall be chosen by AAA if the Parties cannot agree.
 
11.6            The arbitrators shall determine what discovery will be permitted consistent with the goal of limiting the costs and time for such a proceeding. The Parties and arbitrators shall use all reasonable efforts to complete any arbitration subject to this Section within six (6) months from the selection of arbitrators.
 
11.7            The Parties agree that any award of damages shall not include punitive, special, consequential, or indirect damages except as specifically allowed in this Contract and shall comply with the limitation of liability provisions set forth herein.
 
11.8            The arbitrators’ decision shall be in a detailed writing setting forth the reasons for their decision and shall be provided concurrently to each Party.
 
11.9            The arbitration award shall be final and binding on the Parties.
 
11.10        Unless otherwise agreed to by the Parties, each Party shall pay one-half of the arbitration fees and expenses and shall bear all of its own expenses in connection with the arbitration.
 
11.11        Notwithstanding any of the foregoing, either Party shall have the right to seek, at its own cost and expenses, preliminary and temporary injunctive relief pending resolution of the dispute via arbitration.
 
11.12        The United Nations Convention on the International Sale of Goods applies unless otherwise expressly stated in this Contract.
 
12.      Confidential Information
 
12.1            The Parties acknowledge that they may receive information from the other Party which may be considered confidential and proprietary. The receiving Party agrees to avoid any un-authorized disclosure, dissemination, or use of such information that, if disclosed in writing, is identified and marked as confidential (or with words of similar meaning) at the time of its disclosure (or that, if disclosed verbally, is designated as confidential at the time of disclosure and is summarized and identified as confidential in a writing delivered to the receiving Party within thirty (30) days after the disclosure) or that are observed during a visit of the manufacturing facilities of one of the Parties and such information would appear to a reasonable person as confidential information ("Confidential Information"). Both parties agree that this Contract is the Confidential Information of both Parties.
 

10 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


12.2            The receiving Party will use the Confidential Information solely for the purpose of performing its rights and obligations under the Contract. For the avoidance of doubt, if Buyer transfers the Dry Equipment to Project Company in accordance with Section 17.5.1, Buyer shall have the right to transfer Confidential Information to Project Company, provided that upon the completion of such transfer Buyer shall no longer have any rights to use such Confidential Information.
 
12.3            The receiving Party will not disclose Confidential Information to a Third Party without the prior written consent of the disclosing Party. The receiving Party will protect such information from un-authorized disclosure, use or dissemination with at least the same degree of care as the receiving Party exercises to protect its own information of similar type and importance, but in no event less than reasonable care. Notwithstanding the foregoing, the receiving Party may disclose the Confidential Information to its authorized representatives (e.g. directors, employees, officers, professional advisors and agents) having a need to know and who have signed confidentiality agreements or are otherwise bound by confidentiality obligations at least as restrictive as those contained herein.
 
12.4            The obligations of confidentiality and protection required by this Section will survive the expiration, termination, or cancellation of this Contract for a period of five years thereafter.
 
12.5            The obligation of confidentiality will not apply, or will cease to apply, to any information that: (a) was known to the receiving Party prior to its receipt of Confidential Information under this Contract; (b) is or becomes publicly available without breach of this Contract by the receiving Party; (c) is received from a Third Party without an obligation of confidentiality to the disclosing Party; or (d) is developed independently by employees of the receiving Party not having access to such information.
 
12.6            Notwithstanding anything to the contrary in this Section 8, each Party shall be permitted to lawfully disclose Confidential Information of the other Party to any governmental agency to the extent such disclosure is required by law (including but not limited to the SEC, USPTO, and pursuant to a subpoena); provided, however that before making such disclosure, the Party about to make such disclosure shall seek the highest level of protection available and give the other Party an adequate opportunity to interpose an objection or take action to assure confidential handling of such information.
 
13.      Miscellaneous
 
13.1            Amendment
 
No change or modification in the terms hereof, in a manner not expressly provided in this Contract shall be binding unless reduced to writing and duly executed by the Parties in the same manner as the execution of this Contract. Any attempt to so change or modify the terms of this Contract shall be considered void and of no effect.
 
13.2            No Implied License
 
Only the licenses granted pursuant to the express terms of this Contract shall be of any legal force or effect. No other license rights shall be created by implication, estoppel or otherwise. Each Party reserves all rights not expressly granted to the other Party under this Contract.
 
13.3            Assignment
 
13.3.1.        Neither Party shall assign or transfer this Contract either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other Party.
 
13.3.2.        Any attempt to assign without such consent shall be void and of no effect.
 
13.3.3.        Notwithstanding the foregoing, either Party may assign this Contract with the prior written consent of the other Party (which consent will not be unreasonably withheld), to an Affiliate and the terms of the Contract shall continue in effect without modification after such assignment.
 
13.4            Drafting
 
In interpreting and applying the terms and provisions of this Contract, the Parties acknowledge that its lawyers reviewed and participated in the drafting and agree that no presumption shall exist or be implied against the Party that drafted such terms and provisions.
 
13.5             Governing Law
 
This Contract shall be governed by and construed in accordance with the laws of the State of California in the United States, without regard to its conflicts of law principles.

 
13.6            Venue
 
All disputes between the Parties in connection to this Contract shall be addressed in accordance with Section 11. If no solution can be found to settle the dispute, then the dispute will be submitted to a court of competent jurisdiction in the county of Santa Clara, CA, USA.
 
13.7            Independent Contractors  
 

11 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


The relationship of the Parties is that of independent contractors. Neither Party shall be deemed to be an agent, partner, joint venturer or legal representative of the other for any purpose as a result of this Contract or the transactions contemplated thereby. Personnel supplied by either Party are not the other Party's employees or agents and such supplying Party assumes responsibility for their acts or omissions, The supplying Party shall be solely responsible for the payment of compensation of such Party's employees or agents assigned to perform services hereunder and such employees or agents shall be informed that they are not entitled to any employee benefits of the other Party. Neither Party shall be responsible for paying worker's compensation, disability benefits, and unemployment insurance or for withholding and paying employment taxes for any employee or agent of the other Party.
 
13.8            Notices
 
13.8.1.        Unless otherwise agreed to by the Parties, the communications required or permitted to be given or made under this Contract shall be made in writing, via personal delivery, registered mail, facsimile transmission (with written confirmation copy by registered first-class mail), addressed to the appropriate Party at the address indicated below and a copy to the receiving Party’s legal department.
 
13.8.2.        All communications made pursuant to this section shall be deemed made or given on the date of such personal delivery, mailing or transmission.
 
13.8.3.        If to Buyer:
Ulyanovsk Center for Technology Transfer
67 Krymova St.,
Ulyanovsk,
Russia, 432071
 
 
 
13.8.4.        With a copy to:
 
 Limited liability Company “Russkie Tehnoparki” 
1 Sirenevyi bulv., c.c. Troitsk, Moscow,
Russia, 142191

 
13.8.5.        If to Seller:
 
Intermolecular Inc.
 
3011 North First St.
 
San Jose
 
CA 95134
 
 
 
13.8.6.        With a copy to:
 
Intermolecular Inc.
 
Attention: General Counsel
 
3011 North First St.
 
San Jose
 
CA 95134
 
 
 
 
 
13.8.7.        The Parties may change the name and address to which communications should be sent under this section by providing prior written notice to the other Party.
 
13.9            Captions
 
The captions to the several sections hereof are not part of this Contract, but are included merely for convenience of reference and shall not affect its meaning or interpretation. As used in this Contract, the word "including" means "including without limitation”.
 
13.10        Counterparts
 
This Contract may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.
 
13.11        Signatures by Electronic Mail or Facsimile
 
The delivery by electronic mail or facsimile of the signatures of the Parties shall be deemed valid and binding as if they were originally made.
 

12 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


13.12        Copies
 
A scanned or photocopied version of this Contract shall be deemed to be an original and shall have the full force and effect of an original document.
 
13.13        Non-waiver
 
The failure of either Party at any instance to require performance of any provision hereof by the other Party shall not be deemed a waiver and thereafter shall not deprive that Party of its full right to require such performance of that provision at another instance. Any waiver must be in writing executed by the waiving Party.
 
13.14        Severability
 
If any term, provision, covenant or condition of this Contract is held by a court of competent jurisdiction to be illegal, invalid, void or unenforceable, the remainder of the terms, provisions, covenants or conditions shall remain in full force and effect and shall in no way be affected, impaired or invalidated. The Contract shall continue in full force and effect to the fullest extent permitted by law without said provision or with said provision being modified and narrowly tailored to achieve the original intent of the Parties.
 
13.15        Third Party Beneficiaries
 
Except as expressly provided in this Contract, there are no third party beneficiaries expressly or impliedly intended under this Contract.
 
13.16        Integration
 
This Contract, together with all Annexes hereto, constitutes the entire agreement and understanding of the Parties relating to the subject matter hereof and supersedes all prior negotiations and understandings between the Parties, both oral and written, regarding such subject matter.
 
13.17        Representation by Legal Counsel
 
Each Party hereto represents that it has been represented by legal counsel in connection with this Contract and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Contract, the Parties agree that no presumption shall exist or be implied against the Party that drafted such terms and provisions.
 
13.18. Governing Language

 
This Contract has been executed by the parties in counterpart originals, one in the English language and one in the Russian language. Notwithstanding the foregoing, the parties agree that in the event of controversy between the parties regarding the interpretation or application of the terms of this Contract, the English language version of the Contract will be controlling. All communications and notices to be made or given pursuant to this Contract shall be in the English language.
 
14.      Addresses and Banking Details of the Parties
 
14.1            Seller
 
14.1.1.        All payments due to Seller under this Contract shall be made by bank wire transfer as follows:
 
 
 
Domestic Wire Instructions:
 
Route all wires via FEDWIRE to the following ABA number
 
To: [***]
 
Routing and Transit #: [***]
 
For Credit of: Intermolecular, Inc.
 
Credit Account Number: [***]
 
By Order of: [name of sender]International Wire Instructions:
Instruct the paying financial institution to advise their US correspondent to pay as follows:
Pay to: [***]Routing & Transit:[***]Swift Code: [***]For Credit of: Intermolecular, Inc. [***]Final Credit Account#:[***]By Order of: [Name of Sender]

 
15.      Term and Termination
 
15.1            Term
 
This Contract shall be effective as of the Effective Date. The term of this Contract shall commence on the Effective Date, and, unless terminated earlier as provided in this Section15.1, shall continue in full force and effect until the termination of all HPC Licenses and HPC-Enabled Informatics Software Licenses granted under this Contract (the "Term").     
 

13 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


15.2            Termination for Breach
 
Either Party may terminate this Contract if the other Party has materially breached or defaulted in the performance of any of its material obligations, and such default has continued for ninety (90) calendar days after written notice was provided to the breaching Party by the non-breaching Party.
 
Termination will be effective at the end of the ninety (90) day period unless the breach has been cured before the expiration of the ninety (90) day period.
 
15.3            Effect of Termination
 
15.3.1.        Accrued Rights and Obligations
 
Termination of this Contract for any reason shall not release either Party from any liability or obligation that, at the time of termination, has already accrued to the other Party or that is attributable to a period prior to termination, nor shall it preclude either Party from pursuing any rights and remedies it may have at law or in equity with respect to any breach of this Contract.  
 
15.3.2.        Termination of Licenses
 
All licenses granted under the Contract (including the HPC Licenses and HPC-Enabled Informatics Software Licenses) shall terminate upon termination of the Contract. For the avoidance of doubt, upon termination, Buyer shall have no right to use the Dry Combinatorial R&D Platform in HPC Mode. However, Buyer shall continue to have the right to use the Dry Combinatorial R&D Platform in non-HPC Mode.
 
 
 
15.4            Survival
 
Sections 1, 2, 4, 7, 8, 9, 10, 11, 12 and 13 shall survive the expiration or termination of this Contract for any reason.  
 
16.      Ownership OF Intellectual Property Rights and Know-How
 
16.1            HPC Technology
 
16.1.1.        Seller shall own all right, title, and interest in and to the HPC Technology and HPC Derivatives.
 
16.1.2.        Buyer hereby agrees to assign to Seller, all of Buyer’s right, title and interest in and to any HPC Technology and PC Technology and HPC Derivatives that are developed during the term of this Contract.  
 
16.1.3.        All Intellectual Property Rights and Know-How rights arising out of the sole activities of Buyer’s personnel conducted for Buyer’s customers or for Buyer’s internal development programs with the use of Dry Combinatorial R&D Platform  shall be owned by Buyer. 
 
16.1.4.        All Intellectual Property Rights and Know-How rights arising out of the sole activities of Seller’s personnel conducted for Seller’s customers or for Seller’s internal development programs with the use of Dry Combinatorial R&D Platform  shall be owned by Seller. 
 
16.1.5.        All Intellectual Property Rights and Know-How rights arising out of the joint activities of Seller’s personnel and Buyer’s personnel with the use of Dry Combinatorial R&D Platform  shall be jointly owned by Buyer and Seller. 
 
 
 
17.      LICENSES
 
17.1            HPC License
 
Subject to the terms and conditions of this Contract including the payments in Sections 2.4 and 2.5, Seller hereby grants to Buyer a non-exclusive, non-transferable, license, under Seller’s rights in HPC Technology (without the right to sublicense) to use the Equipment solely for the purpose of developing and commercializing materials in the Field.  
 
17.2            License Grant for Informatics Software
 
17.2.1.        Subject to the terms and conditions of this Contract including the payments in Sections 2.4 and 2.5, Seller hereby grants to Buyer a non-exclusive, non-transferable, license, under Seller’s rights in Informatics Software (without the right to sublicense) to use the HPC-Enabled Informatics Software with the Equipment. The aforementioned license (hereinafter “HPC-Enabled Informatics Software License”) shall only be for the sole purpose of developing and commercializing materials and products incorporating such materials, both in the Field.
 
17.2.2.        Buyer shall have no right to use HPC Technology under this Contract unless it purchases HPC-Enabled Informatics Software and purchases an HPC License.
 

14 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


17.2.3.        Further, Buyer’s license to use HPC Technology shall only be for operation of the Equipment for which it has purchased HPC-Enabled Informatics Software, and only for the license term for such software and the HPC License.
 
17.3            Term of License
 
The term of the HPC License and the Informatics Software license granted by Seller to Buyer shall be for a period of [***] starting from Sign-Off. Subject to Buyer’s payment of the renewal fees in accordance with the payment terms of this Contract (including Annex 1.5.6), the term of the HPC License shall automatically renew for the [***]for which the [***].
 
17.4            Limited scope of license for use of Third Parties
 
The scope of the HPC License and the Informatics Software license granted by Seller to Buyer hereunder does not include the right to use the Dry Combinatorial R&D Platform on behalf of or for the benefit of Third Parties, except where the intended purpose of such activities is the qualification or sale by Buyer or one or more of its partners of a resulting materials and products incorporating such materials, both in the Field.
 
17.5            No Transfer to or use by Third Party of Equipment in HPC Mode
 
Except as stated in Section 17.5.1 below, Buyer agrees not to sell, lease, or otherwise dispose of (“ Transfer ”) the Equipment sold hereunder, or allow access to any Third Party to use the Equipment in HPC Mode (“ Access ”) without explicit written approval by Seller, which Seller may grant in its sole discretion and subject to Seller entering into a license agreement, if necessary under the circumstances, with such Third Party. Buyer can Transfer the Equipment for [***] and agrees to inform any such Third Party purchaser that the Equipment cannot be used to perform HPC Technology without appropriate licenses from Seller.
 
17.5.1. Buyer shall have the right to Transfer the Equipment sold hereunder to [***] a company [***] and hereinafter referred to as Project Company provided Project Company, in addition to Buyer, agrees to assume all of Buyer’s obligations related to the Equipment except for the obligation to pay for the Equipment, and provided, pursuant to such Transfer, Buyer no longer has any rights in such Equipment. For the avoidance of doubt, at no time shall both Buyer and Project Company have simultaneous ownership, use or possession of the Equipment. In the event of such transfer,
 
(i) Project Company shall, [***] acquire Buyer’s rights (including all associated licenses) to use the Equipment in HPC Mode and to use HPC-Enabled Informatics Software and HPC Technology granted to Buyer by Seller under this Contract;
 
(ii) Seller shall fulfill all of Seller’s obligations related to the Equipment (such as Installation, start-up and adjustment, Training, warranty, maintenance and support obligations etc.) for Project Company [***], provided such obligations have not been fulfilled by Seller for Buyer;
 
(iii) Buyer remains a Party to be charged under this Contract.



 
17.6            Software is licensed and not owned
 
Buyer shall not be an owner of any copies of the Informatics Software or any documentation delivered to Buyer, but Buyer is licensed pursuant to this Contract to use any of the Informatics Software and documentation specified in Pricing Sheet.
 
17.7            Informatics Software is owned by Seller
 
Buyer acknowledges that the features and the graphical user interface of the Informatics Software (“ User Interface ”), including, without limitation, icons, menus and screen designs, screen layouts, and command and screen sequence, are the Confidential Information of Seller or its licensors, and are subject to the terms and conditions of this Contract with regards to Confidentiality . Buyer agrees that it will not create software programs incorporating the Confidential Information of the User Interface. Nevertheless, if Buyer creates one or more data loaders for metrology and/or testing equipment that it wishes to integrate into the Dry Combinatorial R&D Platform, Seller will work with Buyer on a time and materials basis (subject to the mutual prior written agreement of the Parties) to facilitate the use of said data loader(s) with the User Interface. Buyer further acknowledges that Seller or its licensors have asserted copyright ownership over the User Interface.
 

15 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


17.8            Buyer agrees that it will not itself, and will not through any parent, subsidiary, Affiliate, agent, or other Third Party, directly or indirectly, do any of the following:
 
17.8.1.        reproduce, distribute, copy, sell, create derivative works of, lease, license, or sublicense the Informatics Software or any component of either, or any documentation delivered to it pursuant to this Contract;
 
17.8.2.        use the Informatics Software in connection with any equipment other than the Equipment and test & characterization equipment used in connection with the Equipment;
 
17.8.3.        attempt, or permit any Third Party, to reverse engineer, disassemble, decrypt, decompile, or otherwise attempt to derive source code from the Informatics Software;
 
17.8.4.        use any Informatics Software in connection with any time-sharing or other multi-user network or service bureau.
 
17.9            Subject to payment by Buyer of the amounts set forth in the applicable Pricing Sheet and during any period in which Buyer makes the payments as set forth in Section 2.5, Seller will provide to Buyer the Support in accordance with Annex 1.5.6. Seller will provide Informatics Updates and improvements (provided such improvements are generally made available to all other licensees) at no additional charge.
 
17.10         Legend.  All copies of the Informatics Software shall include Seller’s copyright, trademarks, patent numbers, and other proprietary notices in the manner in which such notices were placed by Seller on such Informatics Software. Further, Seller may label the Equipment with a permanent non-erasable identification label including but not limited to Seller’s name, Seller’s model number, a sequential serial number in Seller’s standard format, date of manufacture, location manufactured, and specification version to which the Equipment was manufactured. Buyer shall not remove, obscure, or alter Seller’s copyright notices, trademarks, patent numbers, or other proprietary rights notices affixed to or contained within the Informatics Software or the Equipment.
 
17.11        THIS SECTION INTENTIONALLY LEFT BLANK
 
18.      Compliance with Laws.
 
The Parties shall comply with all laws, rules or ordinances of the United States and any applicable state or other governmental agency while performing under this Contract.
 
18.1            Compliance with Securities Laws.  Buyer agrees that certain of the information provided by Seller to Buyer hereunder may be “material, nonpublic information” for purposes of federal or state securities laws, the awareness of which prohibits Seller and its employees, contractors, representatives and agents from (i) buying or selling Seller’s securities (stock, options, etc.) (i.e., “insider trading”) and (ii) passing information to anyone who may buy or sell Seller’s securities (i.e., “tipping”), until after the information has been disclosed to the public and absorbed by the market.  Without limiting any of Buyer’s other obligations under this Contract, Buyer will comply with all federal and state securities laws prohibiting insider trading and tipping, and shall immediately notify Seller in the event of any insider trading or tipping by Buyer or its employees, contractors, representatives or agents of which it becomes aware.
 
18.2            In accordance with the requirements of the Foreign Corrupt Practices Act of the United States (15 U.S.C. § 78dd-1 and 2) (“FCPA”), each Party agrees and warrants that it shall not make, offer, promise or authorize any payment, loan, gift, donation or other giving of money or things of value, directly or indirectly, whether through itself, its affiliates, partners, officers, employees, agents or representatives, whether in cash or kind, and whether pursuant to a written agreement, to or for the use of any government official, any political party or official thereof or any candidate for political office, for the purpose of influencing or inducing any official act or decision in order to further the activities contemplated by this Contract, including obtaining or retaining any government approval or funding related to such activities.
 
 
 
IN WITNESS WHEREOF , the parties hereto have caused this Contract to be executed by their duly authorized representatives:
 
 
 
“Buyer”
 
Ulyanovsk Center for Technology Transfer Ltd.
 
Date: September 29, 2013
 
Name: /s/Andrey Redkin
 
(Print): Andrey Redkin
 
Title: CEO
 
 
 
“Seller”
 

16 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


Intermolecular, Inc
 
Date: September 29, 2013
 
Name: /s/David E. Lazovsky
 
(Print): David E. Lazovsky
 
Title: President and CEO
 
 
 
“Customer’s Engineer”
 
Limited liability Company “Russkie Tehnoparki”
 
Date: September 29, 2013
 
Name: /s/Konstantin B. Popov
 
(Print): Konstantin B. Popov
 
Title: CEO
 
 
 


17 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract




ANNEX 1.5.1

PRICING SHEET


Table-1.
S/N
Product
Manufacturer, country of origin
Unit of measure
Qty. in units of measure
Unit price
Total price
1.
Tempus™ AP-30M
Intermolecular, USA
Unit
[***]
[***]
[***]
2.
Tempus™ P-30
Intermolecular, USA
Unit
[***]
[***]
[***]
3.
HPC & Informatics License*
Intermolecular, USA
Year
[***]
[***]
[***]
4.
Maintenance & Support*
Intermolecular, USA
Year
[***]
[***]
[***]
TOTAL
х
х
Х
[***]
* The fees for HPC & Informatics License and Maintenance & Support (“License-Support”) are included in the above price for a period of [***] from Sign-Off (the “Initial Term”). Additional fees for the License/Support for the first year beyond the Initial Term (the “First Renewal Term”) shall be priced at [***] for the HPC & Informatics License fees and [***] for the Maintenance & Support fees for a combined total of [***]. The parties agree to enter into good faith discussions for pricing of the License-Support fees beyond the First Renewal Term, where such pricing shall take into account the fair market value of the License-Support fees.

18 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


Table-2. Calculation of cost of supplied equipment considering additional payments and services
S/N
Expense item
Cost (indicate currency)
 1 .
Price of product (total in table-1)
[***]
 2.     
Price of customs clearance of cargo ( in case if foreign equipment is offered )
[***]
3.
Price of insurance for maintaining Dry Equipment at Seller Site to be paid directly to insurance carrier by Seller on Buyer’s behalf (including the Seller’s fee for acting as an agent for obtainment of the insurance)
[***]
   4.
Price of additional services, including:
 
4.1
Installation, start-up and adjustment
[***]
4.2
Training
[***]
4.3
Usage of Seller Site space, electricity, water and other required utilities at Seller Site in accordance with 4.2
[***]
4.4
All permits required for the Dry Equipment to be installed in San Jose, CA (if applicable)
[***]
 
TOTAL (1 + 2 + 3 + 4)
[***]

Payment of all taxes shall be in accordance with Section 3.3


19 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.2

Dry Combinatorial R&D Platform Description

A.      Hardware Description
S/N
Name of delivered equipment and specification
Configuration
Quantity
1.     
Tempus™ AP-30
1.1.
[***]
[***]
[***]
1.2.
[***]
[***]
1.3
[***]
[***]
[***]
1.4
[***]
[***]
[***]
1.5
[***]
[***]
2.     
Tempus™ P-30
 
2.1.
[***]
[***]
[***]
2.2.
[***]
[***]
2.3.
[***]
[***]
2.4.
[***]
[***]
2.5
[***]
[***]
2.6
[***]
[***]
2.7
[***]
[***]
2.8
[***]
[***]
2.9
[***]
[***]
2.10
[***]
[***]
2.11
[***]
[***]
2.12
[***]
[***]
[***]
2.13
[***]
[***]
[***]
2.14
[***]
[***]
2.15
[***]
[***]
2.16
[***]
[***]
[***]
2.17
[***]
[***]
[***]
Operational characteristics of equipment
Refer to Facilities Manuals attached for operational characteristics of each equipment:
Manual, Installation and Plan Maintenance, AP-30, [***]
P-30, Manual, Installation, [***]


20 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


B.      Software Description

Informatics Software

Informatics Software is a comprehensive Web-based R&D information management system that serves as the backbone for integrating experimental process data, characterization results and analysis tools into unified R&D workflows. This system enables experimental design, planning, and tracking of experimental splits, the associated metrology, and e-test data.

Following are the various modules of Informatics Software
Workflow manager (web & mobile app)
R&D Database
Data loader framework
Data search & export module
Analysis – Electrical Distribution, Spectra, Defect Distribution, Process Distribution, Sample Map, Image gallery
Collaboration forum
Administrator module to control user access privileges


21 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.3

Delivery Schedule

S/N
Stage
AP-30 and two P-30s
[***]
[***]
[***]
[***]
[***]
1.1
[***]
[***]
 
 
 
 
1.2
[***]
 
[***]
 
 
 
1.3
[***]
 
 
[***]
 
 
1.4
[***]
 
 
 
[***]
 
1.5
[***]
 
 
 
 
[***]


22 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract




ANNEX 1.5.4

Payment Schedule

S/N
Stage
Stage number in Delivery schedule
Payment term
Payment amount*
1.
Sign-Off of AP-30 and two P-30s at Seller Site in San Jose, CA, USA
1.2
Payment due [***]from [***]
[***]
2.
Sign-Off of AP-30 and two P-30s at Seller Site in San Jose, CA, USA
1.2
Payment due [***]from [***]
[***]
TOTAL
(total sum considering all obligatory payments)
х
х
[***]
*The amounts are prior to any applicable taxes. Any applicable taxes are in addition to the Payment amount and shall be due and payable in accordance with Section 3.3.

23 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract




ANNEX 1.5.5
 
 
 
 
 
Acceptance Criteria
 
 
 
 
 
The acceptance criteria are described in the following documents which are incorporated herein by reference:
 
 
1.       Procedure Ti Standard Acceptance P-30 [***]
 
 
2.       Procedure Standard Acceptance AP-30 [***]
 
 



24 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.6
 
Seller Maintenance and Support Services
 
 
 
This Annex describes the maintenance and support services that Seller will provide with respect to the Dry Combinatorial R&D Platform.
 
Term and renewal of services
 
Seller will provide maintenance and support services set forth herein for the Dry Combinatorial R&D Platform. Such services will commence upon Sign-Off and continue for a period of [***] thereafter (the “Initial Term”).
 
 
 
Seller will continue to provide said services during any additional term during which Buyer renews maintenance and support services (“Renewal Term”) in accordance with the procedure set forth below.
 
 
 
Not less than [***] prior to the conclusion of the Initial Term, Seller shall send Buyer written notice of the date that the Initial Term is scheduled to expire, together with an invoice for HPC & Informatics License fees (“License Fees”) and maintenance & support   fees (‘Support Fees”) for the first year beyond the Initial Term (the “First Renewal Term”) at USD [***] For the License Fees and USD [***] for the Support Fees (for a combined total of [***]), which invoice shall be payable within [***].
 
 
 
The fees for HPC & Informatics License and Maintenance & Support (“License-Support”) are included in the pricing in Annex 1.5.1 for a period of [***] from Sign-Off (the “Initial Term”). The parties agree to enter into good faith discussions for pricing of the License-Support fees beyond the First Renewal Term, where such pricing shall take into account the fair market value of the License-Support fees.
 
 
 
Seller will advise Buyer in advance when Seller believes that maintenance and support services fall outside of the range of supported services (“Non-Covered Services”) and will provide Buyer with a description of such Non-Covered Services and any applicable charges. All charges by Seller shall be at Seller’s then-current rates.
 
 
 
Response Times
 
 
 
Seller customer service may be initiated by calling 1-408 582-5700 or such other number or email provided to Buyer for that purpose. Seller will use its best judgment to determine the priority level of each error reported by Buyer and shall inform Buyer of any change and the basis thereof. Seller shall provide and maintain for Buyer contact and escalation procedures for Buyer personnel to reach an appropriate Seller employee as follows:
 
 
 
In the event of a call reporting an error, Seller will acknowledge the Buyer call within the next business day of Buyer contacting Seller, followed by initial assessment and an error resolution plan within [***] days of the assessment. Seller will use commercially reasonable efforts to schedule and execute error resolution activities in a timely fashion and in accordance with the error resolution plan. Provided that Seller’s activities under the error resolution plan are not related to activities outside Seller’s control (e.g. shipping delays, long-lead design and parts procurement), Seller will make commercially reasonable efforts to execute the plan within a period of [***]. In the event Seller’s activities under the error resolution plan are related to activities outside Seller’s control (e.g. shipping delays, long-lead design and parts procurement), Seller shall notify Buyer accordingly.
 
 
 
Maintenance and Support Services
 
 
 
A. Informatics Hardware and Equipment Support
 
 
 
During the Initial Term and any Renewal Term, provided Seller receives the reasonable requested cooperation from Buyer, Seller will do the following:
 
 
 

25 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


(a)      Remedial maintenance will be provided by Seller during normal working hours. Buyer will provide [***] access to the Hardware as needed to perform any services hereunder.
 
 
 
(b)      During the Warranty Period (as defined in Section 8.3), Seller will[***] maintain the Hardware in accordance with the warranty set forth in the Contract, including replace or repair (collectively “Remedy”) parts as deemed necessary by Seller. After the end of the Warranty Period (provided Buyer extends the maintenance and support services to be provided under this Annex beyond the Initial Term), Seller will Remedy parts at Buyer’s expense. In either of the foregoing, Seller will pay for the labor and services required to Remedy the parts (but will not pay for the parts beyond the Warranty Period). Buyer shall inform Seller if any replaced parts may be contaminated with hazardous or toxic materials. All parts may be furnished on an exchange basis and may be new or refurbished spares. Replaced parts removed from the Hardware will, at Seller’s sole option, become the property of Seller. All [***] items, including but not limited to [***] are excluded from coverage hereunder. Cost of [***]and [***], including [***] are to be covered by Buyer. Buyer is responsible for maintenance, and cost, of support equipment which are not listed in the Sign-Off.
 
 
 
(c)      Seller shall not be responsible for maintenance and support services under the contract based on damage caused by (i) Equipment operation outside of specified hardware limits and process conditions,
(ii) adjustments, repairs or replacement parts required because of operator-caused error or repeated misuse of Hardware;
(iii) a non-conformity arising from or after relocation of the Hardware without prior written approval of Seller, which shall not be unreasonably withheld, unless Buyer can demonstrate by clear and convincing evidence that the relocation did not cause the non-conformity, in whole or in part, or (iv) damages covered arising out of force majeure. All repairs required by such excluded damage will be subject to an additional charge, as agreed in advance in writing by Seller and Buyer.
 
 
 
B. Software Support
 
 
 
During the Initial Term and during any Renewal Term, Seller shall use commercially reasonable efforts to do the following:
 
 
 
(a)   Remedial maintenance will be provided by Seller during normal working hours. Buyer will provide full and free access to the Software as needed to perform any services hereunder.
 
(b)   During the Warranty Period (as defined in Section 8.3), Seller will maintain the Software in accordance with the warranty set forth in the Contract. Buyer will provide VPN site-to-site Internet access to the data network located at the Seller Facility to improve Seller’s ability to support Buyer.
 
 
 
c) Seller is not required to support or maintain any version of the Software except its then-current, commercially released version, and the version that immediately preceded that version. For such immediately preceding software version, Seller shall use commercially reasonable efforts to provide error-fixing updates, but shall have no obligation to provide upgrades that improve the functionality of that software version.
 
 
 
(d) Seller is not obligated to provide, free of charge services, additional services, outside of the range of normal support services, such as debugging problems in non-Seller-supported software or products, or in combinations of supported and non-supported software or products where the problem occurs in products or software not supplied by Seller,
 


26 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract





ANNEX 1.5.7

Installation and Facility Requirements

The facility requirements are described in the following documents which are incorporated herein by reference:
1.
AP-30 Facility Requirements
2.
P-30 Facility Requirements

The installation requirements specifying the exact and exhaustive additional equipment, infrastructure and certain requirements needed for the Equipment being installed and stared-up at the Buyer site shall be drafted and incorporated herein by the Parties within a term of [***] since the Execution date.

27 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract




ANNEX 1.5.8
 
 
 
Documents at Sign-Off
 
 
 
 
 
Operation Manuals:
 
 
 
1.       Manual, Installation and Plan Maintenance, AP-30[***]
 
2.       Manual, User, Brooks Automation, M2[***]
 
3.       P-30, Manual, Installation, Operation, [***]
 
4.       P-30, Manual, Maintenance[***]
 
5.       P-30, Manual, Safety[***]
 
6.       P-30, Manual, User[***]
 
7.       Procedure, Blowout, Teardown, Shipping, P-30[***]
 
8.       Procedure, Decontamination, P-30[***]
 
 
 
Certificates:
 
 
 
None from Seller
 
 
 



28 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.9

HPC Technology as Know How includes the following Informatics Modules


1.
R&D Workflow management : [***]
2.
Data loading framework: [***]
3.
Collaboration forum: [***]
4.
Analysis : [***]
5.
Data search & export: [***]
6.
Visual Data analysis : [***]
7.
R&D data warehouse: [***]

The documentary and supplementary information listed above shall be transferred by the Seller to the Buyer in PDF files in digital within a period of [***] since the execution date.
The Parties shall confirm save receipt of the Know How information by drafting a Completion act in [***] after the transfer of data has occurred.
 




29 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



Annex 1.5.10

Acceptance completion act
 
 
No. __
 
 
 
 
 
September ___ , 2013
 
 
 
 
 
The present Acceptance completion act (hereinafter referred to as the “Act”) is concluded between
Limited Liability Company Ulyanovsk Center for Technology Transfer,  a Russian Federation corporation doing business at 67 Krymova St., Ulyanovsk, Russia, 432071, hereinafter referred to as the "Buyer", on the one part,



and Intermolecular, Inc ., a Delaware, USA corporation doing business at 3011 North First St., San Jose, CA 95134, USA, hereinafter referred to as the "Seller",


and Limited liability Company  “ Russkie Tehnoparki ” a Russian Federation corporation doing business at 1 Sirenevyi bulv., c.c. Troitsk, Moscow, Russia, 142191 hereinafter referred to as the " Customer’s Engineer ",



(jointly referred to as the “Parties” and individually referred to as the “Party”) as follows:.
 
 
 
 
 
1. All Parties entered into the Equipment Supply and Technology Licensing Contract, __th, 2013 (hereinafter the “Contract”).
 
 
2. All Parties acknowledge that prior to the execution of this Act the Parties have performed the examination of the installation of the Equipment by the Acceptance Commission in accordance with the Contract and that the results of such examination are satisfactory to all Parties. The Parties further acknowledge that since the date of this Act the Buyer has been granted the license to use the Seller’s Technology (including Know-How) as stated in the Contract and that title and risk of loss in the Equipment has transferred to the Buyer.
 
 
 
 
 
3. The Buyer recognizes that the Equipment satisfies the Acceptance Criteria specified in the Contract, and therefore recognizes the execution of the Contract by the Seller as full and appropriate.
 
 
 
 
 
4. Further to the Contract, this Act is a basis for the submission of an invoice for a part of the Contract price in accordance with the Payment Schedule.
 
 
 
 
 
5. Each Party has received its equally enforceable original copies of the Contract and Annexes thereto that have been signed by each Party.
 
 
 
 
 
6. The present Act is executed in three original counterparts in English and Russian. All capitalized terms used in this Act shall have the same meaning as in the Contract, unless otherwise expressly stated herein.
 
 
 
 
 
 
 
 
IN WITNESS WHEREOF , the parties hereto have caused this Act to be executed by their duly authorized representatives:
 
 
 
“Buyer”
 

30 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


Ulyanovsk Center for Technology Transfer Ltd.
 
Date:
 
Name:
 
(Print)
 
Title:
 
 
 
“Seller”
 
Intermolecular, Inc
 
Date:
 
Name:
 
(Print)
 
Title:
 
 
 
“Customer’s Engineer”
 
Limited liability Company “Russkie Tehnoparki”
 
Date:
 
Name:
 
(Print)
 
Title:
 
 
 


31 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



Annex 1.5.11

Start-up Act
 
 
No. __
 
 
 
 
 
September ___ , 2013
 
 
 
 
 
The present Start-up (hereinafter referred to as the “Act”) is concluded between

 
 
Limited Liability Company Ulyanovsk Center for Technology Transfer,  a Russian Federation corporation doing business at 67 Krymova St., Ulyanovsk, Russia, 432071, hereinafter referred to as the "Buyer", on the one part,

 
 
and Intermolecular, Inc ., a Delaware, USA corporation doing business at 3011 North First St., San Jose, CA 95134, USA, hereinafter referred to as the "Seller",

 
 
and Limited liability Company  “ Russkie Tehnoparki ” a Russian Federation corporation doing business at 1 Sirenevyi bulv., c.c. Troitsk, Moscow, Russia, 142191 hereinafter referred to as the " Customer’s Engineer ",
 
 
(jointly referred to as the “Parties” and individually referred to as the “Party”) as follows:.
 
 
 
 
 
1. All Parties entered into the Equipment Supply and Technology Licensing Contract, __th, 2013 (hereinafter the “Contract”).
 
 
 
 
 
2. Hereby the Parties confirm that the Dry Equipment has been properly installed, started-up and adjusted at Buyer Site and that the Dry Equipment conforms with the Specifications and that training obligations are duly performed by the Seller.
 
 
 
 
 
3. Each Party has received its equally enforceable original copies of the Contract and Annexes thereto that have been signed by each Party.
 
 
 
 
 
4. The present Act is executed in three original counterparts in English and Russian. All capitalized terms used in this Act shall have the same meaning as in the Contract, unless otherwise expressly stated herein.
 
 
 
 
 
 
 
 
IN WITNESS WHEREOF , the parties hereto have caused this Act to be executed by their duly authorized representatives:
 
 
 
“Buyer”
 
Ulyanovsk Center for Technology Transfer Ltd.
 
Date:
 
Name:
 
(Print)
 
Title:
 
 
 
“Seller”
 
Intermolecular, Inc
 
Date:
 
Name:
 

32 33
 





[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


(Print)
 
Title:
 
 
 
“Customer’s Engineer”
 
Limited liability Company “Russkie Tehnoparki”
 
Date:
 
Name:
 
(Print)
 
Title:
 
 
 



33 33
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



Equipment Supply and Technology Licensing Contract

No. US/87799546/00002

September, 29 th 2013
San Jose, California, United States
The present equipment supply and technology licensing contract (hereinafter referred to as the “ Contract ”) is concluded between

Limited Liability Company Ulyanovsk Center for Technology Transfer a Russian Federation corporation doing business at 67 Krymova St., Ulyanovsk, Russia, 432071, hereinafter referred to as the " Buyer ", on the one part,


and Intermolecular, Inc. , a Delaware, USA corporation doing business at 3011 North First St., San Jose, CA 95134, USA, hereinafter referred to as the " Seller ",

and Limited liability Company Russkie Tehnoparki ” a Russian Federation corporation doing business at 1 Sirenevyi bulv., c.c. Troitsk, Moscow, Russia, 142191 hereinafter referred to as the " Customer’s Engineer ",



(the Seller and the Buyer, as well as the Project Company, as defined below, in case of transfer of the Equipment to such Company in accordance with the Contract, jointly referred to as the “Parties” and individually referred to as the “Party”)      

in accordance with the Minutes of open request for proposals No. 1/У-ЭС (the open tender for the right of concluding a contract dated September 03rd, 2013) for supply of Complex R&D equipment, consisting of two - Combinatorial R&D Platforms:     
one vacuum cluster tool (AP-30) with two combinatorial PVD chambers (P-30) («Dry» equipment),
one combinatorial wet process tool (F-20) including one informatics server with software (S-80) («Wet» equipment),
    
 concluded this Contract regarding Wet equipment as follows:
 
1. Subject of contract      
1.1 Seller has developed proprietary Equipment (as more fully defined in Section 1.6.11 below) and Informatics Software (as more fully defined in Section 1.6.19 below) to enable research, design, experimentation, development and commercialization in the area of and with the use of HPC Technology (as more fully defined in Section 1.6.18 below).      
1.2 Seller is in the business of selling Equipment and licensing HPC Technology.     
1.3 Buyer is engaged in the research, design, development and commercialization of materials, manufacturing processes, and technologies in the Field as more fully defined in Section 1.6.12 below.     



1.4 Buyer desires to purchase from Seller and Seller desires to sell to Buyer Equipment and associated licenses to HPC Technology and Informatics Software from Seller.
Customer’s Engineer exercises full control for compliance by the Seller its obligations under the

1 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


Contract.
1.5               Annexes     
The following annexes are hereby incorporated into the Contract:      
1.5.1.           Pricing Sheet      
1.5.2.           Combinatorial R&D Platform description      
1.5.3.           Delivery Schedule      
1.5.4.           Payment Schedule      
1.5.5.           Acceptance Criteria     
1.5.6.           Seller Maintenance and Support Services     
1.5.7.           Installation and Facility Requirements     
1.5.8.           Documents at Sign-Off
1.5.9. HPC Technology
1.5.10. Acceptance completion act.    
1.5.11. Start-up Act    

1.6               Definitions     
The following definitions are hereby incorporated into the Contract:     
1.6.1.           Acceptance Criteria shall have the meaning set forth in Annex 1.5.5.     
1.6.2.           Affiliate means a corporation, company or other entity now or hereafter, directly or indirectly, owned or controlled by, or owning or controlling, or under common control with Buyer or Seller respectively, but such corporation, company or other entity shall be deemed to be a Affiliate only so long as such ownership or control exists.     
For purposes of this definition "control" of a corporation, company or other entity shall mean -     
i.                     to have more than fifty percent (50%) of the voting rights or of the outstanding shares or securities representing the right to vote for either the election of the board of directors or a similar managing authority, or a supervisory board, or     
ii.                   if there do not exist outstanding shares or securities as may be the case in a partnership, joint venture or unincorporated association, to have more than fifty percent (50%) of the ownership interest representing the right to make decisions for such entity.     
1.6.3.           Background Technology of a Party means Intellectual Property Rights and Know-How,     
i.                     that is owned, acquired, or licensed by the Party at any time during the term of this Contract; and     
ii.                   that is not created within the scope of this Contract.
1.6.4.           Buyer Site means Buyer’s facilities located at Ulyanovsk, Russia, or a replacement location subsequently agreed to by the Parties in writing. All special requirements for Buyer Site are specified by the Parties in Annex 1.5.7.
1.6.5.           THIS SECTION INTENTIONALLY LEFT BLANK.     
1.6.6.           Confidential Information means any non-public information disclosed by one Party to the other in connection with this Contract and as further defined in Section 12.      
1.6.7.           Contract Price is defined in Section 2.
1.6.8. Customer Tool Installation Completion Signoff means the procedures to be followed by Seller at Buyer Site in order to complete installation of Equipment at Buyer Site, which procedures are outlined in the Customer Acceptance document in Annex 1.5.5. Upon successful completion of the Customer Tool Installation Completion Signoff the Parties and the Customer’s Engineer will execute the Start-up Act in accordance with Section 4.8.     
1.6.9.           Dry Equipment means the equipment described in Annex 1.5.2 of the Equipment Supply and Technology Licensing Contract for Dry Equipment to be signed by the Parties concurrently with this Contract.    
1.6.10. Effective Date means the later of the dates next to the signatures of the Parties below.     
1.6.11.        Equipment means the equipment described in Annex 1.5.2. Equipment does not include software described in Annex 1.5.2.      
1.6.12.        Field means the field of glass coatings, photovoltaics, power electronics and displays.     

2 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


1.6.13.        HPC Derivatives means any and all improvements, derivatives and modifications of HPC Technology developed by either Party or both Parties as a direct result of using the Combinatorial R&D Platform pursuant to the Contract. HPC Derivatives shall not include any rights whatsoever in the Background Technology of Buyer.     
1.6.14.        HPC-Enabled Informatics Software means Informatics Software that enables Equipment to use HPC Technology. Use of HPC-Enabled Informatics Software by Buyer requires an HPC License, in addition to a license to use the Informatics Software.     
1.6.15.        Non-HPC-Enabled Informatics Software means Informatics Software and other software that in combination operates Equipment without enabling it to use HPC Technology.      
1.6.16.        HPC Mode means the mode of using the Equipment which requires use of HPC-Enabled Informatics Software and an HPC License.     
1.6.17.        HPC License means the license as set forth in Section 17.1      
1.6.18.        HPC Technology means Intellectual Property Rights and Know-How related to techniques, methodologies, processes, test vehicles, synthetic procedures, technology, systems, or combination thereof used for the simultaneous parallel or rapid serial      
1.       design,      
2.       synthesis,      
3.       processing,      
4.       process sequencing,      
5.       process integration,      
6.       device integration,      
7.       analysis, or     
8.       characterization,      
of two (2) more compounds, compositions, mixtures, processes, or synthesis conditions, or the structures derived from such as a result of using either alone or in combination the Equipment and Informatics Software. The structure and definition of assets contained in the HPC Technology is provided in Annex 1.5.9. If any of such assets are not patented in the territory of Russian Federation, the Buyer shall under the present Contract be deemed to have only received a license to the Know-How representing such assets.
    
After the Seller has been granted patents, allowed in the territory of Russian Federation the Parties shall perform certain license agreements in accordance with Russian legislation providing for the rights of use of such inventions as prescribed by the present Contract.
    
If any information provided to Buyer by Seller is not Intellectual Property Rights or Know-How, then Buyer shall be deemed to have been granted the rights to use relevant design projects, scientific research results and documentation without a license.
    
The Know-How representing HPC Technology consists of methods and systems to perform combinatorial processing using Atomic Layer Deposition systems and Physical Vapor Deposition (commonly known as dry systems) and fluids based systems (commonly known as wet systems).
    
1.6.19.        Informatics Software means software in the form of machine readable, object code, and related documentation, together with any Informatics Updates, if any, that may be provided by Seller to Buyer. Informatics Software may consist of either HPC-Enabled Informatics Software or Non-HPC-Enabled Informatics Software.      
1.6.20.        Informatics Improvements means improvements, additions, or modifications to the Informatics Software developed and released by Seller to add features, support additional Equipment or support new uses or applications of the Equipment. Seller will periodically offer Informatics Improvements for license to Buyer.     
1.6.21.        Informatics Updates means error corrections, bug fixes or workarounds to the Informatics Software that are developed and released by Seller solely to ensure that the Informatics Software performs in accordance with the Specifications, along with any improvements to the Informatics

3 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


Software that may be developed and release by Seller from time to time and which it makes available to customers at no charge. Seller shall make Informatics Updates available to Buyer at no charge. Informatics Updates do not include Informatics Improvements.     
1.6.22.        Intellectual Property Rights means allowed and enforceable on the territory of Russian Federation Statutory Rights in and to any and all of the following -     
i.                     patents and patent applications claiming any inventions or discoveries made, developed, conceived, or reduced to practice, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof,      
ii.                   copyrights,      
iii.                  trademarks, service marks, trade names, trade dress, domain names and similar rights,      
iv.                 mask work rights, and      
v.                   Any other moral, intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction in the world.     
1.6.23.        Know-how means any know-how, technology, trade secrets, information (including inventions eligible for statutory protection), software (including source code), circuitry, circuit designs, design descriptions, specifications, formulas, processes, process conditions, materials, material stacks, structures, architectures, specifications for the procurement of parts and drawings, whether in tangible or intangible form and all other experience, drafts, ideas, concepts and business information, rights to which objects are allowed and enforceable on the territory of the Russian Federation.     
i.                     Know-How does not include Intellectual Property Rights, however Know-How shall include without limitation copyrights or intellectual property rights (other than Intellectual Property Rights) that are not Statutory Rights.     
1.6.24.        License Fees shall have the meaning as defined in Section 2.4.     
1.6.25.        Pricing Sheet means the price as set forth in Annex 1.5.1     
1.6.26.        Seller Site means Seller’s facilities located at the following address: 3011 North First Street, San Jose, CA, USA.
1.6.27.        Sign-Off means satisfaction and signing of the Acceptance Criteria and completion of the activities set forth in Section 4.13. Parties shall perform such activities upon satisfaction and signing of the Acceptance Criteria.
Sign-Off does not mean transfer of title or possession of the Equipment and provision of licenses.     
1.6.28.        Specifications means the specifications listed in Annex 1.5.2 for:     
i.                     Equipment,     
ii.                   Informatics Software.     
1.6.29.        Statutory Rights means rights that come into force in the Russian Federation by (i) application to or registration with a governmental entity, and (ii) approval of such application or registration by such entity.     
1.6.30.        Support means the maintenance and support services as described in Annex 1.5.6.     
1.6.31.        Term shall have the meaning defined in Section 15.1.      
1.6.32.        Third Party means a party other than Seller, Buyer, Customer’s Engineer or their Affiliates.     
1.6.33.        THIS SECTION INTENTIONALLY LEFT BLANK.     
1.6.34.        Wet Equipment means the Equipment.     
1.6.35.        Wet Combinatorial R&D Platform means a part of the Combinatorial R&D Platform referred to in the Preamble of the Contract, which part comprises one or more of the following items provided such items are described in the Pricing Sheet:      
i.                     Equipment;     
ii.                   HPC License;     
iii.                  Informatics Software License;      
      
2.         Contract price      
2.1               Purchase of Software means license.     

4 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


Any software provided to Buyer under this Contract is licensed, not sold, to Buyer and any reference to the “sale” or “purchase” of software shall be deemed to mean “license.”      
2.2               Purchase
Subject to the terms and conditions set forth in this Contract including but not limited to the licenses set forth in Section 17 and the payments set forth in Section 2.4 and Section 2.5, and the training referenced in Section 0, Buyer hereby agrees to purchase the Wet Combinatorial R&D Platform from Seller and Seller hereby agrees to sell the Wet Combinatorial R&D Platform to Buyer.     
2.3               The price of the Equipment and Services shall be in USD (United Stated Dollars), USD shall be the Contract currency. Payment currency is USD, payments shall be in USD.
2.4 License and Equipment Fees. Buyer shall pay Seller the fees for the HPC License, the Informatics Software License and the Equipment in accordance with the Pricing Sheet. In the event Buyer does not make the payments due to Seller when due in accordance with Annex 1.5.4, Seller shall have the right but not the obligation to terminate the licenses granted to Buyer in Sections 17.1 and 17.2. Seller shall inform Buyer of such termination and no later than ten (10) days after receiving such notice, Buyer shall cease use of the Equipment in HPC Mode.
2.5 Support fees
Buyer shall pay Seller the fees for the Support in accordance with the Pricing Sheet.
2.6               Pricing Sheet     
The Pricing Sheet is hereby incorporated by reference into this Contract. Seller will invoice Buyer in accordance with the terms of the Pricing Sheet, Payment Schedule and the Contract. The Pricing Sheet together with this Contract shall constitute the complete agreement regarding the purchase of the Wet Combinatorial R&D Platform.      
2.6.1.           Notwithstanding the foregoing, nothing contained in any invoice shall in any way modify the terms and conditions of this Contract, or add any additional terms or conditions.     
2.6.2.           The Pricing Sheet shall be subject to the terms and conditions of this Contract. In the event of a conflict between the terms of the Pricing Sheet and the terms of this Contract, the terms of this Contract shall control.      
2.7               Upon the complete satisfaction of payment to Seller by Buyer, in accordance with Section 3 and Annex 1.5.4, Buyer ownership interest in and title to the Equipment shall be free and clear of any and all encumbrances.
2.7.1.           Except as provided in Section 17.5.1, in the event Buyer wishes to transfer ownership of the Wet Equipment to a Third Party, Buyer shall first offer the Wet Equipment for sale back to Seller at the fair market value of the Wet Equipment. Seller shall have [***] from the date of such offer to agree to purchase the Wet Equipment. If Seller does not exercise its right to purchase the Equipment within [***] from the date of the offer, Buyer is entitled to sell the Equipment to a Third Party.
2.7.2. In the event of a foreclosure of Buyer’s assets by a Third Party (hereinafter “Foreclosing Party”) to which Buyer’s assets have been pledged subject to a pre-existing loan agreement between Buyer and the Foreclosing Party, Seller shall not have any first right to purchase the Wet Equipment, provided that any such sale pursuant to a foreclosure shall be limited to the sale of the hardware included in the Equipment and not any software or associated licenses. The purchaser of the Wet Equipment pursuant to this Section 2.7.2 shall request such licenses from Seller Upon receiving such request Seller shall grant such licenses to such purchaser at Seller’s then-prevailing standard prices for such licenses.

    
2.8. Training
Seller agrees to provide training to certain UCTT personnel in accordance with the terms of Section 2.1 of the JDP Agreement between UCTT and IMI to be signed concurrently herewith. Said terms of said Section 2.1 are incorporated herein by reference. For the avoidance of doubt, notwithstanding the inclusion of this Section 2.1 in this Contract and in the JDP Agreement and in any other agreement, Seller shall provide such training only once. Seller’s satisfaction of this obligation under either one of the agreements shall be deemed to satisfy Seller’s obligation under all agreements.

5 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


At the Buyer’s request the Seller will provide additional training to the personnel pointed by the Buyer under terms and conditions agreed by the Parties separately and for an additional fee based on Seller’s then prevailing standard rates for such training.
    
3.         Terms of Payment      
3.1               Payment Method      
All payments hereunder shall be made in U.S. dollars by Buyer and in accordance with the Payment Schedule in Annex 1.5.4.
The Buyer will make a payment under the invoice of the Seller which shall be issued upon execution of the Acceptance completion act and arrival of the Wet Equipment for customs inspection at the destination point in Ulyanovsk, the Russian Federation.     
3.2               Late payments      
All payments not paid when due shall bear simple interest at a rate of [***] per month or the highest rate allowed by law, whichever is less.     
3.3               Taxes      
Payments due to Seller are exclusive of all present and future taxes, duties, levies and other charges by any name (including any interest, penalties or additions thereto) imposed by any foreign, federal, state, local or other taxing authorities (including, without limitation, export, sales, use, excise and value-added taxes) on or with respect to the transactions or payments under this Contract.     
3.4               Records; Inspection      
3.4.1.           Buyer shall keep complete, true and accurate books of account and records on its own behalf for the purpose of determining the amounts payable under this Contract. Such books and records shall be kept at Buyer for at least [***] following the end of the calendar quarter to which they pertain.      
3.4.2.           Such records will be open for inspection during such [***] period by an independent auditor reasonably acceptable to Buyer, solely for the purpose of verifying amounts payable to Seller hereunder. Such inspections may be made no more than once each calendar year, at reasonable times and on reasonable notice.     
3.4.3.           Inspections conducted under this Section 3.4 shall be at the expense of Seller, unless a variation or error producing an increase exceeding [***]percent ([***]%) of the amounts payable for any period covered by the inspection is established and confirmed in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by Buyer. Each Party agrees to hold in confidence pursuant to Section 8 all information concerning payments and reports, and all information learned in the course of any audit or inspection, except to the extent necessary for that Party to reveal such information in order to enforce its rights under this Contract or if disclosure is required by law.     
4.         Terms and Conditions of Equipment Supply      
4.1               Seller will install the Equipment for Sign-Off at the Seller Site. The Acceptance Criteria shall be applied in accordance with Section 4.13.     
4.2               Upon Sign-Off, the Wet Equipment will be delivered to Ulyanovsk, Russian Federation based on [***] per Incoterms 2010 and this Contract. For the avoidance of doubt, delivery of the Wet Equipment shall be deemed to have occurred and obligations of the Seller to deliver fulfilled when the Wet Equipment arrives for customs inspection at the destination point in Ulyanovsk, the Russian Federation. For the avoidance of doubt, [***] per Incoterms 2010 applies unless otherwise expressly stated in this Contract.     
4.3 THIS SECTION INTENTIONALLY LEFT BLANK.     
4.4 Seller shall obtain at his own risk and expense any export license or other official authorization and carry out all customs formalities necessary for the export of the Equipment.     
4.5               Buyer shall be solely responsible for receiving the Equipment and ensuring that the Equipment clears customs.      
Seller agrees to furnish Buyer with such documentation and information about the Equipment, as Buyer may reasonably request, in order to comply with Russian customs and import requirements, for entry of the equipment into Russia.

6 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


4.6 Buyer will accept the Equipment from the transportation company at the customs inspection at the destination point in Ulyanovsk (the Russian Federation), for which purposes the Parties and the Customer’s Engineer will sign the Acceptance completion act in the form attached hereto as Annex 1.5.10, and provide for all necessary customs, certification and licensing procedures at its own risk and expense.
The Equipment then shall be delivered by the Buyer or a transportation company (to be arranged for and paid by Buyer) to the Buyer Site and unloaded from the carrier and left for unpacking and installment.
4.7 Seller will unpack, install, start-up and adjust the Equipment at Buyer Site in accordance with the Delivery Schedule in Annex 1.5.3. Notwithstanding the Delivery Schedule, Seller will take all commercially reasonable measures, which are within Seller’s reasonable control, to ensure that the Equipment is installed no later than March 31, 2014. Buyer shall have no more than [***] from the date of installation (“Review Period”) at Buyer Site to inspect the Equipment for conformity with the Specifications. If, during such Review Period, Buyer reasonably determines that the Equipment is not in conformity with the Specifications, Buyer’s sole remedy and Seller’s sole obligation will be to re-install the Equipment to ensure such conformity.
4.8  Upon performance of all actions referred to in Section 4.7 and provided that the Equipment fully conforms with the Specifications, the Seller, the Buyer and the Customer’s Engineer will execute the Start-up Act in the form attached hereto as Annex 1.5.11.
4.9 Buyer is solely responsible for and, in accordance with Annex 1.5.7,shall prepare the Buyer Site for installation of the Wet Combinatorial R&D Platform and shall ensure that all necessary infrastructure specified in Annex 1.5.7 is available.
4.10 Notwithstanding anything to the contrary in the Contract, title and risk of loss in the Equipment will transfer to Buyer at the moment when the Wet Equipment arrives for customs inspection at the destination point in Ulyanovsk, the Russian Federation.
4.11 For shipment, the Equipment will be packaged in double bags and vacuum-sealed, put in wooden crates. Due to the sensitive nature of components, the Equipment requires shipment by air.
4.12 Seller shall unpack the Equipment at the Buyer Site.
4.13 The Sign-Off shall include the examination of the installation at Seller Site of the Equipment and also examination of presence of necessary documents (Operation manual, certificates as described in Annex 1.5.8) in accordance with the Acceptance Criteria. Such examination shall be conducted jointly by the Acceptance Commission which is defined as one representative of the Seller, the Buyer and Customer’s Engineer.           
      
5.         Technical documentation      
The technical documents (operation manual as listed in Annex 1.5.8, spare parts catalogue) will be delivered with the equipment in form of a CD in Russian/English. The costs of translation to Russian language are included in the total Contract Price.     
The following documents will be delivered with the equipment when it ships:     
International Consignment Note    
Proforma Invoice with translation into Russian    
Packing List    
Export Declaration    
Certificate of Origin    
    
6.         Packing, packaging and labeling      
6.1               The cost of [***] and [***] is included in the Contract Price.     
6.2               The casing and packaging shall become the Buyer’s property, once the Equipment has been supplied.      
6.3               Packaging of the Equipment shall secure its absolute safety during the transport. The Seller shall be liable to the Buyer and shall be obliged to reimburse any losses that arose because of spoilage, damage or breakage of the goods entailed by undue or low quality packaging.     

7 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


6.4               There shall be labeling in English and in Russian on each separate package of the Equipment and it shall contain the following information:     
6.4.1.           •The Seller’s name and address;    
6.4.2.           • The Buyer’s name and address;    
6.4.3.           • The final delivery address;    
6.4.4.           • Contract Number;    
6.4.5.           • Number of the package lot, in accordance with the packing list;    
6.4.6.           • Gross and net weight;    
6.4.7.           • Packaging dimensions;    
6.4.8.           • Name of the equipment;    
6.4.9.           • Special requirements (if any).    

7.         ACCEPTANCE AND SUPPORT SERVICES      
7.1               Wet Combinatorial R&D Platform Assembly       
Seller shall complete the assembly and configuration of the Wet Combinatorial R&D Platform and make it available for Buyer’s Sign-Off at the Seller Site provided during the process of assembly and configuration, Buyer cooperates with Seller as reasonably requested by Seller.      
7.2               Buyer Acceptance      
7.2.1.           Upon completion of assembly and configuration of the Wet Combinatorial R&D Platform, Seller will provide Buyer with a written notice that the Wet Combinatorial R&D Platform is available for Sign-Off.      
7.2.2.           Seller shall demonstrate to Buyer that the Wet Combinatorial R&D Platform satisfies the acceptance criteria set forth in Annex 1.5.5 (“Acceptance Criteria”) and allow Buyer to conduct tests to ensure compliance with the Acceptance Criteria.      
7.2.3.           This demonstration and testing shall take place at the Seller Site (Buyer agrees to attend at its own expense) and shall commence no later than [***] days following the written notice from Seller to Buyer.
7.2.4.           Upon completion of said demonstration and testing, Buyer will either (i) confirm in writing that acceptance of the Wet Combinatorial R&D Platform has occurred in compliance with Section 4.1.3, and Buyer shall make the payment associated therewith as set forth in the Pricing Sheet (“Buyer Acceptance”) [***].
7.2.5. Seller will complete the Sign-Off at Seller Site and will complete the Customer Tool Installation Completion Sign-off at Buyer Site.
    
7.3               Support      
Subject to the terms and conditions set forth in this Contract including but not limited to the licenses set forth in Section 17 and the payments set forth in Sections 2.4 and 2.5, Seller agrees to provide Support to the Buyer. Any support or services other than the Support, including services not covered by a warranty or pursuant to pre-paid maintenance, will be provided at Seller’s then-current rates (plus reasonable travel expenses and other out-of-pocket expenses, if any) pursuant to a statement of work signed by the Parties.      
8.         Warranty; Limitation of Liability      
8.1               By Seller     
Seller represents and warrants that:      
8.1.1.           It has the right and authority to enter into this Contract, and to fully perform its obligations hereunder; and      
8.1.2.           This Contract is a legal and valid obligation binding upon it and enforceable in accordance with its terms.     
8.1.3. The title to the Wet Equipment conveyed to Buyer by Seller shall be good, and the Wet Equipment shall be delivered free from any security interest or other lien or encumbrance to any Third Party     
8.1.4. The Wet Equipment is fit for the purpose of performing combinatorial processing

8 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


8.1.5. That as of the Effective Date, to the best of the Seller’s knowledge, the Wet Equipment and Buyer’s ownership, use and possession of the Wet Equipment in the manner as instructed by and in accordance with the documentation and manuals provide herewith and appended as Annex 1.5.7 and 1.5.8 does not infringe any patent, copyright, trademark or trade secret rights of a Third Party issued prior to the Effective Date.
8.1.6 The Wet Equipment, the HPC License and the Informatics Software License provided by the Seller to the Buyer hereunder are altogether sufficient for the use of the Equipment in the HPC Mode in the Field.
8.1.7. The Seller has obtained all necessary licenses, permissions and authorizations required for the export of the Equipment and the provision of the HPC-License and Informatics Software License to the Buyer or the Project Company, as well as for providing Training on the Equipment to the personnel of the Buyer or the Project Company (as the case may be).    
    
8.2               By Buyer     
Buyer represents and warrants that:      
8.2.1.           It has the right and authority to enter into this Contract, and to fully perform its obligations hereunder; and      
8.2.2.           This Contract is a legal and valid obligation binding upon it and enforceable in accordance with its terms.      
8.3               Warranty on the hardware included in the Equipment     
Seller warrants to Buyer that for a period of [***] (“Warranty Period”) from Customer Tool Installation Completion Signoff, the hardware comprising the Equipment (“Hardware”) will be free from defects in materials and workmanship and shall conform in all material respects to its specifications.      
If, during the Warranty Period, the Hardware does not meet the warranty specified above, Seller shall, at its option, repair or replace at no cost to Buyer any defective or nonconforming component of the Hardware in accordance with Annex 1.5.6. The foregoing represents Buyer’s sole remedy for breach of the warranty on the Hardware. The warranty set forth in this section shall apply only to the Seller supplied components of the Hardware and will specifically excludes consumables and any components to be provided by Buyer.      
8.4               Warranty on the software included in the Equipment     
Seller will warrant to Buyer that for a period of [***] (“Warranty Period”) from Customer Tool Installation Completion Signoff, the software included in the Equipment (“Software”) will conform in all material aspects to its specifications. Seller will correct any nonconformities reported to Seller in writing or in electronic form during the Warranty Period in accordance with Annex 1.5.6. The foregoing represents Buyer’s sole remedy for breach of the warranty for the Software.     
8.5               Exclusions     
The warranties and remedies set forth in Sections 8.3 and 8.4 will be void as to the following:     
8.5.1.           any Hardware or Software that has been damaged, modified, or altered (other than by Seller or approved by Seller)      
8.5.2.           any Hardware or Software that has been subjected to physical, electrical or other environmental abuse or misuse, including improper storage or conditions not in accordance with Seller’s specifications,      
8.5.3.           any damage or non-conformities, in whole or in part, arising from use of the Hardware or Software with any other hardware, software, firmware, devices, or other products not provided by Seller or chemicals not recommended or approved for use by Seller.     
8.6               Disclaimer     
Except as provided above for the Hardware and the Software, Seller does not otherwise warrant the Equipment and does not warrant that operation of the Equipment will be uninterrupted or error free.      
Seller specifically disclaims any representation, warranty or guarantee that the use of the Hardware or Software, will be successful, in whole or in part. It is understood that the failure of Buyer to successfully develop or commercialize technology shall not constitute a breach of any representation or warranty or other obligation under this Contract. Except as otherwise expressly set forth above,

9 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


seller makes no representations and extends no warranties or conditions of any kind, either express or implied with respect to any information disclosed hereunder, any activities conducted hereunder or any deliverables provided hereunder, and hereby expressly disclaim any warranties of merchantability, or fitness for a particular purpose or validity of any technology, patented or unpatented, or non-infringement of the intellectual property rights of third parties.     
9.         Limitation of Liability      
9.1               To the maximum extent permitted by applicable law, and except for any breach of any confidentiality obligation under this contract, in no event shall either party or its affiliates be liable to the other party, its affiliates or to any third party claiming through or under the other party hereto, for any lost profits, lost revenue, loss of data, equipment downtime or for any special, consequential, indirect or incidental damages, however caused and under any theory of liability (including contract, strict liability, negligence or other legal or equitable theory) arising in any way out of this contract, whether or not such party has been advised of the possibility of such damages.      
9.2               Except for a breach of a confidentiality obligation, in no event shall either party’s cumulative liability to the other under this contract exceed the amounts received by such party from the other party in the past [***] preceding the claim.     
9.2.1. The limitation of liability described above in Section 9.2 does not apply to any loss or damage to the Wet Equipment that is solely attributable to and solely caused by the gross negligence or willful act of the Seller or Seller’s personnel. For the avoidance of doubt, if Buyer or Buyer personnel are jointly or severally responsible for such loss or damage, then Seller’s liability for such loss or damage that is attributable to Seller shall be subject to the limitation of liability described above in Section 9.2.
9.3               The Parties acknowledge and agree that the foregoing limitations of liability are an essential element of this agreement and that in their absence the terms of this agreement would be substantially different.      
10.      Force Majeure      
Neither Party shall lose any rights hereunder or be liable to the other Party for damages or losses (except for payment obligations then owing) on account of failure of performance by the defaulting Party if the failure is occasioned by war, strike, fire, act of God, earthquake, flood, lockout, embargo, act of terrorism, governmental acts or orders, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or misconduct of the non-performing Party and such Party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a Party be required to settle any labor dispute or disturbance.


      
11.      Dispute Resolution      
11.1            All disputes between the Parties in connection with or arising out of this Contract shall first be discussed in good faith between the Parties in order to try to find an amicable solution.      
11.2            If no solution can be found to settle the dispute, then such dispute shall be finally settled by arbitration in accordance with the default rules and procedures of American Arbitration Association (“AAA”) sitting in New York City, NY, USA and conducted in English.      
11.3            Within 30 days of notice that a Party wants to submit a dispute to arbitration, the Parties shall each select one independent arbitrator and will attempt to mutually agree upon a third independent arbitrator. Each arbitrator will have expertise in the thin film technology industry and will not be an employee, affiliate or contractor for either Party.     
11.4            If the Parties are unable to agree on the third arbitrator within fifteen (15) days, the two arbitrators shall select the third arbitrator within thirty (30) days.      
11.5            If the amount in dispute is less than [***], then the Parties shall agree upon a single arbitrator meeting the above conditions within thirty (30) days of the notice of arbitration or such arbitrator shall be chosen by AAA if the Parties cannot agree.      

10 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


11.6            The arbitrators shall determine what discovery will be permitted consistent with the goal of limiting the costs and time for such a proceeding. The Parties and arbitrators shall use all reasonable efforts to complete any arbitration subject to this Section within six (6) months from the selection of arbitrators.      
11.7            The Parties agree that any award of damages shall not include punitive, special, consequential, or indirect damages except as specifically allowed in this Contract and shall comply with the limitation of liability provisions set forth herein.      
11.8            The arbitrators’ decision shall be in a detailed writing setting forth the reasons for their decision and shall be provided concurrently to each Party.      
11.9            The arbitration award shall be final and binding on the Parties.      
11.10        Unless otherwise agreed to by the Parties, each Party shall pay one-half of the arbitration fees and expenses and shall bear all of its own expenses in connection with the arbitration.      
11.11        Notwithstanding any of the foregoing, either Party shall have the right to seek, at its own cost and expenses, preliminary and temporary injunctive relief pending resolution of the dispute via arbitration.      
11.12        The United Nations Convention on the International Sale of Goods applies unless otherwise expressly stated in this Contract.     

12.      Confidential Information      
12.1            The Parties acknowledge that they may receive information from the other Party which may be considered confidential and proprietary. The receiving Party agrees to avoid any un-authorized disclosure, dissemination, or use of such information that, if disclosed in writing, is identified and marked as confidential (or with words of similar meaning) at the time of its disclosure (or that, if disclosed verbally, is designated as confidential at the time of disclosure and is summarized and identified as confidential in a writing delivered to the receiving Party within thirty (30) days after the disclosure) or that are observed during a visit of the manufacturing facilities of one of the Parties and such information would appear to a reasonable person as confidential information ("Confidential Information"). Both parties agree that this Contract is the Confidential Information of both Parties.     
12.2            The receiving Party will use the Confidential Information solely for the purpose of performing its rights and obligations under the Contract. For the avoidance of doubt, if Buyer transfers the Wet Equipment to Project Company in accordance with Section 17.5.1, Buyer shall have the right to transfer Confidential Information to Project Company, provided that upon the completion of such transfer Buyer shall no longer have any rights to use such Confidential Information.      
12.3            The receiving Party will not disclose Confidential Information to a Third Party without the prior written consent of the disclosing Party. The receiving Party will protect such information from un-authorized disclosure, use or dissemination with at least the same degree of care as the receiving Party exercises to protect its own information of similar type and importance, but in no event less than reasonable care. Notwithstanding the foregoing, the receiving Party may disclose the Confidential Information to its authorized representatives (e.g. directors, employees, officers, professional advisors and agents) having a need to know and who have signed confidentiality agreements or are otherwise bound by confidentiality obligations at least as restrictive as those contained herein.     
12.4            The obligations of confidentiality and protection required by this Section will survive the expiration, termination, or cancellation of this Contract for a period of five years thereafter.      
12.5            The obligation of confidentiality will not apply, or will cease to apply, to any information that: (a) was known to the receiving Party prior to its receipt of Confidential Information under this Contract; (b) is or becomes publicly available without breach of this Contract by the receiving Party; (c) is received from a Third Party without an obligation of confidentiality to the disclosing Party; or (d) is developed independently by employees of the receiving Party not having access to such information.     

11 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


12.6            Notwithstanding anything to the contrary in this Section 8, each Party shall be permitted to lawfully disclose Confidential Information of the other Party to any governmental agency to the extent such disclosure is required by law (including but not limited to the SEC, USPTO, and pursuant to a subpoena); provided, however that before making such disclosure, the Party about to make such disclosure shall seek the highest level of protection available and give the other Party an adequate opportunity to interpose an objection or take action to assure confidential handling of such information.     

13.      Miscellaneous      
13.1            Amendment       
No change or modification in the terms hereof, in a manner not expressly provided in this Contract shall be binding unless reduced to writing and duly executed by the Parties in the same manner as the execution of this Contract. Any attempt to so change or modify the terms of this Contract shall be considered void and of no effect.     
13.2            No Implied License      
Only the licenses granted pursuant to the express terms of this Contract shall be of any legal force or effect. No other license rights shall be created by implication, estoppel or otherwise. Each Party reserves all rights not expressly granted to the other Party under this Contract.     
13.3             Assignment     
13.3.1.        Neither Party shall assign or transfer this Contract either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other Party.     
13.3.2.        Any attempt to assign without such consent shall be void and of no effect.     
13.3.3.        Notwithstanding the foregoing, either Party may assign this Contract with the prior written consent of the other Party (which consent will not be unreasonably withheld), to an Affiliate and the terms of the Contract shall continue in effect without modification after such assignment.      
13.4            Drafting       
In interpreting and applying the terms and provisions of this Contract, the Parties acknowledge that its lawyers reviewed and participated in the drafting and agree that no presumption shall exist or be implied against the Party that drafted such terms and provisions.      


13.5            Governing Law       
This Contract shall be governed by and construed in accordance with the laws of the State of California in the United States, without regard to its conflicts of law principles.      
13.6            Venue       
All disputes between the Parties in connection to this Contract shall be addressed in accordance with Section 11. If no solution can be found to settle the dispute, then the dispute will be submitted to a court of competent jurisdiction in the county of Santa Clara, CA, USA.      
13.7            Independent Contractors      
The relationship of the Parties is that of independent contractors. Neither Party shall be deemed to be an agent, partner, joint venturer or legal representative of the other for any purpose as a result of this Contract or the transactions contemplated thereby. Personnel supplied by either Party are not the other Party's employees or agents and such supplying Party assumes responsibility for their acts or omissions, The supplying Party shall be solely responsible for the payment of compensation of such Party's employees or agents assigned to perform services hereunder and such employees or agents shall be informed that they are not entitled to any employee benefits of the other Party. Neither Party shall be responsible for paying worker's compensation, disability benefits, and unemployment insurance or for withholding and paying employment taxes for any employee or agent of the other Party.     
13.8            Notices      
13.8.1.        Unless otherwise agreed to by the Parties, the communications required or permitted to be given or made under this Contract shall be made in writing, via personal delivery, registered mail,

12 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


facsimile transmission (with written confirmation copy by registered first-class mail), addressed to the appropriate Party at the address indicated below and a copy to the receiving Party’s legal department.     
13.8.2.        All communications made pursuant to this section shall be deemed made or given on the date of such personal delivery, mailing or transmission.
13.8.3.        If to Buyer:
Ulyanovsk Center for Technology Transfer
67 Krymova St.,
Ulyanovsk,
Russia, 432071     
      
13.8.4.        With a copy to:
Limited liability Company “Russkie Tehnoparki” 
1 Sirenevyi bulv., c.c. Troitsk, Moscow,
Russia, 142191     

13.8.5.        If to Seller:      
Intermolecular Inc.     
3011 North First St.     
San Jose     
CA 95134     
      
13.8.6.        With a copy to:     
Intermolecular Inc.     
Attention: General Counsel     
3011 North First St.     
San Jose     
CA 95134     
      
      
13.8.7.        The Parties may change the name and address to which communications should be sent under this section by providing prior written notice to the other Party.      
13.9            Captions      
The captions to the several sections hereof are not part of this Contract, but are included merely for convenience of reference and shall not affect its meaning or interpretation. As used in this Contract, the word "including" means "including without limitation”.     
13.10        Counterparts      
This Contract may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.      
13.11        Signatures by Electronic Mail or Facsimile      
The delivery by electronic mail or facsimile of the signatures of the Parties shall be deemed valid and binding as if they were originally made.      
13.12        Copies      
A scanned or photocopied version of this Contract shall be deemed to be an original and shall have the full force and effect of an original document.     
13.13        Non-waiver      
The failure of either Party at any instance to require performance of any provision hereof by the other Party shall not be deemed a waiver and thereafter shall not deprive that Party of its full right to require such performance of that provision at another instance. Any waiver must be in writing executed by the waiving Party.      
13.14        Severability      
If any term, provision, covenant or condition of this Contract is held by a court of competent jurisdiction to be illegal, invalid, void or unenforceable, the remainder of the terms, provisions, covenants or conditions shall remain in full force and effect and shall in no way be affected, impaired

13 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


or invalidated. The Contract shall continue in full force and effect to the fullest extent permitted by law without said provision or with said provision being modified and narrowly tailored to achieve the original intent of the Parties.     
13.15        Third Party Beneficiaries      
Except as expressly provided in this Contract, there are no third party beneficiaries expressly or impliedly intended under this Contract.     
13.16        Integration      
This Contract, together with all Annexes hereto, constitutes the entire agreement and understanding of the Parties relating to the subject matter hereof and supersedes all prior negotiations and understandings between the Parties, both oral and written, regarding such subject matter.     
13.17        Representation by Legal Counsel      
Each Party hereto represents that it has been represented by legal counsel in connection with this Contract and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Contract, the Parties agree that no presumption shall exist or be implied against the Party that drafted such terms and provisions.
13.18. Governing Language
This Contract has been executed by the Parties in counterpart originals, one in the English language and one in the Russian language. Notwithstanding the foregoing, the Parties agree that in the event of controversy between the Parties regarding the interpretation or application of the terms of this Contract, the English language version of the Contract will be controlling. All communications and notices to be made or given pursuant to this Contract shall be in the English language.







    
14.      Addresses and Banking Details of the Parties      
14.1            Seller     
14.1.1.        All payments due to Seller under this Contract shall be made by bank wire transfer as follows:      
      
Domestic Wire Instructions:     
Route all wires via FEDWIRE to the following ABA number     
To: [***]     
Routing and Transit #: [***]     
For Credit of: Intermolecular, Inc.     
Credit Account Number: [***]     
By Order of: [name of sender]

International Wire Instructions:         
Instruct the paying financial institution to advise their US correspondent to pay as follows:
Pay to:     [***]
Routing & Transit:    [***]         
Swift Code:    [***]         
For Credit of:    Intermolecular, Inc.         
Final Credit Account#:    [***]         
By Order of:    [Name of Sender]
 
15.      Term and Termination      
15.1            Term      

14 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


This Contract shall be effective as of the Effective Date. The term of this Contract shall commence on the Effective Date, and, unless terminated earlier as provided in this Section15.1, shall continue in full force and effect until the termination of all HPC Licenses and HPC-Enabled Informatics Software Licenses granted under this Contract (the "Term").       
15.2            Termination for Breach      
Either Party may terminate this Contract if the other Party has materially breached or defaulted in the performance of any of its material obligations, and such default has continued for ninety (90) calendar days after written notice was provided to the breaching Party by the non-breaching Party.      
Termination will be effective at the end of the ninety (90) day period unless the breach has been cured before the expiration of the ninety (90) day period.     
15.3            Effect of Termination      
15.3.1.        Accrued Rights and Obligations      
Termination of this Contract for any reason shall not release either Party from any liability or obligation that, at the time of termination, has already accrued to the other Party or that is attributable to a period prior to termination, nor shall it preclude either Party from pursuing any rights and remedies it may have at law or in equity with respect to any breach of this Contract.      
15.3.2.        Termination of Licenses      
All licenses granted under the Contract (including the HPC Licenses and HPC-Enabled Informatics Software Licenses) shall terminate upon termination of the Contract. For the avoidance of doubt, upon termination, Buyer shall have no right to use the Wet Combinatorial R&D Platform in HPC Mode. However, Buyer shall continue to have the right to use the Wet Combinatorial R&D Platform in non-HPC Mode.     
15.4            Survival      
Sections 1, 2, 4, 7, 8, 9, 10, 11, 12 and 13 shall survive the expiration or termination of this Contract for any reason.      


16.      Ownership OF Intellectual Property Rights and Know-How      
16.1            HPC Technology      
16.1.1.        Seller shall own all right, title, and interest in and to the HPC Technology and HPC Derivatives.      
16.1.2.        Buyer hereby agrees to assign to Seller, all of Buyer’s right, title and interest in and to any HPC Technology and PC Technology and HPC Derivatives that are developed during the term of this Contract.      
16.1.3.        All Intellectual Property Rights and Know-How rights arising out of the sole activities of Buyer’s personnel conducted for Buyer’s customers or for Buyer’s internal development programs with the use of Wet Combinatorial R&D Platform shall be owned by Buyer.      
16.1.4.        All Intellectual Property Rights and Know-How rights arising out of the sole activities of Seller’s personnel conducted for Seller’s customers or for Seller’s internal development programs with the use of Wet Combinatorial R&D Platform shall be owned by Seller.      
16.1.5.        All Intellectual Property Rights and Know-How rights arising out of the joint activities of Seller’s personnel and Buyer’s personnel with the use of Wet Combinatorial R&D Platform shall be jointly owned by Buyer and Seller.      
      
17.      LICENSES      
17.1            HPC License      
Subject to the terms and conditions of this Contract including the payments in Sections 2.4 and 2.5, Seller hereby grants to Buyer a non-exclusive, non-transferable, license, under Seller’s rights in HPC Technology (without the right to sublicense) to use the Equipment solely for the purpose of developing and commercializing materials in the Field.      
17.2            License Grant for Informatics Software      
17.2.1.        Subject to the terms and conditions of this Contract including the payments in Sections 2.4 and 2.5, Seller hereby grants to Buyer a non-exclusive, non-transferable, license, under Seller’s

15 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


rights in Informatics Software (without the right to sublicense) to use the HPC-Enabled Informatics Software with the Equipment. The aforementioned license (hereinafter “HPC-Enabled Informatics Software License”) shall only be for the sole purpose of developing and commercializing materials and products incorporating such materials, both in the Field.      
17.2.2.        Buyer shall have no right to use HPC Technology under this Contract unless it purchases HPC-Enabled Informatics Software and purchases an HPC License.      
17.2.3.        Further, Buyer’s license to use HPC Technology shall only be for operation of the Equipment for which it has purchased HPC-Enabled Informatics Software, and only for the license term for such software and the HPC License.      
17.3            Term of License      
The term of the HPC License and the Informatics Software license granted by Seller to Buyer shall be for a period of [***] starting from Customer Tool Installation Completion Signoff. Subject to Buyer’s payment of the renewal fees in accordance with the payment terms of this Contract (including Annex 1.5.6), the term of the HPC License shall automatically renew for the [***] for which the [***].      
17.4            Limited scope of license for use of Third Parties      
The scope of the HPC License and the Informatics Software license granted by Seller to Buyer hereunder does not include the right to use the Wet Combinatorial R&D Platform on behalf of or for the benefit of Third Parties, except where the intended purpose of such activities is the qualification or sale by Buyer or one or more of its partners of a resulting materials and products incorporating such materials, both in the Field.     
17.5            No Transfer to or use by Third Party of Equipment in HPC Mode      
Except as stated in Section 17.5.1 below, Buyer agrees not to sell, lease, or otherwise dispose of (“ Transfer ”) the Equipment sold hereunder, or allow access to any Third Party to use the Equipment in HPC Mode (“ Access ”) without explicit written approval by Seller, which Seller may grant in its sole discretion and subject to Seller entering into a license agreement, if necessary under the circumstances, with such Third Party. Buyer can Transfer the Equipment for [***] and agrees to inform any such Third Party purchaser that the Equipment cannot be used to perform HPC Technology without appropriate licenses from Seller.

17.5.1 Buyer shall have the right to Transfer the Equipment sold hereunder to [***], a company [***] and hereinafter referred to as Project Company provided Project Company, in addition to Buyer, agrees to assume all of Buyer’s obligations related to the Equipment except for the obligation to pay for the Equipment, and provided, pursuant to such Transfer, Buyer no longer has any rights in such Equipment. For the avoidance of doubt, at no time shall both Buyer and Project Company have simultaneous ownership, use or possession of the Equipment. In the event of such transfer,

i. Project Company shall[***] acquire Buyer’s rights (including all associated licenses) to use the Equipment in HPC Mode and to use HPC-Enabled Informatics Software and HPC Technology granted to Buyer by Seller under this Contract;
    
ii. Seller shall fulfill all of Seller’s obligations related to the Equipment (such as Installation, start-up and adjustment, Training, warranty, maintenance and support obligations etc.) for Project Company [***], provided such obligations have not been fulfilled by Seller for Buyer;    

iii. Buyer remains a Party to be charged under this Contract.    

17.6            Software is licensed and not owned      
Buyer shall not be an owner of any copies of the Informatics Software or any documentation delivered to Buyer, but Buyer is licensed pursuant to this Contract to use any of the Informatics Software and documentation specified in Pricing Sheet.      
17.7            Informatics Software is owned by Seller      
Buyer acknowledges that the features and the graphical user interface of the Informatics Software (“ User Interface ”), including, without limitation, icons, menus and screen designs, screen layouts,

16 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


and command and screen sequence, are the Confidential Information of Seller or its licensors, and are subject to the terms and conditions of this Contract with regards to Confidentiality . Buyer agrees that it will not create software programs incorporating the Confidential Information of the User Interface. Nevertheless, if Buyer creates one or more data loaders for metrology and/or testing equipment that it wishes to integrate into the Wet Combinatorial R&D Platform, Seller will work with Buyer on a time and materials basis (subject to the mutual prior written agreement of the Parties) to facilitate the use of said data loader(s) with the User Interface. Buyer further acknowledges that Seller or its licensors have asserted copyright ownership over the User Interface.      
17.8            Buyer agrees that it will not itself, and will not through any parent, subsidiary, Affiliate, agent, or other Third Party, directly or indirectly, do any of the following:      
17.8.1.        reproduce, distribute, copy, sell, create derivative works of, lease, license, or sublicense the Informatics Software or any component of either, or any documentation delivered to it pursuant to this Contract;      
17.8.2.        use the Informatics Software in connection with any equipment other than the Equipment and test & characterization equipment used in connection with the Equipment;      
17.8.3.        attempt, or permit any Third Party, to reverse engineer, disassemble, decrypt, decompile, or otherwise attempt to derive source code from the Informatics Software;     
17.8.4.        use any Informatics Software in connection with any time-sharing or other multi-user network or service bureau.      

17.9            Subject to payment by Buyer of the amounts set forth in the applicable Pricing Sheet and during any period in which Buyer makes the payments as set forth in Section 2.5, Seller will provide to Buyer the Support in accordance with Annex 1.5.6. Seller will provide Informatics Updates and improvements (provided such improvements are generally made available to all other licensees) at no additional charge.

17.10        Legend.
All copies of the Informatics Software shall include Seller’s copyright, trademarks, patent numbers, and other proprietary notices in the manner in which such notices were placed by Seller on such Informatics Software. Further, Seller may label the Equipment with a permanent non-erasable identification label including but not limited to Seller’s name, Seller’s model number, a sequential serial number in Seller’s standard format, date of manufacture, location manufactured, and specification version to which the Equipment was manufactured. Buyer shall not remove, obscure, or alter Seller’s copyright notices, trademarks, patent numbers, or other proprietary rights notices affixed to or contained within the Informatics Software or the Equipment.     
17.11        THIS SECTION INTENTIONALLY LEFT BLANK     

18.      Compliance with Laws.      
The Parties shall comply with all laws, rules or ordinances of the United States and any applicable state or other governmental agency while performing under this Contract.      
18.1            Compliance with Securities Laws.  Buyer agrees that certain of the information provided by Seller to Buyer hereunder may be “material, nonpublic information” for purposes of federal or state securities laws, the awareness of which prohibits Seller and its employees, contractors, representatives and agents from (i) buying or selling Seller’s securities (stock, options, etc.) (i.e., “insider trading”) and (ii) passing information to anyone who may buy or sell Seller’s securities (i.e., “tipping”), until after the information has been disclosed to the public and absorbed by the market.  Without limiting any of Buyer’s other obligations under this Contract, Buyer will comply with all federal and state securities laws prohibiting insider trading and tipping, and shall immediately notify Seller in the event of any insider trading or tipping by Buyer or its employees, contractors, representatives or agents of which it becomes aware.     
18.2            In accordance with the requirements of the Foreign Corrupt Practices Act of the United States (15 U.S.C. § 78dd-1 and 2) (“FCPA”), each Party agrees and warrants that it shall not make, offer, promise or authorize any payment, loan, gift, donation or other giving of money or things of

17 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


value, directly or indirectly, whether through itself, its affiliates, partners, officers, employees, agents or representatives, whether in cash or kind, and whether pursuant to a written agreement, to or for the use of any government official, any political party or official thereof or any candidate for political office, for the purpose of influencing or inducing any official act or decision in order to further the activities contemplated by this Contract, including obtaining or retaining any government approval or funding related to such activities.       
    
IN WITNESS WHEREOF , the parties hereto have caused this Contract to be executed by their duly authorized representatives:    
    
“Buyer”    
Ulyanovsk Center for Technology Transfer Ltd.     
Date: September 29, 2013    
Name: /s/Andrey Redkin    
(Print): Andrey Redkin    
Title: CEO    
    
“Seller”     
Intermolecular, Inc     
Date: September 29, 2013    
Name: /s/David E. Lazovsky    
(Print): David E. Lazovsky    
Title: President and CEO    
    
“Customer’s Engineer”     
Limited liability Company “Russkie Tehnoparki”     
Date: September 29, 2013    
Name: /s/Konstantin B. Popov    
(Print): Konstantin B. Popov    
Title: CEO    
    


18 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract




ANNEX 1.5.1

PRICING SHEET

Table-1.
S/N
Product
Manufacturer, country of origin
Unit of measure
Qty. in units of measure
Unit price
Total price
1.
Tempus™ F-20
Intermolecular, USA
Unit
[***]
[***]
[***]
2.
Tempus™ S-80
Intermolecular, USA
Unit
[***]
[***]
[***]
3.
HPC & Informatics License*
Intermolecular, USA
Year
[***]
[***]
[***]
4.
Maintenance & Support*
Intermolecular, USA
Year
[***]
[***]
[***]
TOTAL
х
х
Х
[***]
* The fees for HPC & Informatics License and Maintenance & Support (“License-Support”) are included in the above price for a period of [***] from Customer Tool Installation Completion Signoff (the “Initial Term”). Additional fees for the License/Support for the first year beyond the Initial Term (the “First Renewal Term”) shall be priced at [***] for the HPC & Informatics License fees and [***] for the Maintenance & Support fees for a combined total of [***] . The parties agree to enter into good faith discussions for pricing of the License-Support fees beyond the First Renewal Term, where such pricing shall take into account the fair market value of the License-Support fees.

19 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


Table-2. Calculation of cost of supplied equipment considering additional payments and services
S/N
Expense item
Cost (indicate currency)
1.     
Price of product (total in table-1)
[***]
2.     
Price of customs clearance of import cargo ( in case if foreign equipment is offered )
[***]
3.     
Price of customs clearance of export cargo
[***]
4.     
Price of transport expenses of Wet Equipment ([***] per Incoterms 2010) to the customs inspection at the destination point in Ulyanovsk, the Russian Federation. (including insurance for shipment of Wet Equipment)
[***]
5.     
Price of additional services, including:
 
5.1
Installation, start-up and adjustment
[***]
5.2
Training at Seller Site
[***]
 
TOTAL (1 + 2 + 3 + 4+5)
[***]

Payment of all taxes shall be in accordance with Section 3.3



20 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.2

Wet Combinatorial R&D Platform Description

A.
Hardware Description
S/N
Name of delivered equipment and specification
Configuration
Quantity
1.     
Tempus™ F-20
 
1.1
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
1.2
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
1.3
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
    
 
     [***]
[***]
     [***]
[***]
1.4
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]

21 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


1.5
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
     [***]
[***]
1.6
[***]
[***]
[***]
1.7
[***]
[***]
[***]
1.8
[***]
[***]
[***]
1.9
[***]
[***]
[***]
1.10
[***]
[***]
[***]
1.11
[***]
[***]
[***]
1.12
[***]
[***]
[***]
1.13
[***]
[***]
[***]
1.14
[***]
[***]
[***]
2.
Tempus™ S-80
 
2.1
[***]
[***]
[***]
2.2
[***]
[***]
2.3
[***]
[***]
2.4
[***]
[***]
2.5
[***]
[***]
2.6
[***]
[***]
2.7
[***]
[***]
2.8
[***]
[***]
2.9
[***]
[***]
[***]
2.10
[***]
[***]
[***]
2.11
[***]
[***]
[***]
2.12
[***]
[***]
[***]
2.13
[***]
[***]
[***]
2.14
[***]
[***]
[***]

22 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


2.15
[***]
[***]
[***]
2.16
[***]
[***]
[***]
2.17
[***]
[***]
[***]

B.
Operational characteristics of equipment
Refer to Facilities Manuals attached for operational characteristics of each equipment:
Manual, Installation, F-20 System [***]

C.
Software Description

Informatics Software

Informatics Software is a comprehensive Web-based R&D information management system that serves as the backbone for integrating experimental process data, characterization results and analysis tools into unified R&D workflows. This system enables experimental design, planning, and tracking of experimental splits, the associated metrology, and e-test data.

Following are the various modules of Informatics Software
Workflow manager (web & mobile app)
R&D Database
Data loader framework
Data search & export module
Analysis – Electrical Distribution, Spectra, Defect Distribution, Process Distribution, Sample Map, Image gallery
Collaboration forum
Administrator module to control user access privileges


23 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.3

Delivery Schedule

S/N
Stage
 
 
 
 
 
[***]
[***]
[***]
[***]
[***]
1.1
[***]
[***]
 
 
 
 
1.2
[***]
 
[***]
 
 
 
1.3
[***]
 
 
[***]
 
 
1.4.
[***]
 
 
 
[***]
 
1.5.
[***]
 
 
 
 
[***]



24 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


ANNEX 1.5.4

Payment Schedule

S/N
Stage
Stage number in Delivery schedule
Payment term
Payment amount*
1.
Wet Equipment arrives for customs inspection at the destination point in Ulyanovsk, the Russian Federation
End of 1.4
Payment due [***] [***] days from invoice
[***]
TOTAL
(total sum considering all obligatory payments)
х
х
[***]
* The amounts are prior to any applicable taxes. Any applicable taxes are in addition to the Payment amount and shall be due and payable in accordance with Section 3.3.



25 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.5

Acceptance Criteria

The acceptance criteria are described in the following documents which are incorporated herein by reference:

1.
Procedure Standard Acceptance F-20 [***]
2.
Procedure, Standard Acceptance, S-80, [***]
 



26 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.6
Seller Maintenance and Support Services
 
This Annex describes the maintenance and support services that Seller will provide with respect to the Wet Combinatorial R&D Platform.
Term and renewal of services
Seller will provide maintenance and support services set forth herein for the Wet Combinatorial R&D Platform. Such services will commence upon Customer Tool Installation Completion Signoff and continue for a period of [***] thereafter (the “Initial Term”).
 
Seller will continue to provide said services during any additional term during which Buyer renews maintenance and support services (“Renewal Term”) in accordance with the procedure set forth below.
 
Not less than [***] prior to the conclusion of the Initial Term, Seller shall send Buyer written notice of the date that the Initial Term is scheduled to expire, together with an invoice for HPC & Informatics License fees (“License Fees”) and maintenance & support fees (‘Support Fees”) for the first year beyond the Initial Term (the “First Renewal Term”) at USD [***] For the License Fees and USD [***] for the Support Fees (for a combined total of [***]), which invoice shall be payable within [***].
 
The fees for HPC & Informatics License and Maintenance & Support (“License-Support”) are included in the pricing in Annex 1.5.1 for a period of [***] from Customer Tool Installation Completion Signoff (the “Initial Term”). The parties agree to enter into good faith discussions for pricing of the License-Support fees beyond the First Renewal Term, where such pricing shall take into account the fair market value of the License-Support fees.
 
Seller will advise Buyer in advance when Seller believes that maintenance and support services fall outside of the range of supported services (“Non-Covered Services”) and will provide Buyer with a description of such Non-Covered Services and any applicable charges. All charges by Seller shall be at Seller’s then-current rates.
 
Response Times
 
Seller customer service may be initiated by calling 1-408 582-5700 or such other number or email provided to Buyer for that purpose. Seller will use its best judgment to determine the priority level of each error reported by Buyer and shall inform Buyer of any change and the basis thereof. Seller shall provide and maintain for Buyer contact and escalation procedures for Buyer personnel to reach an appropriate Seller employee as follows:
 
In the event of a call reporting an error, Seller will acknowledge the Buyer call within the next business day of Buyer contacting Seller, followed by initial assessment and an error resolution plan within [***] days of the assessment. Seller will use commercially reasonable efforts to schedule and execute error resolution activities in a timely fashion and in accordance with the error resolution plan. Provided that Seller’s activities under the error resolution plan are not related to activities outside Seller’s control (e.g. shipping delays, long-lead design and parts procurement), Seller will make commercially reasonable efforts to execute the plan within a period of [***]. In the event Seller’s activities under the error resolution plan are related to activities outside Seller’s control (e.g. shipping delays, long-lead design and parts procurement), Seller shall notify Buyer accordingly.
 
Maintenance and Support Services

27 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


       
A. Informatics Hardware and Equipment Support
 
During the Initial Term and any Renewal Term, provided Seller receives the reasonable requested cooperation from Buyer, Seller will do the following:
 
(a)
Remedial maintenance will be provided by Seller during normal working hours. Buyer will provide [***] access to the Hardware as needed to perform any services hereunder.
 
(b)
During the Warranty Period (as defined in Section 8.3), Seller will[***] maintain the Hardware in accordance with the warranty set forth in the Contract, including replace or repair (collectively “Remedy”) parts as deemed necessary by Seller. After the end of the Warranty Period (provided Buyer extends the maintenance and support services to be provided under this Annex beyond the Initial Term), Seller will Remedy parts at Buyer’s expense. In either of the foregoing, Seller will pay for the labor and services required to Remedy the parts (but will not pay for the parts beyond the Warranty Period). Buyer shall inform Seller if any replaced parts may be contaminated with hazardous or toxic materials. All parts may be furnished on an exchange basis and may be new or refurbished spares. Replaced parts removed from the Hardware will, at Seller’s sole option, become the property of Seller. All [***] items, including but not limited to [***] are excluded from coverage hereunder. Cost of [***]and [***], including [***] are to be covered by Buyer. Buyer is responsible for maintenance, and cost, of support equipment which are not listed in the Sign-Off.
 
(c)
Seller shall not be responsible for maintenance and support services under the contract based on damage caused by (i) Equipment operation outside of specified hardware limits and process conditions, (ii) adjustments, repairs or replacement parts required because of operator-caused error or repeated misuse of Hardware; (iii) a non-conformity arising from or after relocation of the Hardware without prior written approval of Seller, which shall not be unreasonably withheld, unless Buyer can demonstrate by clear and convincing evidence that the relocation did not cause the non-conformity, in whole or in part, or (iv) damages covered arising out of force majeure. All repairs required by such excluded damage will be subject to an additional charge, as agreed in advance in writing by Seller and Buyer.
 
B. Software Support
 
During the Initial Term and during any Renewal Term, Seller shall use commercially reasonable efforts to do the following:
 
(a)   Remedial maintenance will be provided by Seller during normal working hours. Buyer will provide full and free access to the Software as needed to perform any services hereunder.
(b)   During the Warranty Period (as defined in Section 8.3), Seller will maintain the Software in accordance with the warranty set forth in the Contract. Buyer will provide VPN site-to-site Internet access to the data network located at the Seller Facility to improve Seller’s ability to support Buyer.
 
c) Seller is not required to support or maintain any version of the Software except its then-current, commercially released version, and the version that immediately preceded that version. For such immediately preceding software version, Seller shall use commercially reasonable efforts to provide error-fixing updates, but shall have no obligation to provide upgrades that improve the functionality of that software version.
 
(d)
Seller is not obligated to provide, free of charge services, additional services, outside of the range of normal support services, such as debugging problems in non-Seller-supported software or products,

28 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


or in combinations of supported and non-supported software or products where the problem occurs in products or software not supplied by Seller.


29 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract





ANNEX 1.5.7

Installation and Facility Requirements

The facility requirements are described in the following documents which are incorporated herein by reference:
1.
F-20 Facility Requirements
2.
S-80 Facility Requirements

The installation requirements specifying the exact and exhaustive additional equipment, infrastructure and certain requirements needed for the Equipment being installed and started-up at the Buyer site shall be drafted and incorporated herein by the Parties within a term of [***] since the Execution date.






30 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.8

Documents at Sign-Off
 
 
Operation Manuals:
 
1.       Manual, Installation, F-20 System [***]
2.       Manual, Maintenance, F-20 System [***]
3.       Manual, Safety, F-20 System [***]
4.       Manual, User, F-20 System [***]

5.       Procedure, Decontamination, F-20, [***]
6.       Procedure, Standard Operating, for Operator Level User, F-20, [***]
7.       Procedure, Informatics Site Preparation, [***]
 
Certificates:
 
None from Seller
 



31 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



ANNEX 1.5.9

Informatics Modules

HPC Technology as Know How includes the following Informatics Modules 
1. R&D Workflow management : [***]
2. Data loading framework: [***]
3. Collaboration forum: [***]
4.  Analysis : [***]
5. Data search & export: [***]
6.   Visual Data analysis : [***]
7.  R&D data warehouse: [***]
 The documentary and supplementary information listed above shall be transferred by the Seller to the Buyer in PDF files in digital within a period of [***] since the execution date.

The Parties shall confirm save receipt of the Know How information by drafting a Completion act in [***] after the transfer of data has occurred.

32 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



Annex 1.5.10

Acceptance completion act


No. __





September ___, 2013


 


The present Acceptance completion act (hereinafter referred to as the “Act”) is concluded between



Limited Liability Company Ulyanovsk Center for Technology Transfer, a Russian Federation corporation doing business at 67 Krymova St., Ulyanovsk, Russia, 432071, hereinafter referred to as the "Buyer", on the one part,



and Intermolecular, Inc ., a Delaware, USA corporation doing business at 3011 North First St., San Jose, CA 95134, USA, hereinafter referred to as the "Seller",



and Limited liability Company Russkie Tehnoparki ” a Russian Federation corporation doing business at 1 Sirenevyi bulv., c.c. Troitsk, Moscow, Russia, 142191 hereinafter referred to as the " Customer’s Engineer ",





(jointly referred to as the “Parties” and individually referred to as the “Party”) as follows:.


 


1. All Parties entered into the Equipment Supply and Technology Licensing Contract for Wet ,Equipment __th, 2013 (hereinafter the “Contract”).



33 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


2. All Parties acknowledge that the Seller transferred and the Buyer accepted the Wet Equipment at the customs inspection at Ulyanovsk, Russian Federation. The acceptance was held without unpacking the Equipment, but only based on the quantity of packages and other data about cargo specified in the documents referred to in Section 5 of the Contract. The Parties confirm that the packaging was undamaged and that labels on the cargo conform with Section 6.4 and the data set out in the documents delivered along with the cargo.





3. The Parties further acknowledge that since the date of this Act the title in the Equipment and risk of loss and damage thereof has been transferred to the Buyer.





4. Further to the Contract, this Act is a basis for the submission of an invoice for the Contract price in accordance with the Payment Schedule.





5. Each Party has received its equally enforceable original copies of the Contract and Annexes thereto that have been signed by each Party.


 


6. The present Act is executed in three original counterparts in English and Russian. All capitalized terms used in this Act shall have the same meaning as in the Contract, unless otherwise expressly stated herein.


 


 


IN WITNESS WHEREOF , the parties hereto have caused this Act to be executed by their duly authorized representatives:






“Buyer”

Ulyanovsk Center for Technology Transfer Ltd.

34 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



Date:

Name:

(Print)

Title:



“Seller”

Intermolecular, Inc

Date:

Name:

(Print)

Title:



“Customer’s Engineer”

Limited liability Company “Russkie Tehnoparki”

Date:

Name:

(Print)

Title:






35 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



Annex 1.5.11

Start-up Act


No. __





September ___ , 2013


 


The present Start-up act (hereinafter referred to as the “Act”) is concluded between



Limited Liability Company Ulyanovsk Center for Technology Transfer, a Russian Federation corporation doing business at 67 Krymova St., Ulyanovsk, Russia, 432071, hereinafter referred to as the "Buyer", on the one part,



and Intermolecular, Inc ., a Delaware, USA corporation doing business at 3011 North First St., San Jose, CA 95134, USA, hereinafter referred to as the "Seller",



and Limited liability Company Russkie Tehnoparki ” a Russian Federation corporation doing business at 1 Sirenevyi bulv., c.c. Troitsk, Moscow, Russia, 142191 hereinafter referred to as the " Customer’s Engineer ",



(jointly referred to as the “Parties” and individually referred to as the “Party”) as follows:.





1. All Parties entered into the Equipment Supply and Technology Licensing Contract, __th, 2013 (hereinafter the “Contract”).






36 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract


2. Hereby the Parties confirm successful completion of the Customer Tool Installation Completion Signoff, in particular, that the Wet Equipment has been properly installed, started-up and adjusted at Buyer Site and that the Wet Equipment conforms with the Specifications and that training obligations are dully performed by the Seller.





3. The Parties further acknowledge that since the date of this Act the Buyer has been granted the license to use the Seller’s Technology (including Know-How) as stated in the Contract.





4. Each Party has received its equally enforceable original copies of the Contract and Annexes thereto that have been signed by each Party.


 


5. The present Act is executed in three original counterparts in English and Russian. All capitalized terms used in this Act shall have the same meaning as in the Contract, unless otherwise expressly stated herein.








IN WITNESS WHEREOF , the parties hereto have caused this Act to be executed by their duly authorized representatives:



“Buyer”

Ulyanovsk Center for Technology Transfer Ltd.

Date:

Name:

(Print)

Title:



“Seller”

37 38
 




    [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Confidential Information
 
Equipment Supply & Technology Licensing Contract



Intermolecular, Inc

Date:

Name:

(Print)

Title:



“Customer’s Engineer”

Limited liability Company “Russkie Tehnoparki”

Date:

Name:

(Print)

Title:





38 38
 



[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


JDP Agreement

This JDP Agreement (“ Agreement ”) is made by and between Limited Liability Company Ulyanovsk Center for Technology Transfer a corporation doing business in the Russian Federation (“ UCTT ”), and Intermolecular, Inc. , a Delaware corporation doing business at 3011 North First St., San Jose, CA 95134 (“ IMI ”). The effective date of this Agreement shall be September 29, 2013 (the “ Effective Date ”).

Background

1.
UCTT is engaged in, among other things, research, design, experimentation, development and commercialization of materials, manufacturing processes, and technologies in the Field as more fully defined in Section 1.12 below.
2.
IMI is engaged in, among other things, research, design, experimentation, development and commercialization in the area of and using HPC Technology as more fully defined in Section 1.13 below.
3.
UCTT purchased certain equipment (“Wet Equipment”) from IMI under a Wet Equipment Supply and Technology Licensing Contract.
4.
UCTT purchased certain equipment (“Dry Equipment”) from IMI under a Dry Equipment Supply and Technology Licensing Contract.
5.
UCTT wishes to engage in this joint development program with IMI in which joint development teams from IMI and UCTT will utilize IMI facilities, Dry Equipment, Wet Equipment and Informatics software to speed technology development and dramatically reduce time to market new, high-value products.


NOW THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties agree as follows.

1.
DEFINITIONS
1.1
Affiliate means a corporation, company or other entity now or hereafter, directly or indirectly, owned or controlled by UCTT or IMI respectively, but such corporation, company or other entity shall be deemed to be an Affiliate only so long as such ownership or control exists. For purposes of this definition "control" of a corporation, company or other entity shall mean -

a.
to have more than fifty percent (50%) of the voting rights or of the outstanding shares or securities representing the right to vote for either the election of the board of directors or a similar managing authority, or a supervisory board, or

b.
if there do not exist outstanding shares or securities as may be the case in a partnership, joint venture or unincorporated association, to have more than fifty percent (50%) of the ownership interest representing the right to make decisions for such entity.














[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


1.2
Background Technology of a party means Intellectual Property Rights and Know-How
a.
that is owned by the party at any time during the Term; and
b.
that was developed prior to the Effective Date.
1.3 Business Brought By shall have the meaning given to it in Section 7.3.
1.4
Business Development Committee shall the meaning given to it in Section 6.
1.5
CDP means an engagement between UCTT as provider of technology and/or services and IMI or Third Party as customer and recipient of such technology and/or services (regardless of whether or not UCTT is paid for such engagement) in which UCTT will use HPC Technology (including Dry Equipment and Wet Equipment) in the Field in any way to test, screen, develop or evaluate technologies or intellectual property pertaining to the deposition, cleaning, stripping, etching, or patterning of chemistries, thin films, coatings or other materials on a stand-alone basis or in integrated devices.
1.6
CDP Agreement means an agreement for a CDP.
1.7
CDP Licenses shall have the meaning given to it in Section 7.2.
1.8
CDP License Fees shall have the meaning given to it in Section 8.1b.
1.9
CDP Services shall have the meaning given to it in Section 7.2.
1.10
CDP Service Fees shall have the meaning given to it in Section 8.1a.
1.11
Confidential Information means information as defined in Section 12.
1.12
Field means the field of glass coatings, photovoltaics, power electronics and display.
1.13
HPC Technology means Intellectual Property Rights and Know-How related to techniques, methodologies, processes, test vehicles, synthetic procedures, technologies, systems, tools, tool configurations, tool designs or combination thereof, used for the simultaneous parallel or rapid serial design, discovery, synthesis, processing, process sequencing, process integration, device integration, analysis, or characterization of two (2) or more compounds, compositions, mixtures, processes, or conditions, or the structures derived from such.
1.14
IMI Projects means projects, engagements or activities conducted by IMI for IMI’s customers or for IMI’s internal development programs.
1.15
IMI Site means San Jose, CA, USA.
1.16
IMI Technical Contribution to CDP IP shall have the meaning given to it in Section 7.4.
1.17
Intellectual Property Rights means Statutory Rights in and to any and all of the following -
a.
U.S. and foreign patents and patent applications claiming any inventions or discoveries made, developed, conceived, or reduced to practice, including all divisions, substitutions, continuations, continuation-in-part applications, and reissues, re-examinations and extensions thereof,
b.
U.S. and foreign copyrights,
c.
U.S. and foreign trademarks, service marks, trade names, trade dress, domain names and similar rights,
d.
U.S. and foreign mask work rights, and
a.
Any other moral, intellectual or other proprietary rights of any kind now known or hereafter recognized in any jurisdiction in the world.
1.18
JDP means the joint development program as more fully described in this Agreement.
1.19
JDP Technology means the technology developed during and as a result of UCTT Engineers working on IMI Projects.




[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


1.20
Know-how means any know-how, technology, trade secrets, information (including inventions eligible for statutory protection), software (including source code), circuitry, circuit designs, design descriptions, specifications, formulas, processes, process conditions, materials, material stacks, structures, architectures, specifications for the procurement of parts and drawings, whether in tangible or intangible form and all other experience, drafts, ideas, concepts and business information.
a.
Know-How does not include Intellectual Property Rights, however Know-How shall include without limitation copyrights or intellectual property rights (other than Intellectual Property Rights) that are not Statutory Rights.
1.21
Licensing Royalty Profits shall have the meaning given to it in Section 8.3.
1.22
Outside Third Party means a Third Party
a.
whose principal offices are located outside the Russian Federation; or
b.
a majority of whose assets are located outside the Russian Federation ; or
c.
that is Controlled by a corporation, company or other entity as of the Effective Date whose principal offices are located outside the Russian Federation or a majority of whose assets are located outside the Russian Federation, but such Third Party shall be deemed to be an Outside Third Party for only so long as such Control exists. For purposes of this Section 1.22, "Control" shall mean -
i.
to directly or indirectly have more than [***]percent ([***]%) of the voting rights or of the outstanding shares or securities representing the right to vote for either the election of the board of directors or a similar managing authority, or a supervisory board, or
ii.
if there do not exist outstanding shares or securities as may be the case in a partnership, joint venture or unincorporated association, to directly or indirectly have more than [***]percent ([***]%) of the ownership interest representing the right to make decisions for such Third Party.
1.23
Service Net Profits shall have the meaning given to it in Section 8.2.
1.24
Sign-Off shall have the meaning given to it in the Dry Equipment Supply and Technology Licensing Contract.
1.25
Statutory Rights means rights that come into force by the process of the following steps -
a.
Application to or registration with a governmental entity; and
b.
Approval of such application or registration by such entity.
1.26
Term shall have the meaning defined in Section 15.1.
1.27
Third Party means a party other than IMI or UCTT or their Affiliates.
1.28
Tool Stay Period means the period
a.
Starting on the Sign-Off date, and
b.
Ending [***] thereafter.
1.29
Tools mean the Dry Equipment and an IMI-owned functional equivalent of the Wet Equipment, either alone or in combination, as applicable.
1.30
Training Period means the period
a.
Starting on the Sign-Off date, and
b.
Ending [***] thereafter.
1.31
UCTT Engineers means up to a maximum of [***] UCTT engineering personnel who will be provided training by IMI in accordance with Section 2.1.
1.32
UCTT Projects means projects, engagements or activities conducted under a CDP.

1.33
UCTT Site means Ulyanovsk, Russian Federation.



[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


2.
IMI ACTIVITIES
2.1
Training
a.
During the Training Period, IMI will provide training for UCTT Engineers at IMI Site. In the event UCTT Engineers are not able to be physically present at the IMI Site for such training (e.g. due to a delay in the processing of their visa permits), IMI and UCTT will arrange for a mutually agreeable means and medium for remotely training the UCTT Engineers until such time when the UCTT Engineers are able to be physically present at IMI Site.

b.
The training will include the following activities:
i.
The UCTT Engineers will be trained on IMI Projects and UCTT Projects.
ii.
With respect to the Tools, IMI will provide UCTT Engineers training on:
A.
Use of the Tools.
B.
Designing experiments on the Tools.
C.
Designing workflows on the Tools.
D.
Use Informatics to program the Tools.
iii.
With respect to HPC Technology, IMI will provide UCTT Engineers training on:
A.
Combinatorial techniques.
B.
Combinatorial methodologies.
C.
Combinatorial processes.
D.
Test vehicles for combinatorial processing.
E.
Configurations of combinatorial systems.
F.
Screening, discovery, synthesis and processing of materials.
G.
Screening, discovery and identification of process conditions for device manufacturing.
H.
Process sequencing.
I.
Process integration.
J.
Device integration.
K.
Analysis and characterization of combinatorial data.
iv.
In the event IMI, in its sole discretion, believes that the training may involve dissemination of information that requires an export license or a deemed export license, IMI shall only provide such training after such licenses are obtained.

2.2
Expense
a.
During the Training Period and subject to Section 11.1, IMI, and not UCTT, will pay for the costs associated with operating the Dry Equipment.
b.
During the Training Period, IMI will reimburse UCTT for UCTT’s expenses related to the training of the UCTT Engineers. Such expenses may include the salaries, room and board for the UCTT Engineers (collectively “Expenses”). In accordance with the foregoing, UCTT shall invoice IMI for the Expenses on the first day of each [***]for the first [***]in [***] equal amounts of [***] each and IMI shall make all approved payments no later than [***] days after invoicing.
i.
Notwithstanding the foregoing, IMI’s obligation to reimburse Expenses to UCTT shall be limited to a total of [***]. UCTT, and not IMI, shall be responsible for any Expenses that exceed [***].
c.
Except as set forth in this Section 2.2, UCTT and IMI will each bear their own respective costs associated with the JDP.  

2.3
Facilities and Workspace
a.
IMI will provide adequate facilities and workspace for UCTT Engineers at IMI Site and additional resources as are necessary to support IMI’s obligations to provide training to UCTT Engineers pursuant to Section 2.1. Such additional resources include access to clean room facilities, badge access, land-line phone connections, Internet access, and cubicle or office space for such UCTT Engineers.


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


b.
The UCTT Engineers shall complete IMI’s standard confidentiality and safety training prior to receiving access to IMI Site.
c.
In connection with use of the Tools, IMI will also provide the UCTT Engineers access to the metrology tools.

2.4
Assist UCTT in signing CDP Agreement
a.
Effective after Sign-Off, IMI will make commercially reasonable efforts to sub-contract to UCTT a portion of the activities under its current customer engagements for [***], at the sole discretion of IMI and subject to the approval of such current customer. Subject to such discretion and such approval,

i.
The detailed process, steps and timeline for such sub-contracting will be proposed by IMI and agreed upon with UCTT.
ii.
UCTT agrees to assist IMI including providing IMI with an understanding of the cost structure of R&D services at UCTT Site.
iii.
The minimum gross margin for these engagements (between customer and IMI) prior to such sub-contracting will be [***]than [***].

b.
IMI will assist UCTT to sign one or more CDP Agreements.
c.
If, within [***] of the Sign-Off, UCTT is unable to sign CDP Agreements for which [***] is [***] and where the cumulative revenue that UCTT can receive under all such CDP Agreements is at least [***], IMI agrees to pay UCTT up to a maximum of [***] in the following manner:

i.
If, [***] from the Sign-Off (“First Date”), the cumulative revenue that UCTT can receive under all CDP Agreements signed by UCTT on or prior to the First Date (“First Revenue”), is less than [***], IMI will make a payment to UCTT (“First Payment”) in the amount computed as follows -

[***]


ii.
If, [***] from the Sign-Off (“Second Date”), the cumulative revenue that UCTT can receive under all CDP Agreements signed by UCTT on or prior to the Second Date (“Second Revenue”), is less than [***], IMI will make a payment to UCTT (“Second Payment”) in the amount computed as follows -
  
[***]


iii.
If, [***] from the Sign-Off (“Third Date”), the cumulative revenue that UCTT can receive under all CDP Agreements signed by UCTT on or prior to the Third Date (“Third Revenue”), is less than [***], IMI will make a payment to UCTT (“Third Payment”) in the amount computed as follows -

[***]


iv.
If, [***] from the Sign-Off (“Fourth Date”), the cumulative revenue that UCTT can receive under all CDP Agreements signed by UCTT on or prior to the Fourth Date (“Fourth Revenue”), is less than [***], IMI will make a payment to UCTT (“Fourth Payment”) in the amount computed as follows -


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.



[***]



d.
The First Payment, Second Payment, Third Payment and Fourth Payment will be non-refundable. For the avoidance of doubt, the total cumulative payments from IMI to UCTT under this Section 2.4c shall not exceed [***].
e.
Making payments in accordance with Section 2.4c does not release IMI from its obligation to make commercially reasonable efforts to sub-contract to UCTT a portion of the activities under its current customer engagements for [***] as it provided in Section 2.4a.

f.
UCTT shall make commercially reasonable efforts in signing CDP Agreements where Business Brought By is IMI (“IMI CDPs”) and shall not give preference to signing CDP Agreements where Business Brought By is UCTT (“UCTT CDPs”). The decision to sign an IMI CDP shall be solely based on the [***] and [***] that UCTT may obtain from such CDP. In determining whether or not to sign IMI CDPs, UCTT shall not take into account the [***]. Additionally, in determining whether or not to sign IMI CDPs, UCTT shall not take into account the [***] to be provided to [***].

g.
If, during the period beginning upon Sign-Off and ending [***] thereafter, UCTT does not sign an IMI CDP for reasons not solely based on the [***] and [***] that UCTT could have obtained from such CDP, then the parties shall agree to discuss in good faith a [***] IMI’s obligations under Section 2.4c.


2.5
IMI rights but not obligations
a.
Within [***] from the Effective Date and at IMI’s sole discretion, the parties agree to discuss in good faith the opportunity for IMI to [***] at the [***] no more than [***] of the [***] of [***], a company [***] and hereinafter referred to as Project Company, on a [***] basis. Notwithstanding the foregoing, nothing in this Agreement obligates IMI to make such [***].
b.
The parties agree that IMI shall have the right but not the obligation to propose candidates for election to [***] of Project Company’s Board of Directors.


3.
IMI Projects on DRY EQUIPMENT
3.1
CDP Agreement
a.
Upon the signing of a CDP Agreement, the Dry Equipment will be used for UCTT Projects.


3.2
During the Tool Stay Period
a.
In addition to being used for UCTT Projects, the parties agree that during the Tool Stay Period, IMI will use the Tools for IMI Projects at the IMI Site to satisfy IMI’s obligations to provide training to UCTT Engineers pursuant to Section 2.1.


4.
UCTT ACTIVITIES
4.1
Personnel
a.
During the Tool Stay Period, UCTT will ensure that no less than [***] UCTT Engineers (“Minimum Engineers”) are present at IMI Site and are available for supporting the UCTT Projects to satisfy UCTT’s obligations to its CDP customers and for IMI Projects to satisfy IMI’s obligations to provide training to UCTT Engineers pursuant to Section 2.1.


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.



i.
IMI will provide advisory services to UCTT to ensure that UCTT Engineers assigned by UCTT have the appropriate technical competency and are suitable candidates for training.
ii.
In the event, UCTT is unable to provide the Minimum Engineers during the Tool Stay Period, the parties agree to discuss in good faith other alternatives as appropriate remedies to address the shortfall. Such remedies will include but will not be necessarily limited to one or more of the following:

A.
Possible transfer of CDP activity to UCTT Site.
B.
Possible hiring campaign to recruit additional personnel. or
C.
Possible reduction in either the First Payment that may be owed by IMI to UCTT pursuant to Section 2.4c.i, Second Payment that may be owed by IMI to UCTT pursuant to Section 2.4c.ii, Third Payment that may be owed by IMI to UCTT pursuant to Section 2.4c.iii or Fourth Payment that may be owed by IMI to UCTT pursuant to Section 2.4c.iv.

b.
UCTT will ensure that the UCTT Engineers execute all required documents in order for IMI to comply with IMI’s confidentiality obligations under any IMI Projects.


5.
ACTIVITIES BY BOTH PARTIES
5.1
Project Managers
UCTT and IMI will each appoint by written notice to the other party a principal point of contact to be its project manager (the "Project Managers") who will coordinate and act as a liaison with the other party with respect to this Agreement and oversee the work under this Agreement. The parties will use reasonable efforts to direct communications under this Agreement through the project managers. Either party may from time to time change its project manager at its discretion by providing written notice to the other party.

5.2
Dispute Escalation Process
If either party believes that the other party has failed to perform its obligations under this Agreement, it will notify the other party of the perceived deficiency. The parties will, in good faith, attempt to resolve the matter within thirty (30) days in accordance with the following procedure:

a.
Project Managers
i.
Upon receipt of notice the Project Managers will promptly discuss a corrective action plan in person or by telephone and will attempt in good faith to agree to a mutually acceptable corrective action plan.
ii.
If the Project Managers cannot agree upon a corrective action plan within ten (10) days of receipt of notice, the issue will be escalated to senior management at the respective parties.
b.
Senior Management Representatives
i.
The respective senior management representatives will promptly discuss the issue in person or by telephone and the parties will attempt in good faith to resolve the issue for a period of (10) days.
ii.
If the issue is not resolved by mutual agreement within the second ten (10) day period, the issue will be escalated to senior most individual at the respective parties.
c.
Senior most individual
i.
The respective senior most individual will promptly discuss the issue in person or by telephone and the parties will attempt in good faith to resolve the issue for a period of (10) days.
ii.
If the issue is not resolved by mutual agreement within the third ten (10) day period, the parties may resort to remedies available in this Agreement or at law.




[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.



5.3
Progress Reports; Meetings
UCTT and IMI will discuss the progress of work under this Agreement at least on a monthly basis.

5.4
Development Records
UCTT and IMI shall maintain records of JDP activities (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved in the performance of the JDP activities (including information sufficient to establish dates of conception and reduction to practice of inventions).  

5.5
Obligation to notify
If UCTT intends to communicate with an Outside Third Party for the purpose of engaging in a CDP with such Outside Third Party, it will depend on whether such Outside Third Party is included in the Category A List, Category B List or Category C List (collectively “Lists”). The Lists are attached hereto as Annex A. The Parties agree to update the Lists upon mutual agreement. In the event a Third Party is not included in either of the Lists, the parties agree to discuss in good faith the inclusion of such party in one of the Lists. The following shall govern whether UCTT can contact an Outside Third Party for the purpose of engaging in a CDP with such Outside Third Party.

a.
With respect to an Outside Third Party that is on the Category A List, UCTT is free to engage with such Outside Third Party for the purpose of signing a CDP without IMI’s prior consent.
i.
In the event UCTT has established communications with an Outside Third Party with the good faith intent for UCTT to sign a CDP with such Outside Third Party, UCTT shall notify IMI in writing of such communications.
ii.
In the event IMI has established communications with an Outside Third Party with the good faith intent for IMI to sign a CDP with such Outside Third Party, IMI shall notify UCTT in writing of such communications.
iii.
In the event a party (“First Party”) has established communications with an Outside Third Party with the good faith intent for the First Party to sign a CDP with such Outside Third Party and as of the date of establishing of such communications the First Party has not received the other party’s written notification of establishing communication with such Outside Third Party in accordance with 5.5 (a) (i) or 5.5 (a) (ii), as the case may be,, then for the purpose of Section 7.3b, the First Contacting Party shall be the First Party.
iv.
Each party purporting to be the First Contacting Party under this section shall provide written documents (including but not limited to email records) to support its assertion that it is the First Contacting Party.
v.
Notwithstanding the foregoing, in order to maximize the chances of signing such CDP with such Outside Third Party, the parties may agree in good faith to amend the foregoing (including amending the identification of First Contacting Party and/or its impact on Section 7.3b) and discuss priorities and strategies in advance of establishing such communications.
b.
With respect to an Outside Third Party that is on the Category B List, UCTT shall not communicate with such Outside Third Party for the purpose of engaging in a CDP with such Outside Third Party without IMI’s prior written consent. If UCTT has received such IMI written consent, then for the purpose of Section 7.3b, the First Contacting Party shall be UCTT.

c.
With respect to an Outside Third Party that is on the Category C List, UCTT shall not communicate with such Outside Third Party for the purpose of engaging in a CDP with such Outside Third Party.

d.
For a period of 5 years from the Effective Date, IMI cannot sign a JDP in the field of glass coatings with a third party where such JDP will be similar in structure to this JDP, without UCTT’s prior consent. In the event IMI has established communications with a Third Party with the good faith intent for IMI to sign an agreement similar in structure to this JDP with such Third


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


Party in the field of [***], IMI shall notify UCTT in writing of such communications.
    
6.
BUSINESS DEVELOPMENT COMMITTEE
6.1
Membership
a.
The parties shall form and operate a committee for managing the JDP (hereinafter the “Business Development Committee”).
b.
The Business Development Committee shall consist of four (4) members. UCTT shall appoint two (2) members of the Business Development Committee and IMI shall appoint two (2) members. Each party may designate a third member such that each party may have an alternate or substitute member available at any given time, but only two (2) such members of each party shall vote in meetings of the Business Development Committee. At any time upon written notice to the other party, a party may at its sole discretion replace any member(s) of the Business Development Committee that such party has appointed.
c.
No later than thirty (30) days from the Effective Date, IMI will identify by name three (3) IMI members of the Business Development Committee.
d.
No later than thirty (30) days from the Effective Date, UCTT will identify by name three (3) UCTT members of the Business Development Committee.

6.2
Meetings
a.
The Business Development Committee shall meet at least once per month for a period of not less than [***] from Sign-Off, which meetings may be conducted telephonically, except as may be otherwise agreed by mutual consent.

6.3
Non-binding and advisory role
a.
The Business Development Committee shall generally review and on an advisory and non-binding basis, provide guidance and recommendations to the parties with respect to the activities of the parties under the JDP. Such guidance and recommendations may include one or more of the following:
i.
Evaluate business opportunities
ii.
Determine slot schedule of the Dry Equipment and Wet Equipment.
iii.
Resolve any issues related to profit sharing for each opportunity.

7.
CDP
7.1
CDP Activities
UCTT will engage in CDPs with Third Parties where the CDP activities may include (but are not necessarily limited to) the following:
a.
Providing R&D services to and creation of IP for its customers. Such customers may include but are not limited to domestic, international, government, research institutions and newly formed ventures
b.
Conducting internal R&D activities.
c.
Sale or licensing of the IP created as a result of internal R&D;
d.
Creation of joint ventures with third parties (Start Ups) based on the IP created as a result of internal R&D.

7.2
CDP Services and CDP Licenses
As part of the CDP activities, UCTT will provide to such Third Party the use of its R&D platform (including the Equipment) and the services of its personnel (collectively “CDP Services”). Additionally, in each instance, UCTT will grant licenses to such Third Party under certain Intellectual Property Rights or Know-How and may sell, assign or transfer certain Intellectual Property Rights or Know-How (collectively “CDP Licenses”).



[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.




7.2
Business Brought By
Upon the signing of each CDP Agreement, absent mutual consent of the parties to the contrary, the following definition of “Business Brought By” will prevail:
a.
If the Third Party is not an Outside Third Party, then for such CDP, Business Brought By shall be defined as UCTT.
b.
If the Third Party is an Outside Third Party, and, UCTT was established to be the First Contacting Party (as defined in Sections 5.5.a and 5.5b), then for such CDP, Business Brought By shall be defined as UCTT.
c.
If the Third Party is an Outside Third Party other than as defined in Section 7.3b, then for such CDP, Business Brought By shall be defined as IMI.


7.4
IMI Technical Contribution to CDP IP
Upon the signing of each CDP Agreement, absent mutual consent of the parties, the following will determine the definition of “IMI Technical Contribution to CDP IP”:
a.
If pursuant to or in preparation of the CDP or as a condition of Third Party signing the CDP Agreement, IMI has signed a separate agreement with UCTT or the Third Party, under which IMI will provide services to either UCTT or the Third Party as part of the CDP activities or as part of the performance of the CDP Agreement, then for such CDP, IMI Technical Contribution to CDP IP shall be defined as Yes.
b.
If pursuant to or in preparation of the CDP or as a condition of Third Party signing the CDP Agreement, IMI has signed a separate agreement with UCTT or the Third Party, under which IMI will grant a license to UCTT or Third Party under IMI’s Intellectual Property Rights or under IMI’s Know-How rights, to enable UCTT or Third Party to conduct CDP activities as part of the performance of the CDP Agreement, then for such CDP, IMI Technical Contribution to CDP IP shall be defined as Yes. Notwithstanding the foregoing, if the aforementioned separate agreement is only between IMI and UCTT (and not between IMI and a Third Party) and such separate agreement is either the Dry Equipment Supply and Technology Licensing Contract or Wet Equipment Supply and Technology Licensing Contract (but no other agreement), then IMI Technical Contribution to CDP IP shall be defined as No.
c.
If IMI does not provide any services or grant a license under its Intellectual Property Rights or Know-How rights to either UCTT or Third Party, then for such CDP, IMI Technical Contribution to CDP IP shall be defined as No.


8.
REVENUE SHARING FROM CDP
8.1
As part of the CDP activities,
a.
In exchange for providing CDP Services to a Third Party, UCTT will receive consideration from such Third Party (“CDP Service Fees”).
b.
In exchange for granting CDP Licenses to a Third Party, UCTT will receive consideration from such Third Party (“CDP License Fees”).

8.2
Service Net Profits shall mean the CDP Service Fees less the following -
a.
[***] separately stated on the invoice sent by UCTT to Third Party for payment of CDP Service Fees.
b.
UCTT’s [***] of [***] associated with the CDP, determined by UCTT’s customary accounting procedures.
c.
UCTT’s other costs [***]associated with the CDP. For the avoidance of doubt, [***] associated with the CDP [***] shall be considered costs. However [***] expenses and [***] expenses shall not be considered costs under this section.


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.





8.3
Licensing Royalty Profits shall mean the CDP License Fees less the following -
a.
[***] separately stated on the invoice sent by UCTT to Third Party for payment of CDP License Fees.


8.4
UCTT pricing of Services or Licenses
In order to provide to IMI its full commensurate share of the Service Net Profits and Licensing Royalty Profits contemplated hereunder, for CDP Agreements where the Business Brought By is IMI and/or the IMI Technical Contribution to CDP IP is Yes, UCTT shall ensure the following guidelines for providing CDP Services or granting CDP Licenses:
a.
UCTT shall charge commercially reasonable prices for CDP Service Fees and CDP License Fees. The pricing shall reflect what such CDP Services or CDP Licenses of similar kind and quality, sold in similar quantities, should be offered in a competitive marketplace.
b.
UCTT shall make commercially reasonable efforts to not provide CDP Services or grant CDP Licenses in exchange for [***]. In the event UCTT wishes to provide CDP Services or grant CDP Licenses in exchange for [***], UCTT and IMI will discuss in good faith an [***]for the purpose of computing IMI’s commensurate share of the Service Net Profits and Licensing Royalty Profits contemplated in this Agreement.


8.5
Profit Sharing
a.
Profit Sharing - UCTT shall pay to IMI a percentage of the Service Net Profits and Licensing Royalty Profits depending on whether the Business Brought By is IMI or UCTT and whether IMI Contribution is Yes or No.

Business Brought By
IMI Technical Contribution to CDP IP
Profit Sharing

(% of Service Net Profits and Licensing Royalty Profits to be paid by UCTT to IMI)
 
 
 
IMI
Yes
[***]
No
[***]
UCTT
Yes
[***]
No
[***]

b.
Notwithstanding Section 8.5a, for revenue that UCTT can receive under all CDP Agreements within [***] of the Sign-Off for which Business Brought By is IMI and provided the cumulative total of such revenue from all such CDP Agreements is less than [***] (“Initial Revenue”), the percentage of Service Net Profits (derived from the CDP Service Fees portion of the Initial Revenue) to be paid by UCTT to IMI shall be [***] regardless of whether the IMI Technical Contribution to CDP IP is Yes or No.
c.
Alternative Structure - Notwithstanding Section 8.5a and Section 8.5b, on a CDP-by-CDP basis, the parties may enter into good faith discussions to agree to use an alternative structure for providing compensation to IMI when Business Brought By is IMI and/or IMI Contribution of IP is Yes. Such alternative structures may include, but are not necessarily limited to, a [***] structure.
8.6
Payment and Reporting
a.
No later than [***] after the end of each calendar [***] period for the [***] and after the end of each [***] thereafter (such [***] or [***] hereinafter referred to as “Period”), UCTT shall,


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


together with the payment due on Service Net Profits and Licensing Royalty Profits, computed in accordance with Section 8.5a, furnish the following to IMI:

i.
A detailed written report, describing the following:
A.
All sales of CDP Services and CDP Licenses, broken down by specific CDP, made by UCTT during the preceding Period.
B.
All CDP Service Fees and Licensing Fees received by UCTT during the preceding Period together with an identification of each CDP customer and a description of any special licensing or other arrangements made with such customer.
C.
An itemized list of all allowable adjustments used in computing Service Net Profits and Licensing Royalty Profits.

ii.
UCTT’s payment for IMI’s share of Service Net Profits and Licensing Royalty Profits as computed in accordance with Section 8.5a. For the avoidance of doubt, UCTT shall provide a detailed written report to IMI in accordance with item (i) above, even if UCTT’s payment for a particular Period are zero.


8.7
Audit
a.
UCTT shall keep full, clear, complete, true and accurate records with respect to the CDP Services and CDP Licenses and the associated CDP Service Fees and CDP License Fees. Such books and records shall be kept in the English language and in compliance with international accounting principles as issued by the International Accounting Standards Board. Such books and records shall be kept at UCTT for at least three (3) years following the end of the calendar quarter to which they pertain. As more fully described in this Section, IMI shall have the right through its accredited representatives to examine and audit at reasonable times all such records and such other records and accounts as may under recognized accounting practices contain information bearing upon the amount of Service Net Profits and Licensing Royalty Profits due to IMI hereunder.
b.
Prompt adjustment shall be made by UCTT to compensate for any errors or omissions disclosed by such examination or audit.
c.
Inspections conducted under this Section shall be at the expense of IMI, unless a variation or error producing an increase exceeding [***] percent ([***]%) of the amounts payable for any period covered by the inspection is established and confirmed in the course of any such inspection, whereupon all reasonable costs relating to the inspection for such period and any unpaid amounts that are discovered will be paid promptly by UCTT.
d.
At IMI’s request, UCTT will permit an independent auditor and technical consultant selected by IMI and reasonably acceptable to UCTT, to examine during ordinary business hours no more than once each calendar year such records and other documents as may be necessary to verify or determine CDP Service Fees, CDP License Fees and other payments paid or payable under this Agreement.
e.
On reasonable notice (provided that IMI shall give UCTT at least 7 calendar days prior written notice of its election to inspect such records)and during regular business hours, IMI or its authorized representative shall each have the right to inspect and copy the books of accounts, records and other relevant documentation of UCTT or of any Affiliate of UCTT insofar as they relate to the CDP Services or CDP Licenses, in order to ascertain or verify the amount of Service Net Profits and Licensing Royalty Profits due to IMI hereunder, and the accuracy of the information provided to IMI in the aforementioned reports.
f.
The audit shall be conducted at the location(s) where such books and records are normally kept, IMI shall also have the right, not more than once each calendar year, to audit UCTT's books and financial records for the purpose of verifying full payment by UCTT of its payment obligations hereunder.
g.
Such audits shall be conducted during normal business hours and shall not unreasonably interfere with UCTT's conduct of its business. Upon ten (10) days written notice and not more


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


than once per calendar year, UCTT agrees to permit one or more Certified Public Accountant(s) appointed by IMI (except one to whom UCTT has a reasonable objection), to enter upon the premises or UCTT during all usual business hours of UCTT at any time following the [***] of any [***] in order to inspect files records pertaining to CDP Service Fees and Licensing Fees under this Agreement, and to make on UCTT's premises and retain copies of any and all parts of the records and accounts kept by UCTT pursuant to this Section, including without limitation, invoices which are relevant to any report required to be rendered by UCTT.
h.
Upon a request by IMI, UCTT shall permit IMI'S auditors to have access during normal business hours to UCTT'S records regarding the reports required to be made under this Agreement, in order to verify the correctness of or necessity for any payment or report by UCTT, as said auditor deems necessary. IMI agrees that such auditors shall not disclose to IMI any information other than information relating solely to correctness of or necessity for the reports and payments made hereunder. If UCTT refuses IMI'S auditors access to UCTT'S records, then upon request of IMI, UCTT shall permit an independent certified public accountant, selected by IMI and approved by UCTT to have access during normal business hours to UCTT'S records under the terms set forth for IMI'S auditors in this paragraph. In the event that an independent certified public accountant is necessary because of UCTT'S refusal of access then UCTT shall bear the cost of such independent certified public accountant.


9.
OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS AND KNOW-HOW
9.1
Background Technology
As between the parties, each party shall retain all right, title and interest in the Background Technology of the party.


9.2
IMI Projects
a.
IMI shall own all Intellectual Property Rights and Know-How rights arising out of the activities of UCTT Engineers on IMI Projects (“IMI Projects IP”).
b.
UCTT hereby assigns, and agrees to assign to IMI in the future when any such IMI Projects IP is first fixed in a tangible medium or reduced to practice, as applicable, all of its right, title and interest in and to any IMI Projects IP.  
c.
UCTT agrees to execute all papers, including patent applications, invention assignments and copyright assignments, and otherwise agrees to assist IMI, as reasonably required and at IMI’s reasonable expense, to perfect in IMI the rights, title and other interests in IMI Projects IP.
 

9.3
HPC Technology
a.
Without limiting the foregoing sections between the parties, IMI shall own all right, title, and interest in and to the HPC Technology and all improvements, derivatives and modifications thereof developed by either party or both parties during the course of the Agreement ("HPC Derivatives").
b.
UCTT hereby assigns, and agrees to assign to IMI in the future when any such HPC Derivatives are first fixed in a tangible medium or reduced to practice, as applicable, all of its right, title and interest in and to any HPC Derivatives.
c.
UCTT agrees to execute all papers, including patent applications, invention assignments and copyright assignments, and otherwise agrees to assist IMI, as reasonably required and at IMI’s reasonable expense, to perfect in IMI the rights, title and other interests in HPC Derivatives. 


9.4
UCTT Projects
a.
All Intellectual Property Rights and Know-How rights arising out of the sole activities of UCTT personnel (and not IMI personnel) on UCTT Projects shall be owned by UCTT.


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


b.
All Intellectual Property Rights and Know-How rights arising out of the sole activities of IMI personnel (and not UCTT personnel) on UCTT Projects shall be owned by IMI. IMI will grant UCTT a non-exclusive royalty-free, worldwide, perpetual license under such rights to practice such rights in the Field.
c.
All Intellectual Property Rights and Know-How rights arising out of the joint activities of UCTT and IMI personnel on UCTT Projects shall be owned jointly by UCTT and IMI. Each party shall have an equal, undivided 50% interest in any jointly owned Intellectual Property Rights and Know-How rights.


10.
INTELLECTUAL PROPERTY PROTECTION  
10.1
IMI controls prosecution
a.
IMI shall have the sole right, but not the obligation, to apply for, seek issuance of, and maintain in the United States and in foreign countries the patent rights associated with the JDP Technology that is solely owned by IMI or jointly owned by IMI and UCTT.
b.
All costs associated with such activity shall be paid by the owner of the Intellectual Property Rights and Know-How rights.
c.
The prosecution, filing and maintenance of all patent rights and applications are the within the sole discretion and responsibility of IMI. All decisions with respect to prosecution of the above patent rights are reserved to IMI.
d.
The parties agree to mutually develop a process for assisting each other in such activities.
  

10.2
Patent Prosecution
a.
IMI shall have the first right to prepare, file, prosecute and maintain, at its own expense and in consultation with UCTT, patent applications and patents claiming JDP Technology, and to conduct any interferences, re-examinations, reissues, oppositions or requests for patent term extension or governmental equivalents thereto.
b.
In the event that IMI does not file, prosecute or maintain any such patent or patent application (including the failure to do so in the Russian Federation) or undertake such other activities described above, then UCTT shall have the right to assume such activities at its own expense but without affecting the ownership and license provisions set forth in Section 9.  


10.3
Cooperation
a.
Each party agrees to execute all papers, including patent applications and invention assignments, and otherwise agrees to assist the other party, as reasonably required and at the other party’s reasonable expense, to perfect the rights, title and other interests in JDP Technology.
b.
IMI and UCTT shall both use reasonable efforts to keep the other fully informed as to the status of patent matters with respect to JDP Technology.
c.
IMI and UCTT shall each reasonably cooperate with and assist the other at its own expense in connection with such activities, at the other party's request. The Project Managers will (a) facilitate communication between the parties regarding patents and patent applications with respect to JDP Technology, (b) discuss and provide input on patent strategy with respect to JDP Technology, and (c) review applications and other substantive papers with respect to JDP Technology prior to filing with the patent office.  


  
11.
PAYMENTS
11.1
Expenses
For activities related to UCTT Projects, UCTT will provide or reimburse IMI for


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


a.
[***], such as [***] and [***],
b.
[***] and [***] not [***] by [***],
c.
reasonable travel and lodging expenses for IMI personnel performing activities at UCTT Site, and
d.
subject to UCTT's prior written approval not to be unreasonably withheld, any other out-of-pocket costs to support the JDP activities.

 
11.2
Payment Method
a.
All payments hereunder shall be made in U.S. dollars by UCTT or one of its U.S. Affiliates.
b.
All payments due to IMI under this Agreement shall be made by bank wire transfer as follows:

Domestic Wire Instructions:          
Route all wires via FEDWIRE to the following ABA number
To: [***]
Routing and Transit #: [***]
For Credit of: Intermolecular, Inc.          
Credit Account Number: [***]
By Order of: [name of sender]          
 
 
International Wire Instructions:          
Instruct the paying financial institution to advise their US correspondent to pay as follows:
Pay to:      [***]
Routing & Transit:      [***]
Swift Code:      [***]          
For Credit of:      Intermolecular, Inc.          
Final Credit Account#:[***]
By Order of:      [Name of Sender]          


11.3
Late payments
All payments shall be made [***] after invoicing. All payments not paid when due shall bear simple interest at a rate of [***] per month or the highest rate allowed by law, whichever is less.


11.4
Taxes
Prices and payments due to IMI are exclusive of all present and future taxes, duties, levies and other charges by any name (including any interest, penalties or additions thereto) imposed by any foreign, federal, state, local or other taxing authorities (including, without limitation, export, sales, use, excise and value-added taxes) on or with respect to the transactions or payments under this Agreement (excluding taxes imposed on IMI's net income by IMI's jurisdiction of organization or by reason of IMI's connection to such jurisdiction other than solely as a result of this Agreement).


12.
CONFIDENTIAL INFORMATION
12.1
The parties acknowledge that they may receive information from the other party which may be considered confidential and proprietary. The receiving party agrees to maintain in strict confidence such information that, if disclosed in writing, is identified and marked as confidential (or with words of similar meaning) at the time of its disclosure (or that, if disclosed verbally, is designated as confidential at the time of disclosure and is summarized and identified as confidential in a writing delivered to the receiving party within thirty (30) days after the disclosure) or that would appear to a reasonable person as confidential information ("Confidential Information").


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.




12.2
The receiving party will use the Confidential Information solely for the purpose of performing its rights and obligations under the Agreement.

12.3
The receiving party will not disclose Confidential Information to a Third Party without the prior written consent of the disclosing party. The receiving party will protect such information from disclosure to others with at least the same degree of care as the receiving party exercises to protect its own information of similar type and importance, but in no event less than reasonable care.

12.4
The obligations of confidentiality and protection required by this Section will survive the expiration, termination, or cancellation of this Agreement for a period of five years thereafter.

12.5
The obligation of confidentiality will not apply, or will cease to apply, to any information that: (a) was known to the receiving party prior to its receipt of Confidential Information under this Agreement; (b) is or becomes publicly available without breach of this Agreement; (c) is received from a third party without an obligation of confidentiality to the disclosing party or (d) is developed independently by employees of the receiving party not having access to such information, or (e) is required by law to be disclosed by the receiving party.


13.
WARRANTY; LIMITATION OF LIABILITY
13.1
By IMI
IMI represents and warrants that:
a.
It has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; and
b.
This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.


13.2
By UCTT
UCTT represents and warrants that:
a.
It has the right and authority to enter into this Agreement, and to fully perform its obligations hereunder; and
b.
This Agreement is a legal and valid obligation binding upon it and enforceable in accordance with its terms.


13.3
Disclaimer
UCTT and IMI specifically disclaim any representation, warranty or guarantee that the JDP activities will be successful, in whole or in part. It is understood that the failure of the parties to successfully develop or commercialize products resulting from JDP activities or any IMI Project or UCTT Project shall not constitute a breach of any representation or warranty or other obligation under this Agreement.
EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, UCTT AND IMI MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED WITH RESPECT TO ANY INFORMATION DISCLOSED HEREUNDER, ANY ACTIVITIES CONDUCTED HEREUNDER OR ANY DELIVERABLES PROVIDED HEREUNDER, AND HEREBY EXPRESSLY DISCLAIM ANY WARRANTIES OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OR VALIDITY OF ANY JDP TECHNOLOGY, PATENTED OR UNPATENTED, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.




[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.



14.
LIMITATION OF LIABILITY
14.1
TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, AND EXCEPT FOR ANY BREACH OF ANY PAYMENT OR CONFIDENTIALITY OBLIGATION UNDER THIS AGREEMENT AND ANY PERSONAL INJURY OR HARM SUFFERED BY THE EMPLOYEES OF A PARTY AND ANY PROPERTY DAMAGE SUFFERED OR INCURRED BY A PARTY DUE TO THE GROSS NEGLIGENCE OF WILLFUL ACT OF THE OTHER PARTY, IN NO EVENT SHALL EITHER PARTY OR ITS AFFILIATES BE LIABLE TO THE OTHER PARTY, ITS AFFILIATES OR TO ANY THIRD PARTY CLAIMING THROUGH OR UNDER THE OTHER PARTY HERETO, FOR ANY LOST PROFITS, LOSS OF DATA, EQUIPMEN'T DOWNTIME OR FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT OR INCIDENTAL DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY WAY OUT OF THIS AGREEMENT, WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
14.2
EXCEPT FOR BREACHES OF ANY PAYMENT AND CONFIDENTIALITY OBLIGATIONS, IN NO EVENT WILL EITHER PARTY’S LIABILITY TO THE OTHER UNDER THIS AGREEMENT EXCEED THE AMOUNTS PAID BY SUCH PARTY TO THE OTHER PARTY IN THE [***] PRECEDING THE CLAIM.
14.3
IN ADDITION, COMPANY ACKNOWLEDGES AND AGREES THAT AS BETWEEN THE PARTIES, IMI SHALL NOT BE LIABLE FOR ANY PRODUCT LIABILITY CLAIMS RESULTING FROM THE MANUFACTURE, SALE OR USE OF ANY PRODUCTS DEVELOPED AS A RESULT OF JDP ACTIVITIES THAT UCTT or THIRD PARTY USES, MAKES OR SELLS.
14.4
The parties acknowledge and agree that the foregoing limitations of liability are an essential element of this agreement and that in their absence the terms of this agreement would be substantially different.
 

15.
TERM AND TERMINATION
15.1
Term
a.
The term of this Agreement shall commence on the Effective Date, and, unless terminated earlier as provided in this Section 15.2, shall continue indefinitely thereafter (the "Term").


15.2
Termination for Breach
a.
Either party may terminate this Agreement if the other party has materially breached or defaulted in the performance of any of its material obligations, and such default has continued for sixty (60) days after written notice was provided to the breaching party by the non-breaching party.
b.
Termination will be effective at the end of the sixty (60) day period unless the breach has been cured before the expiration of such sixty (60) day period.


15.3
Effect of Termination
a.
Accrued Rights and Obligations
Termination of this Agreement for any reason shall not release either party from any liability or obligation that, at the time of termination, has already accrued to the other party or that is attributable to a period prior to termination, nor shall it preclude either party from pursuing any rights and remedies it may have at law or in equity with respect to any breach of this Agreement.  
b.
Termination of Licenses
In the event that UCTT materially breaches its obligations to pay CDP Service Fees or Licensee Fees due hereunder, and does not cure such breach in accordance with Section 15.2 above, then in addition


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


to any other remedy available to IMI, IMI may terminate the licenses granted to UCTT or Third Party pursuant to such CDP.  
c.
Termination of Projects
In the event that UCTT materially breaches its obligations to pay CDP Service Fees or Licensee Fees due hereunder, and does not cure such breach in accordance with Section 15.2 above, then in addition to any other remedy available to IMI, IMI may terminate the providing of services to UCTT or Third Party under a CDP.  


15.4
Survival
Sections 5(Activities by Both Parties), 7(CDP), 8(Revenue Sharing From CDP), 9(Ownership of Intellectual Property Rights and Know-How), 10(INTELLECTUAL PROPERTY PROTECTION), 11(PAYMENTS), 12(Confidential Information), 13(Warranty; Limitation of Liability), 14(LIMITATION OF LIABILITY), 15(Term and Termination), 16(Miscellaneous) shall survive the expiration or termination of this Agreement for any reason.

 
16.
MISCELLANEOUS
16.1
Amendment
No change or modification in the terms hereof, in a manner not expressly provided in this Agreement shall be binding unless reduced to writing and duly executed by the parties in the same manner as the execution of this Agreement. Any attempt to so change or modify the terms of this Agreement shall be considered void and of no effect.

16.2
No Implied License
Only the licenses granted pursuant to the express terms of this Agreement shall be of any legal force or effect. No other license rights shall be created by implication, estoppel or otherwise. Each party reserves all rights not expressly granted to the other party under this Agreement.


16.3
Assignment
a.
Neither party shall assign or transfer this Agreement either voluntarily or by operation of law, in whole or in part, without the prior written consent of the other party.
b.
Any attempt to assign without such consent shall be void and of no effect.
c.
Notwithstanding the foregoing, UCTT may assign this Agreement without such consent, to the Project Company, and the terms of the Agreement shall continue in effect without modification after such assignment. Furthermore, IMI may assign this Agreement without such consent to a successor in interest to its business, whether by merger, acquisition, consolidation, change of control, reorganization or sale of substantially all of its assets.


16.4
Drafting
In interpreting and applying the terms and provisions of this Agreement, the parties acknowledge that its lawyers reviewed and participated in the drafting and agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.


16.5
Governing Law
This Agreement shall be governed by and construed in accordance with the laws of the State of California in the United States, without regard to its conflicts of law principles.

  
16.6
Venue
All disputes between the parties in connection to this Agreement shall be addressed in accordance with Section 16.7. [If no solution can be found to settle the dispute, then the dispute will be submitted


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


to a court of competent jurisdiction in the location of the party accused of breach or failure of an obligation hereunder.]


16.7
Dispute Resolution
All disputes between the parties in connection with or arising out of this Agreement shall first be discussed in good faith between the parties in order to try to find an amicable solution.
a.
If no solution can be found to settle the dispute, then such dispute shall be finally settled by arbitration in accordance with the default rules and procedures of American Arbitration Association sitting in New York City, NY, USA and conducted in English.
b.
Within 30 days of notice that a party wants to submit a dispute to arbitration, the parties shall each select one independent arbitrator and will attempt to mutually agree upon a third independent arbitrator. Each arbitrator will have expertise in the thin film technology industry and will not be an employee, affiliate or contractor for either party.
c.
If the parties are unable to agree on the third arbitrator within fifteen (15) days, the two arbitrators shall select the third arbitrator within thirty (30) days.
d.
If the amount in dispute is less than [***], then the parties shall agree upon a single arbitrator meeting the above conditions within thirty (30) days of the notice of arbitration or such arbitrator shall be chosen by AAA if the parties cannot agree.
e.
The arbitrators shall determine what discovery will be permitted consistent with the goal of limiting the costs and time for such a proceeding. The parties and arbitrators shall use all reasonable efforts to complete any arbitration subject to this Section within six (6) months from the selection of arbitrators.
f.
The parties agree that any award of damages shall not include punitive, special, consequential, or indirect damages except as specifically allowed in this Agreement and shall comply with the limitation of liability provisions set forth herein.
g.
The arbitrators’ decision shall be in a detailed writing setting forth the reasons for their decision and shall be provided concurrently to each party.
h.
The arbitration award shall be final and binding on the parties.
i.
Unless otherwise agreed to by the parties, each party shall pay one-half of the arbitration fees and expenses and shall bear all of its own expenses in connection with the arbitration.
j.
Notwithstanding any of the foregoing, either party shall have the right to seek, at its own cost and expenses, preliminary and temporary injunctive relief pending resolution of the dispute via arbitration.
k.
The parties expressly disclaim the application of the United Nations Convention on the International Sale of Goods to this Agreement.


16.8
Independent Contractors
The relationship of the parties is that of independent contractors. Neither party shall be deemed to be an agent, partner, joint venturer or legal representative of the other for any purpose as a result of this Agreement or the transactions contemplated thereby. Personnel supplied by either party are not the other party's employees or agents and such supplying party assumes responsibility for their acts or omissions, The supplying party shall be solely responsible for the payment of compensation of such party's employees or agents assigned to perform services hereunder and such employees or agents shall be informed that they are not entitled to any employee benefits of the other party. Neither party shall be responsible for paying worker's compensation, disability benefits, and unemployment insurance or for withholding and paying employment taxes for any employee or agent of the other party.






[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


16.9
Compliance with Laws
Each party shall comply with all applicable laws, including, but not limited to, government regulatory requirements and the export control laws of the United States.

  
16.10
Notices
a.
Unless otherwise agreed to by the parties, the communications required or permitted to be given or made under this Agreement shall be made in writing, via personal delivery, registered mail, facsimile transmission (with written confirmation copy by registered first-class mail), addressed to the appropriate party at the address indicated below and a copy to the receiving party’s legal department.
b.
All communications made pursuant to this section shall be deemed made or given on the date of such personal delivery, mailing or transmission.
c.
If to UCTT:
Ulyanovsk Center for Tecnology
Transfer, LLC
67 Krymova St.
Ulyanovsk, 432071
Russia

With a copy to:
Ulyanovsk Center for Tecnology
Transfer, LLC
Attention: Head of Legal
Department
67 Krymova St.
Ulyanovsk, 432071
Russia
d.
If to IMI:
Intermolecular, Inc.
3011 North First St.
San Jose
CA 95134

With a copy to:
Intermolecular, Inc.
Attention: General Counsel
3011 North First St.
San Jose
CA 95134

e.
The Parties may change the name and address to which communications should be sent under this section by providing prior written notice to the other party.


16.11
Captions
The captions to the several sections hereof are not part of this Agreement, but are included merely for convenience of reference and shall not affect its meaning or interpretation. As used in this Agreement, the word "including" means "including without limitation”.


16.12
Counterparts
This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement.


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


16.13
Signatures by Electronic Mail or Facsimile
The delivery by electronic mail or facsimile of the signatures of the parties shall be deemed valid and binding as if they were originally made.


16.14
Copies
A scanned or photocopied version of this Agreement shall be deemed to be an original and shall have the full force and effect of an original document.


16.15
Non-waiver
The failure of either party at any instance to require performance of any provision hereof by the other party shall not be deemed a waiver and thereafter shall not deprive that party of its full right to require such performance of that provision at another instance. Any waiver must be in writing executed by the waiving party.
 

16.16
Severability
If any term, provision, covenant or condition of this Agreement is held by a court of competent jurisdiction to be illegal, invalid, void or unenforceable, the remainder of the terms, provisions, covenants or conditions shall remain in full force and effect and shall in no way be affected, impaired or invalidated. The Agreement shall continue in full force and effect to the fullest extent permitted by law without said provision or with said provision being modified and narrowly tailored to achieve the original intent of the parties.


16.17
Publicity; Disclosure of Agreement
a.
Neither party shall publicize nor disclose the terms of this Agreement without the prior written consen t of the other party, except -
i.
to the extent required by law, to governmental entities under each the applicable laws and regulations (including without limitation in a Form 8-K to the United States Securities and Exchange Commission and to the Russian patent and intellectual property agency, Rospatent), or
ii.
to such party's attorneys, accountants, advisors, investors and financing sources and their advisors and others on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, or
iii.
in connection with the enforcement of this Agreement or rights under this Agreement, or
iv.
in connection with a merger, acquisition, financing transaction or proposed merger, acquisition or financing transaction.
b.
Notwithstanding the foregoing,
i.
no later than thirty (30) days after the Effective Date, the parties will agree to a joint press release,
ii.
IMI may mention UCTT on its web site, and
iii.
UCTT will provide a testimonial to IMI (subject to mutual agreement of the parties) for use on IMI’s web site.


16.18
Force Majeure
Neither party shall lose any rights hereunder or be liable to the other party for damages or losses (except for payment obligations then owing) on account of failure of performance by the defaulting party if the failure is occasioned by war, strike, fire, act of God, earthquake, flood, lockout, embargo, act of terrorism, governmental acts or orders, failure of suppliers, or any other reason where failure to perform is beyond the reasonable control and not caused by the negligence, intentional conduct or


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


misconduct of the non-performing party and such party has exerted all reasonable efforts to avoid or remedy such force majeure; provided, however, that in no event shall a party be required to settle any labor dispute or disturbance.


16.19
Third Party Beneficiaries
Except as expressly provided in this Agreement, there are no third party beneficiaries expressly or impliedly intended under this Agreement.


16.20
Integration
This Agreement, together with all Exhibits hereto, constitutes the entire agreement and understanding of the parties relating to the subject matter hereof and supersedes all prior negotiations and understandings between the parties, both oral and written, regarding such subject matter.


16.21
Representation by Legal Counsel
Each party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the parties agree that no presumption shall exist or be implied against the party that drafted such terms and provisions.


16.22
Compliance with Laws
Each party shall comply with all laws, rules or ordinances of the United States and any applicable state or other governmental agency while performing under this Agreement.
a.
Each party agrees that certain of the information provided by one party to another hereunder may be “material, nonpublic information” for purposes of U.S. federal or state securities laws, the awareness of which prohibits UCTT and its employees, contractors, representatives and agents from (i) buying or selling IMI’s securities (stock, options, etc.) (i.e., “insider trading”) and (ii) passing information to anyone who may buy or sell IMI’s securities (i.e., “tipping”), until after the information has been disclosed to the public and absorbed by the market. Without limiting any of UCTT’s other obligations under this Agreement, UCTT will comply with all federal and state securities laws prohibiting insider trading and tipping, and shall immediately notify IMI in the event of any insider trading or tipping by UCTT or its employees, contractors, representatives or agents of which it becomes aware.
b.
In accordance with the requirements of the Foreign Corrupt Practices Act of the United States (15 U.S.C. § 78dd-1 and 2) (“FCPA”), each party agrees and warrants that it shall not make, offer, promise or authorize any payment, loan, gift, donation or other giving of money or things of value, directly or indirectly, whether through itself, its affiliates, partners, officers, employees, agents or representatives, whether in cash or kind, and whether pursuant to a written agreement, to or for the use of any government official, any political party or official thereof or any candidate for political office, for the purpose of influencing or inducing any official act or decision in order to further the activities contemplated by this Agreement, including obtaining or retaining any government approval or funding related to such activities. Each party represents and warrants that it will strictly comply with the FCPA, and agrees that if it violates the FCPA in the course of performing the activities enumerated in this Agreement, the non-violating party may immediately upon notice to the violating party terminate this Agreement.


16.23
Governing Language
This Contract has been executed by the parties in counterpart originals, one in the English language and one in the Russian language. Notwithstanding the foregoing, the parties agree that in the event of controversy between the parties regarding the interpretation or application of the terms of this


[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


Contract, the English language version of the Contract will be controlling. All communications and notices to be made or given pursuant to this Contract shall be in the English language.

“UCTT”
Ulyanovsk Center for Technology Transfer Ltd.

Date: September 29, 2013
Name: /s/Andrey Redkin
(Print): Andrey Redkin
Title: CEO

“IMI”
Intermolecular, Inc.

Date: September 29, 2013
Name: /s/David E. Lazovsky
(Print): David E. Lazovsky
Title: CEO & President



 



[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.


Annex A

Category A List

Field of Glass Coatings
Field of Photovoltaics
Field of Power Electronics
Field of Display
     [***]

     [***]
     [***]
     [***]

In addition to specific Outside Third Parties listed above and to the extent that such Outside Third Parties is not listed in Category B or Category C, Category A also includes,
a)
any Outside Third Party in the Field with <$50M revenue in the year prior to the year in which UCTT first engages with such Outside Third Party,
b)    any Outside Third Party in the Field whose principal offices are located in one of the following countries Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Uzbekistan and Ukraine and a majority of whose assets are located in the same country, and
c)    for the sole purpose of the field of glass coatings any Outside Third Party in the Field whose principal offices are located in a country that is part of the European Union and a majority of whose assets are located in the same country.


Category B List

Field of Glass Coatings
Field of Photovoltaics
Field of Power Electronics
Field of Display
 • [***]
 [***]
 [***]
 [***]


Category C List

Field of Glass Coatings
Field of Photovoltaics
Field of Power Electronics
Field of Display
• [***]
[***]
[***]
[***]




FIRST AMENDMENT TO LEASE AGREEMENT
THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “ First Amendment ”), dated for reference purposes only as of October 11, 2013, is made by and between S B C & D Co. , a California corporation (“ Landlord ” or “ SBCD ”), and INTERMOLECULAR, INC. , a Delaware corporation (“ Tenant ”).
Recitals :
A. Novellus Systems, Inc., a California corporation (“ Novellus ”), and Tenant entered into that certain Lease Agreement dated as of May 11, 2010 (the “ Lease ”) covering the premises (the “ Premises ”) consisting of approximately 146,159 square feet of rentable area located at 3011 North 1 st Street, San Jose, California and the real property on which the Building is located, all as more particularly set forth in the Lease.
  
B. SBCD and Novellus are parties to that certain Purchase Agreement dated as of October 10, 2013 (the “ Purchase Agreement ”), pursuant to which SBCD, or a permitted assignee of SBCD, has the right to acquire the real property described therein, which real property includes, among other things, the Premises. Landlord anticipates that close of escrow under the Purchase Agreement (“ Close of Escrow ”) will occur on or about October 30, 2013.

C. The Term of the Lease is scheduled to expire on May 31, 2017. Landlord and Tenant desire to amend the Lease to provide for, among other things, (i) the extension of the Termination Date of the Term of the Lease for a period of approximately one hundred thirty-nine (139) months from the Effective Date (defined below), (ii) the modification and establishment of the Basic Rent payable by Tenant during the period commencing on the Effective Date, and (iii) a tenant improvement allowance to be provided by Landlord to Tenant for the purposes specified below, all on the covenants and provisions, and subject to the terms and conditions, set forth in this First Amendment.
 
NOW, THEREFORE, in consideration of the mutual agreements contained in this First Amendment and for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, Landlord and Tenant agree as follows:
1. Incorporation of Recitals and Defined Terms . Landlord and Tenant hereby incorporate the foregoing Recitals into the body of this First Amendment as though fully set forth herein. Landlord and Tenant acknowledge and agree that the foregoing Recitals are true and correct and form the basis for the execution and delivery of this First Amendment. Terms appearing in this First Amendment with initial capital letters that are not expressly defined in this First Amendment shall have the meanings given to such terms in the Lease.

2. Landlord . SBCD has advised Tenant that SBCD has the right under the Purchase Agreement to assign its rights under the Purchase Agreement to an entity in which SBCD or its parent, subsidiary or commonly-controlled affiliate retains a controlling ownership interest or in which the principals of SBCD hold a direct or indirect interest. For purposes of this First Amendment and the Lease, from and after the Effective Date, the term “ Landlord ” shall mean the entity that acquires title to the Premises and assumes the Lease from Lam at the Close of Escrow.
  

4816-8951-6053v3                      1
PLS\07536231




3. Effective Date . This First Amendment shall become effective as of the date on which Landlord acquires title to the Premises pursuant to the Purchase Agreement (i. e., as of the Close of Escrow) (the “ Effective Date ”).
 
The parties acknowledge that the effectiveness of this First Amendment is expressly conditioned and contingent upon the occurrence of Close of Escrow under the Purchase Agreement. If escrow fails to close pursuant to the terms and conditions of the Purchase Agreement for any reason, and Landlord does not acquire title to the Premises, then this First Amendment shall be of no further force or effect and the parties shall have no further rights or obligations hereunder.
4. Extension of Term . As of the Effective Date, the Termination Date of the Lease shall be extended to the last day of the month which is one hundred thirty-nine (139) calendar month following the month in which the Effective Date occurs. (For example, if Close of Escrow, and therefore the Effective Date, occurs on October 30, 2013, then the Termination Date of the Lease will be June 30, 2025. If Close of Escrow, and therefore the Effective Date, occurs on November 12, 2013, then the Termination Date of the Lease will be July 31, 2025.) The period from the Effective Date through the Termination Date is referred to as the “ Extended Term ”. Notwithstanding the foregoing, if Close of Escrow occurs after November 30, 2013, the Termination Date of the Lease shall be July 31, 2025.

5. Early Termination Option . Section 2(e) of the Lease is hereby deleted in its entirety. The Early Termination Option provided in Section 2(e) of the Lease shall be of no further force or effect.

6. Rent .

a. Basic Rent . The schedule of Basic Rent set forth in the Basic Lease Information is hereby deleted in its entirety. During the Extended Term, Tenant shall pay to Landlord Basic Rent in accordance with the following schedule. For the purposes of this schedule, “Initial End Date” is defined as the date which is four (4) calendar months following the Effective Date.
Period
Monthly Basic Rent
Effective Date - Initial End Date
$0.00
Day Following Initial End Date - 2/28/15
$142,397
3/1/15 - 2/28/16

$147,226
3/1/16 - 2/28/17

$195,853
3/1/17 - 2/28/18

$200,749
3/1/18 - 2/28/19

$205,768
3/1/19 - 2/28/20

$210,912
3/1/20 - 2/28/21

$216,185
3/1/21 - 2/28/22

$221,590
3/1/22 - 2/28/23

$227,130
3/1/23 - 2/28/24

$232,808
3/1/24 - 2/28/25

$238,628
3/1/25 - Termination Date
$244,593

Basic Rent shall be payable at the times, in the manner and at the place as set forth in the Lease, as amended by this First Amendment. From and after the Effective Date, Tenant shall pay Rent to

4816-8951-6053v3                      2
PLS\07536231




Landlord at 1690 Dell Avenue, Campbell, California 95008, or at such other address as may be specified by Landlord.
b. Additional Rent - Operating Costs and Taxes . The third sentence of Section 3(b) of the Lease, which reads as follows:

Notwithstanding any contrary implication or expression in the foregoing or elsewhere in this Lease, Tenant shall have no obligation to pay any portion of Tenant’s Proportionate Share of Operating Costs for each calendar year which is attributable to an increase in the sum of Taxes and Insurance Costs which is in excess of the sum of Taxes and Insurance Costs paid by Tenant for the previous calendar year (grossed up to a full calendar year for any partial year during the Term), increased by three percent (3%)
is hereby deleted in its entirety. Tenant’s obligation to pay Tenant’s Proportionate Share of Operating Costs shall not be subject to a limitation or “cap”.
7. Tenant Improvement Allowance . Tenant acknowledges that Tenant is currently in possession and occupancy of the Premises and Tenant is familiar with the condition of the Premises and the suitability of same for Tenant’s purposes. Except for the Tenant Improvement Allowance (defined in this Section 7 below), Landlord shall not be obligated to construct or install any leasehold improvements in, on or around the Premises or the Building or to provide any tenant improvement allowance to Tenant.

Landlord shall grant to Tenant an allowance (“Tenant Improvement Allowance”) to be used for the modification, refurbishment, construction or installation of tenant improvements in the Premises (collectively, “Refurbishment”) in an amount not to exceed One Million Dollars ($1,000,000). Any and all work performed by Tenant in connection with the Refurbishment shall be treated as alterations to the Premises pursuant to Section 7 of the Lease and shall be subject to (or exempted from) Landlord’s prior written consent and shall otherwise performed in accordance with all of the terms and conditions of the Lease. Without limiting the foregoing, Landlord agrees that the Tenant Improvement Allowance may be used by Tenant for paint and carpeting in the Premises, signage, architectural fees, consulting fees, engineering services, mechanical and electrical services, security systems, project management fees and building permit associated with Tenant’s Refurbishment. Before commencing any work of alteration, addition or improvement to the Premises, Tenant shall provide Landlord with a certificate of insurance from each contractor and subcontractor evidencing the insurance coverage required pursuant to Section 7(c) of the Lease.
Landlord shall pay Tenant the Tenant Improvement Allowance in ten (10) equal monthly installments of One Hundred Thousand Dollars ($100,000) each, with the first of said ten payments to be made on the first day of the first month following the month in which the Effective Date occurs.
8. Utilities . The fourth and fifth sentences of Section 8(a) of the Lease, which read as follows:

Notwithstanding the foregoing to the contrary, Landlord shall attempt to maintain, using commercially reasonable efforts, for the benefit of the named Tenant only, its contract pricing terms with Sempra Energy and Air Products (as it relates to the procurement of Nitrogen gas), and to request extensions

4816-8951-6053v3                      3
PLS\07536231




of such contracts as appropriate to endure throughout the term of the named Tenant’s occupancy of the Premises under this Lease, and Tenant’s obligations hereunder shall include without limitation, all surcharges for electricity used at the Premises in excess of the contracted monthly volumes or amounts applicable to the Premises under Landlord’s contracts to obtain electricity for the Premises and Landlord’s other nearby facilities (and Tenant hereby acknowledges that Landlord has provided Tenant with copies of the current pertinent contract terms with Sempra Energy relating to such contracted monthly volumes or amounts of electricity to be provided to the Premises). Landlord shall provide Tenant with copies of all monthly utility usage information received by Landlord from any utility provider for which Landlord invoices Tenant
are hereby deleted in their entirety. Landlord shall have no obligation with respect to the provision of electricity or nitrogen gas to the Premises, or the cost thereof to Tenant.
9. Furniture . Section 28 of the Lease and Exhibit H attached to the Lease are hereby deleted in their entirety.

In consideration for Tenant’s entering into this First Amendment, on the Effective Date, Landlord hereby transfers and conveys ownership of the furniture and cubicles identified in the Furniture Inventory attached as Exhibit A hereto (the “ Furniture ”). Tenant shall accept the Furniture in its “as is” “where is” condition and Tenant acknowledges that Landlord makes no warranty as to the condition of the Furniture or its present condition or future suitability for Tenant’s purposes. During the Extended Term, Tenant shall pay and discharge all license fees, assessments and sales, use, property and other tax or taxes now or hereafter imposed by any state, Federal or local government upon the ownership, sale, possession or use of the Furniture. Tenant shall be required to remove and surrender the Premises free and clear of all the Furniture not later than the expiration or sooner termination of this Lease.
10. Representations and Warranties of Tenant . Tenant, with the understanding that Landlord is relying upon the following representations and warranties of Tenant in entering into this First Amendment, represents and warrants to and for the benefit of Landlord as follows:

a. Tenant is Holder of Leasehold . Tenant is the “Tenant” under the Lease and the sole holder of the leasehold estate created under the Lease.

b. No Assignment . Tenant has not voluntarily, by operation of law or otherwise: (i) assigned the Lease or any of the interest of Tenant in or under the Lease; (ii) sublet the Premises or any part thereof; (iii) allowed the occupancy or use of the Premises, or any portion of the Premises, by any person or entity other than the employees of Tenant; (iv) hypothecated, mortgaged or granted any security interest in all or any portion of the leasehold estate created under the Lease; (v) created any lien or encumbrance, whether voluntary, involuntary or by operation of law, upon all or any portion of the leasehold estate created under the Lease; or (vi) divested itself of all or any portion of the leasehold estate created under the Lease.

c. Lease in Full Force and Effect . The Lease is in full force and effect and has not been previously amended or modified.

4816-8951-6053v3                      4
PLS\07536231




d. Lease is Sole Agreement . The Lease is the sole document between Lam and Tenant relating to the leasing, use and occupancy of the Premises by Tenant and there are no other documents, agreements or understandings, whether written, oral or resulting from course of conduct, relating to the leasing, use or occupancy of the Premises by Tenant.

e. No Default by Landlord . All of the obligations of the “Landlord” under the Lease have been performed, and there is no event or condition that with the giving of notice or the elapse of any period of cure, or both, required under the Lease would constitute a breach or default of any obligation of the “Landlord” under the Lease.

f. No Claims by Tenant . Tenant has no claims, rights of set off, actions, causes of action or demands against Landlord arising out of, related to or connected with the Lease or the Premises.

g. Tenant not Insolvent . (i) Tenant is paying its debts as they become due, is not insolvent and is not otherwise entitled to protection, or intending to file for protection, under any state or federal bankruptcy, insolvency or debtor protection law or statute, and (ii) the entry by Tenant into this First Amendment does not render Tenant insolvent or otherwise entitled to protection, or to file for protection, under any state or federal bankruptcy, insolvency or debtor protection law or statute.

h. Tenant Duly Organized and Existing . Tenant is a corporation duly organized, existing and in good standing under the laws of the Delaware and is qualified to transact business in the State of California.

i. Authority . The person or persons who has or have executed this First Amendment on behalf of Tenant are authorized to execute this First Amendment on behalf of Tenant and to bind Tenant to the covenants and provisions of this First Amendment by her, his or their execution.

The representations and warranties of Tenant set forth in this Paragraph 10 are continuing and shall survive the execution and delivery of this First Amendment.
11. Brokers . Tenant represents and warrants to and for the benefit of Landlord that Tenant has not had any dealings with any realtor, broker or agent in connection with the extension of the Term of the Lease as described herein and/or the negotiation of this First Amendment other than Cornish & Carey Commercial Newmark Knight Frank (Mike Denevi) representing Tenant, and Landlord represents and warrants to and for the benefit of Tenant that Landlord has not had any dealings with any realtor, broker or agent in connection with the extension of the Term of the Lease as described herein and/or the negotiation of this First Amendment other than Cornish & Carey Commercial Newmark Knight Frank (Kurt Heihrich / Chris Shaffer) representing Landlord. Landlord will pay a commission to Cornish & Carey Commercial Newmark Knight Frank pursuant to a separate agreement between Landlord and Cornish & Carey Commercial Newmark Knight Frank. Tenant agrees to indemnify, protect, defend and hold Landlord harmless from and against any cost, expense or liability for any compensation, commission, fee or charge claimed by any realtor, broker, agent or person other than Cornish & Carey Commercial Newmark Knight Frank with respect to the extension of the Term of the Lease as described herein and/or the negotiation of this First Amendment by reason of any claimed agreement, dealings or contact with Tenant. The provisions of the two immediately preceding sentences shall survive the expiration or earlier

4816-8951-6053v3                      5
PLS\07536231




termination of the Lease, as amended hereby.

12. Ratification . Except as amended by the provisions of this First Amendment, the terms and provisions of the Lease remain in full force and effect. Landlord and Tenant ratify and affirm the Lease as amended by this First Amendment.

13. Choice of Law . The terms and provisions of this First Amendment shall be construed in accordance with, and governed by, the laws of the State of California without application of any choice of laws provisions.

14. Entire Agreement and Modification . The Lease as modified by this First Amendment constitutes the final, complete and exclusive statement of the terms of the agreement of Landlord and Tenant, supersedes all prior and contemporaneous understandings or agreements of Landlord and Tenant relating to the extension of the Term of the Lease, and is binding on and inures to the benefit of the respective heirs, representatives, successors and assigns of Landlord and Tenant. This First Amendment shall be deemed to be incorporated into the Lease and made a part thereof. All references to the Lease in any other document shall be deemed to refer to the Lease as modified by this First Amendment. Except as modified by this First Amendment, all of the terms and conditions of the Lease shall remain in full force and effect. In the event that the terms of this First Amendment conflict with the terms of the Lease and its schedules, the terms of this First Amendment shall control. Neither Landlord nor Tenant has been induced to enter in to this First Amendment by, nor is Landlord or Tenant relying upon, any representation or warranty other than those set forth in this First Amendment. Any agreement made after the date of this First Amendment shall be ineffective to amend this First Amendment, in whole or in part, unless such agreement is in writing, is signed by Landlord and Tenant, and specifically states that the agreement amends or modifies this First Amendment (or the Lease, as amended by this First Amendment).
  
15. No Drafting Presumption . The doctrine or rule of construction that ambiguities in a written instrument or agreement shall be construed against the party drafting the same shall not be employed in connection with this First Amendment.

16. Attorneys’ Fees . If Landlord or Tenant fails to perform any of its obligations under this First Amendment or if any dispute arises between Landlord and Tenant concerning the meaning or interpretation of any provision of this First Amendment, then the prevailing party shall be entitled to recover and receive from the defaulting party or the party not prevailing in such dispute, as the case may be, all reasonable costs and expenses incurred by the prevailing party on account of such default and/or in enforcing or establishing the rights of the prevailing party under this First Amendment, including, without limitation, court costs, attorneys’ fees and disbursements. Any reasonable attorneys` fees and other expenses incurred by the prevailing party in enforcing a judgment in its favor under this First Amendment shall be recoverable separately from and in addition to any other amount included in such judgment, and the obligation for the non-prevailing party to pay such attorneys` fees is intended to be severable from the other provisions of this First Amendment and to survive and not be merged into any such judgment.

17. Partial Invalidity . If any term, covenant or provision of this First Amendment is, to any extent, held by a court of competent jurisdiction to be invalid or unenforceable, the remainder of this First Amendment, or the application of that term, covenant or provision to persons or circumstances other than those as to which it is held to be invalid or unenforceable, will not be affected by such invalidity or unenforceability, and all other terms, covenants and conditions of this

4816-8951-6053v3                      6
PLS\07536231




First Amendment will be valid and enforceable to the fullest extent permitted by law.

18. Construction . Unless the context clearly requires otherwise, in this First Amendment (a) the plural and singular numbers shall each be deemed to include the other; (b) the masculine, feminine and neuter genders shall each be deemed to include the others; (c) “shall,” “will,” “must,” “agrees,” and “covenants” are each mandatory; (d) “may” is permissive; (e) “or” is not exclusive; and (f) “includes” and “including” are not limiting. Each covenant, agreement, obligation or other provision of this First Amendment shall be deemed and construed as a separate and independent covenant of the party bound by, undertaking or making the same, not dependent on any other provision of this First Amendment, unless otherwise expressly provided in this First Amendment.

19. Captions . The captions to the Sections in this First Amendment are included for convenience of reference only and do not modify or define any of the provisions of this First Amendment.

20. Counterparts . This First Amendment may be executed in separate counterparts, each of which shall constitute an original and all of which together shall constitute one and the same document. The parties contemplate that they may be executing counterparts of this First Amendment transmitted by facsimile or email in PDF format and agree and intend that a signature by either facsimile machine or email in PDF format shall bind the party so signing with the same effect as though the signature were an original signature.

IN WITNESS WHEREOF, Landlord and Tenant have caused this First Amendment to be executed as of the day and year written below.
LANDLORD:
 
TENANT:
S B C & D CO., INC.,
a California corporation  
By: /s/ Mark Regoli
Name: Mark Regoli
Title: EVP
Dated:October 16, 2013
 
INTERMOLECULAR, INC.,
a Delaware corporation
By: /s/ David E. Lazovsky
Name: David E. Lazovsky
Title: President and CEO
Dated:October 11, 2013








4816-8951-6053v3                      7
PLS\07536231






Exhibit A
Furniture Inventory






















































4816-8951-6053v3                      1
PLS\07536231




 
May 12, 2010
 
 
FURNITURE INVENTORY
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item
Location
Manufactuer
Category
Description
Qty.
Condition and/or Comments
 
 
 
 
 
 
 
1
3011 N.1st St.
Various
Chairs
Task chairs
225
Most old, but useable
2
3011 N.1st St.
Various
Chairs
Side (sled based) chairs
85
Most old, but useable
3
3011 N.1st St.
Various
Desks
Office sets, metal desk with table and/or credenza
68
Most old, but useable
4
3011 N.1st St.
Unknown
Desks
Maple wood office set, desk, credenza, cabinet, file cabinet, bookcase, table and chairs.
1
Most old, but useable
5
3011 N.1st St.
Unknown
Conf Rm set
10 ft laminate table & two chairs
1
Most old, but useable
6
3011 N.1st St.
Unknown
Conf Rm set
8 ft laminate table, credenza & 4 chairs
1
Most old, but useable
7
3011 N.1st St.
Unknown
Conf Rm set
14 ft laminate table & 13 chairs
1
Most old, but useable
8
3011 N.1st St.
Unknown
Conf Rm set
6 ft laminate table & 5 chairs
1
Most old, but useable
9
3011 N.1st St.
Unknown
Conf Rm set
8 ft laminate table, credenza, podium & 75 chairs
1
Most old, but useable
10
3011 N.1st St.
Unknown
Conf Rm set
12 ft. laminate table, credenza & 9 chairs
1
Most old, but useable
11
3011 N.1st St.
Unknown
Conf Rm set
10 ft laminate table, credenza & 6 chairs
1
Most old, but useable
12
3011 N.1st St.
Unknown
Conf Rm set
14 ft laminate table, credenza & 3 chairs
1
Most old, but useable
13
3011 N.1st St.
Unknown
Conf Rm set
12 ft laminate table, credenza & 12 chairs
1
Most old, but useable
14
3011 N.1st St.
Various
File cabinet
2 drawer lateral file cabinet
14
Most old, but useable
15
3011 N.1st St.
Various
File cabinet
3 drawer lateral file cabinet
18
Most old, but useable
16
3011 N.1st St.
Various
File cabinet
4 drawer lateral file cabinet
35
Most old, but useable
17
3011 N.1st St.
Various
Storage cab
18" x 36" x 72" metal storage cabinet
9
Most old, but useable
18
3011 N.1st St.
Various
Bookcase
15" x 36" x various metal bookcases
42
Most old, but useable
19
3011 N.1st St.
Unknown
Whiteboard
Printable white board, mtd on walls
3
Most old, but useable
20
3011 N.1st St.
Unknown
Screen
Electric screens, installed in ceiling
3
Most old, but useable
21
3011 N.1st St.
Unknown
Breakroom
54" round laminate tables
9
Most old, but useable
22
3011 N.1st St.
Unknown
Breakroom
Plastic stacking chairs, metal frames
75
Most old, but useable
23
3011 N.1st St.
Unknown
Breakroom
48" square laminate tables
6
Most old, but useable
24
3011 N.1st St.
Am. Seating
Cubicles
8' x 8' cubes
178
Most old, but useable
25
3011 N.1st St.
Am. Seating
Cubicles
8' x 12' cubes
14
Most old, but useable
26
3011 N.1st St.
Am. Seating
Cubicles
8' x 16' cubes
8
Most old, but useable
27
3011 N.1st St.
Herman Miller
Cubicles
8' x 8' cubes
22
Most old, but useable
28
3011 N.1st St.
 
 
 
 
 
29
3011 N.1st St.
 
 
 
 
 




4816-8951-6053v3                      2
PLS\07536231



Exhibit 31.1
Certification of Chief Executive Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, David E. Lazovsky, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Intermolecular, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 7, 2013
 
/s/ DAVID E. LAZOVSKY
 
 
David E. Lazovsky
  President and Chief Executive Officer





Exhibit 31.2
Certification of Chief Financial Officer
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, C. Richard Neely, Jr., certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Intermolecular, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: November 7, 2013
 
/s/ C. RICHARD NEELY, JR.
 
 
C. Richard Neely, Jr.
Chief Financial Officer





Exhibit 32.1

Certification of Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Intermolecular, Inc. (the "Company") on Form 10-Q for the three months ended September 30, 2013, as filed with the Securities and Exchange Commission (the "Report"), David E. Lazovsky, President and Chief Executive Officer of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 7, 2013

By:
 
/s/ DAVID E. LAZOVSKY
 
 
 
Name:
 
David E. Lazovsky
 
 
 
Title:
 
President and Chief Executive Officer
 
________________________________________________________________________________________________________________________

         A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
         This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.






Exhibit 32.2

Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906
of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Intermolecular, Inc. (the "Company") on Form 10-Q for the three months ended September 30, 2013, as filed with the Securities and Exchange Commission (the "Report"), C. Richard Neely, Jr., Chief Financial Officer of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 7, 2013


By:
 
/s/ C. RICHARD NEELY, JR.
 
 
 
Name:
 
C. Richard Neely, Jr.
 
 
 
Title:
 
Chief Financial Officer
 
________________________________________________________________________________________________________________________


         A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
         This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.